US20090205665A1 - Methods and devices for follow-up care and treatment of a pneumostoma - Google Patents
Methods and devices for follow-up care and treatment of a pneumostoma Download PDFInfo
- Publication number
- US20090205665A1 US20090205665A1 US12/388,459 US38845909A US2009205665A1 US 20090205665 A1 US20090205665 A1 US 20090205665A1 US 38845909 A US38845909 A US 38845909A US 2009205665 A1 US2009205665 A1 US 2009205665A1
- Authority
- US
- United States
- Prior art keywords
- pneumostoma
- treatment
- tissue
- lung
- passage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/04—Artificial pneumothorax apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0833—T- or Y-type connectors, e.g. Y-piece
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A61M16/202—Controlled valves electrically actuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00809—Lung operations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0252—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for access to the lungs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0276—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing or removing fluids into or out of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/025—Helium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/075—Bulb type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7518—General characteristics of the apparatus with filters bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7536—General characteristics of the apparatus with filters allowing gas passage, but preventing liquid passage, e.g. liquophobic, hydrophobic, water-repellent membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
Definitions
- COPD Chronic Obstructive Pulmonary Disease
- COPD Chronic Obstructive Pulmonary Disease
- the symptoms of COPD can range from the chronic cough and sputum production of chronic bronchitis to the severe disabling shortness of breath of emphysema.
- chronic cough and sputum production are the first signs that they are at risk for developing the airflow obstruction and shortness of breath characteristic of COPD.
- Acute infections or certain weather conditions may temporarily worsen symptoms (exacerbations), occasionally where hospitalization may be required.
- shortness of breath may be the first indication of the disease.
- the diagnosis of COPD is confirmed by the presence of airway obstruction on testing with spirometry. Ultimately, severe emphysema may lead to severe dyspnea, severe limitation of daily activities, illness and death.
- LVRS Lung Volume Reduction Surgery
- Applicants have developed a method for treating COPD in which an artificial passageway is made through the chest wall into the lung.
- An anastomosis is formed between the artificial passageway and the lung by pleurodesis between the visceral and parietal membranes surrounding the passageway as it enters the lung.
- the pleurodesis creates an adhesion between the pleural membrane surrounding the passageway which prevents air from entering the pleural cavity and causing a pneumothorax (deflation of the lung due to air pressure in the pleural cavity).
- Pleurodesis results from a fibrotic healing response between the pleural membranes and may be localized to the vicinity of the passageway.
- the artificial passageway through the chest wall also becomes epithelialized. The result is a stable artificial aperture through the chest wall which communicates with the parenchymal tissue of the lung.
- the artificial aperture into the lung through the chest is referred to herein as a pneumostoma.
- the pneumostoma provides an extra pathway that allows air to exit the lung while bypassing the natural airways which have been impaired by COPD and emphysema.
- the pneumostoma allows the stale air trapped in the lung to escape from the lung thereby shrinking the lung (reducing hyperinflation).
- the ventilation bypass reduces breathing effort, reduces expiratory pressures, reduces dyspnea, and allows more fresh air to be drawn in through the natural airways and increases the effectiveness of all of the tissues of the lung for gas exchange.
- Increasing the effectiveness of gas exchange allows for increased absorption of oxygen into the bloodstream and also increased removal of carbon dioxide.
- the pneumostoma thereby achieves the advantages of lung volume reduction surgery without surgically removing or sealing off a portion of the lung or transplanting a lung.
- the present invention provides methods and devices for assessing, and treating the health and functionality of a pneumostoma. Utilizing the methods and devices of the present invention a physician can enhance the health, patency and/or effectiveness of a pneumostoma thereby enhancing the remediation of COPD. Other objects, features and advantages of the invention are apparent from drawings and detailed description to follow.
- FIG. 1A shows the chest of a patient indicating alternative locations for a pneumostoma that may be managed using the devices and methods of the present invention.
- FIG. 1B shows a sectional view of the chest illustrating the relationship between the pneumostoma, lung and natural airways.
- FIG. 1C shows a detailed sectional view of a pneumostoma.
- FIG. 1D shows a perspective view of a pneumostoma management device.
- FIG. 1E shows the chest of a patient showing the pneumostoma management device positioned at alternative pneumostoma locations.
- FIG. 1F shows a detailed sectional view of a pneumostoma management device positioned inside a pneumostoma.
- FIG. 2A is a flow chart illustrating general steps for follow-up care and assessment of a patient having a pneumostoma according to an embodiment of the invention.
- FIG. 2B is a flow chart illustrating general steps for follow-up care and treatment of a patient having a pneumostoma according to an embodiment of the invention.
- FIG. 3A shows an exterior view of an instrument for internal inspection of a pneumostoma according to an embodiment of the invention.
- FIG. 3B shows a sectional view of the instrument for internal inspection of a pneumostoma of FIG. 3A positioned within a pneumostoma.
- FIG. 3C shows an exterior view of an alternative instrument for internal inspection of a pneumostoma according to an embodiment of the invention.
- FIG. 3D is a flow chart illustrating steps for examination of a pneumostoma with a pneumoscope according to an embodiment of the invention.
- FIG. 4A shows a view of a spirometry system for assessing the functionality of a pneumostoma according to an embodiment of the present invention.
- FIG. 4B shows a view of a gas analysis system for assessing the functionality of a pneumostoma according to an embodiment of the present invention.
- FIG. 4C shows a view of lung imaging system for imaging gas diffusion from a pneumostoma according to an embodiment of the present invention.
- FIG. 4D and 4E show views of a diagnostic device for delivering diagnostic gas to a pneumostoma or sampling gas from a pneumostoma according to embodiments of the present invention.
- FIGS. 5A-5C show views of a device for cleaning and treating the pneumostoma according to an embodiment of the invention.
- FIG. 5D is a flow chart illustrating steps for treatment of a pneumostoma with suction, irrigation and/or lavage according to an embodiment of the invention.
- FIG. 6A shows a view of an ultrasound device for cleaning or treating the pneumostoma according to an embodiment of the invention.
- FIG. 6B shows a view of a sound-wave therapy device for cleaning or treating the pneumostoma according to an embodiment of the invention.
- FIG. 6C is a flow chart illustrating steps for treatment of a pneumostoma with sound and/or ultrasound according to an embodiment of the invention.
- FIGS. 7A-7D show views of a mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention.
- FIG. 7E is a flow chart illustrating steps for treatment of a pneumostoma with a mechanical instrument for dilating the pneumostoma according to an embodiment of the invention.
- FIG. 7F shows an alternative mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention.
- FIG. 7G shows an alternative mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention.
- FIGS. 8A-8C show views of a thermotherapy device for treating tissues of a pneumostoma according to an embodiment of the present invention.
- FIGS. 8D-8E show views of an alternate thermotherapy device for treating tissues of a pneumostoma according to an embodiment of the present invention.
- FIGS. 9A-9B show views of an electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention.
- FIG. 9C shows a view of an alternate electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention.
- FIG. 9D shows a view of an alternate electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention.
- FIG. 1A shows the chest of a patient identifying alternative locations for creating a pneumostoma that may be managed using the system of the present invention.
- a first pneumostoma 110 is shown on the front of the chest 100 over the right lung 101 (shown in dashed lines).
- the pneumostoma is preferably positioned over the third intercostal space on the mid-clavicular line.
- the pneumostoma 110 is located on the front of the chest between the third and fourth ribs.
- the pneumostoma 110 is preferably located between two ribs, in alternative procedures a pneumostoma can also be prepared using a minithoracotomy with a rib resection.
- FIG. 1A a second pneumostoma 112 is illustrated in a lateral position entering the left lung 103 (shown in dashed lines).
- the pneumostoma 112 is preferably positioned over the fourth or fifth intercostal space under the left arm 104 .
- one pneumostoma per lung is created; however, more or less than one pneumostoma per lung may be created depending upon the needs of the patient.
- the lobes of the lung are not completely separate and air may pass between the lobes.
- the upper lobe is the preferred location for a pneumostoma as the upper lobe tends to move less during breathing. However depending upon the patient, it may be desirable to position a pneumostoma in any one of the lobes of the lung including the lower lobes.
- a pneumostoma is surgically created by forming an artificial channel through the chest wall and joining that channel with an opening through the visceral membrane of the lung into parenchymal tissue of the lung to form an anastomosis.
- the anastomosis is joined and sealed by sealing the channel from the pleural cavity using adhesives, mechanical sealing and/or pleurodesis.
- FIG. 1B shows a sectional view of chest 100 illustrating the position of the pneumostoma 110 .
- the parenchymal tissue 132 of the lung 130 is comprised principally of alveoli 134 .
- the alveoli 134 are the thin walled air-filled sacs in which gas exchange takes place. Air flows into the lungs through the natural airways including the trachea 136 , carina 137 , and bronchi 138 . Inside the lungs, the bronchi branch into a multiplicity of smaller vessels referred to as bronchioles (not shown). Typically, there are more than one million bronchioles in each lung. Each bronchiole connects a cluster of alveoli to the natural airways.
- pneumostoma 110 comprises a channel through the thoracic wall 106 of the chest 100 between two ribs 107 .
- Pneumostoma 110 opens at an aperture 126 through the skin 114 of chest 100 .
- FIG. 1C shows a detailed sectional view of the pneumostoma 110 .
- pneumostoma 110 comprises a channel 120 through the thoracic wall 106 of the chest 100 between the ribs 107 .
- the channel 120 is joined to cavity 122 in the parenchymal tissue 132 of lung 130 .
- the cavity 122 will typically conform to the shape of the device inserted into the pneumostoma 110 .
- An adhesion or pleurodesis 124 surrounds the channel 120 where it enters the lung 130 .
- the thoracic wall 106 is lined with the parietal membrane 108 .
- the surface of the lung 130 is covered with a continuous sac called the visceral membrane 138 .
- the parietal membrane 108 and visceral membrane 138 are often referred to collectively as the pleural membranes. Between the parietal membrane 108 and visceral membrane 138 is the pleural cavity (pleural space) 140 .
- the pleural cavity usually only contains a thin film of fluid that serves as a lubricant between the lungs and the chest wall.
- pleurodesis 124 the pleural membranes are fused and/or adhered to one another eliminating the space between the pleural membranes in that region.
- An important feature of the pneumostoma is the seal or adhesion 124 surrounding the channel 120 where it enters the lung 130 which may be formed by pleurodesis.
- Pleurodesis creates a fusion or adhesion 124 of the parietal membrane 108 and visceral membrane 138 .
- a pleurodesis may be a complete pleurodesis in which the entire pleural cavity 140 is removed by fusion of the visceral membrane 138 with the parietal membrane 108 over the entire surface of the lung 130 .
- the adhesion 124 is preferably localized to the region surrounding the channel 120 .
- the adhesion 124 surrounding the channel 120 prevents air from entering the pleural cavity 140 . If air is permitted to enter pleural cavity 140 , a pneumothorax will result and the lung may collapse.
- Adhesion 124 can be created between the visceral pleura of the lung and the inner wall of the thoracic cavity using chemical methods including introducing into the pleural space irritants such as antibiotics (e.g. Doxycycline or Quinacrine), antibiotics (e.g. iodopovidone or silver nitrate), anticancer therapeutic agents (e.g. Bleomycin, Mitoxantrone or Cisplatin), cytokines (e.g. interferon alpha-2 ⁇ and Transforming growth factor- ⁇ ); pyrogens (e.g. Corynebacterium parvum, Staphylococcus aureus superantigen or OK432); connective tissue proteins (e.g.
- antibiotics e.g. Doxycycline or Quinacrine
- antibiotics e.g. iodopovidone or silver nitrate
- anticancer therapeutic agents e.g. Bleomycin, Mitoxantrone or Cisplatin
- Pleurodesis can also be performed using surgical methods including pleurectomy.
- the pleural space may be mechanically abraded during thoracoscopy or thoracotomy. This procedure is called dry abrasion pleurodesis.
- a pleurodesis may also be formed using radiotherapy methods, including radioactive gold or external radiation. These methods cause an inflammatory response and or fibrosis, healing, and fusion of the pleural membranes.
- a seal can be created in an acute manner between the pleural membranes using biocompatible glues, meshes or mechanical means such as clamps, staples, clips and/or sutures. The adhesive or mechanical seal may develop cause pleurodesis over time.
- a range of biocompatible glues are available that may be used on the lung, including light-activatable glues, fibrin glues, cyanoacrylates and two part polymerizing glues.
- pneumostoma 110 When formed, pneumostoma 110 provides an extra pathway for exhaled air to exit the lung 130 reducing residual volume and intra-thoracic pressure without the air passing through the major natural airways such as the bronchi 138 and trachea 136 .
- Collateral ventilation is particularly prevalent in an emphysemous lung because of the deterioration of lung tissue caused by COPD.
- Collateral ventilation is the term given to leakage of air through the connective tissue between the alveoli 134 .
- Collateral ventilation may include leakage of air through pathways that include the interalveolar pores of Kohn, bronchiole-alveolar communications of Lambert, and interbronchiolar pathways of Martin. This air typically becomes trapped in the lung and contributes to hyperinflation.
- the pneumostoma allows stale air trapped in the parenchymal tissue 132 to escape from the lung 130 . This reduces the residual volume and intra-thoracic pressure. The lower intra-thoracic pressure reduces the dynamic collapse of airways during exhalation. By allowing the airways to remain patent during exhalation, labored breathing (dyspnea) and residual volume (hyperinflation) are both reduced.
- Pneumostoma 110 not only provides an extra pathway that allows air to exit the lung 130 but also allows more fresh air to be drawn in through the natural airways. This increases the effectiveness of all of the tissues of the lung 130 and improves gas exchange. Pneumostoma 110 thus achieves many of the advantages sought by lung volume reduction surgery without surgically removing a portion of the lung or sealing off a portion of the lung.
- a pneumostoma may be created to treat the symptoms of chronic obstructive pulmonary disease.
- a patient is typically provided with a pneumostoma management system to protect the pneumostoma and keeps the pneumostoma open on a day-to-day basis.
- a pneumostoma management device (“PMD”) comprises a tube which is inserted into the pneumostoma and an external component which is secured to the skin of the patient to keep the tube in place. Gases escape from the lung through the tube and are vented external to the patient.
- the pneumostoma management device may, in some, but not all cases, include a filter which only permits gases to enter or exit the tube.
- the pneumostoma management device may, in some, but not all cases, include a one-way valve which allows gases to exit the lung but not enter the lung through the tube.
- FIGS. 1D , 1 E and 1 F show an example of pneumostoma management device (“PMD”) 150 .
- FIG. 1D shows a perspective view of PMD 150 .
- FIG. 1E shows a view of the chest of a patient showing PMD 150 positioned in pneumostomas.
- FIG. 1F shows a sectional view of PMD 150 positioned within pneumostoma 110 .
- PMD 150 includes a vent tube 152 , a flange 154 and a filter 156 .
- Filter 156 prevents liquid and solid discharge from leaking out of the PMD and such discharge is trapped inside the pneumostoma or vent tube until the PMD is removed and replaced. Filter 156 also prevents the entry of contaminants into the pneumostoma. Filter 156 is preferably a hydrophobic filter to prevent leakage of fluids into or out of the pneumostoma.
- Flange 154 has an adhesive coating 162 (not shown) on the distal side. The adhesive coating 162 temporarily secures flange 154 to the skin 114 of the patient. Flange 154 also prevents over insertion of vent tube 152 by providing a mechanical stop to further insertion.
- vent tube 152 of PMD 150 is pushed into the pneumostoma 1 10 .
- the vent tube is configured to fit into a pneumostoma to keep the pneumostoma open. Gases from the lung enter an opening 158 in the distal end of vent tube 152 .
- Vent tube 152 is sized so as to pass through the thoracic wall into a portion of the pneumostoma 110 within the lung 130 as shown in FIG. 1F . However, vent tube 152 but is not so long that it causes damage to the parenchymal tissue 132 of the lung 130 . Vent tube 152 is preferably rounded over to provide an atraumatic tip 166 at the distal end.
- a patient is provided with a PMD having a vent tube 152 of the appropriate length for their pneumostoma.
- a vent tube 152 of the appropriate length for their pneumostoma.
- the pressure inside the chest is above atmospheric pressure and gases are consequently pushed through the central lumen of vent tube 152 and out through filter 156 . Additional details and variations of pneumostoma management devices are described in applicant's pending and issued patents and applications including those related cases incorporated by reference above.
- the patient is typically responsible for day-to-day management of the pneumostoma including replacement of the PMD and whatever daily cleaning and skin care may be required.
- the PMD is a disposable unit which is changed on a daily basis or as needed. While changing the PMD, the patient and/or caregiver can clean the skin surrounding the pneumostoma and observe the condition of the pneumostoma.
- a patient with a pneumostoma is also under the care of a physician and undergoes periodic checkups to monitor the condition of their lungs and of the pneumostoma. Moreover, the patient is advised to visit the physician if certain conditions are observed. The patient therefore visits the physician for regular follow-up visits and as indicated by observed conditions.
- the patient will also preferably be enrolled in a pulmonary rehabilitation program which will include: medical evaluation and management including monitoring patient compliance with pneumostoma care procedures; setting short term and long-term exercise goals; therapy programs (including smoking cessation if necessary); evaluation; and exercise.
- the rehabilitation program can also monitor the pneumostoma and refer the patient for assessment and treatment of the pneumostoma where indicated.
- the present invention provides a number of methods and devices for pneumostoma assessment and treatment.
- Such assessment and treatment is typically carried by a medical professional, for example a physician, nurse, respiratory therapist and/or medical assistant (this patent will use the term physician to include other medical care providers).
- FIG. 2A shows general assessment steps that may be performed when a patient visits a physician.
- the physician will typically assess the lung function of the patient (step 200 ).
- the physician will also assess each pneumostoma of the patient.
- the assessment of the pneumostoma may include one or more of an external visual inspection of the pneumostoma (step 202 ), an internal visual inspection of the pneumostoma (step 204 ); physical measurement of the pneumostoma (step 206 ), and a functional assessment of the pneumostoma (step 208 ).
- the results of the assessments may be compared with standard results and with prior assessments of the patient (step 210 ) to determine trends and variations in the lung/pneumostoma function. Based on the assessment of the lung function and pneumostoma, the physician determines whether any follow-up assessments and/or treatments are required (step 212 ).
- the assessment of lung function is performed as is typically done for COPD and emphysema patients. Such assessment may utilize one or more of: patient questionnaire/self reporting, spirometry (pre-/post-bronchodilator), pulmonary function test (lung volumes), diffusion capacity (DLLO), and arterial blood gas measurement.
- the physician examines the opening to the pneumostoma and the skin of the chest surrounding the pneumostoma. The physician observes any irritation, inflammation or infection and remediates where necessary.
- the physician examines the inside of the pneumostoma.
- the physician may use a pneumostoma inspection instrument.
- the pneumostoma inspection instrument includes a short inspection tube that may be pushed into the pneumostoma and that provides illumination and magnification for observation of the interior of the pneumostoma. The observation may be achieved using a direct optical train or a video device which displays images on a video display.
- the pneumostoma inspection instrument is typically provided with a range of inspection tubes of different diameters and lengths.
- the physician chooses the inspection tube appropriate to the dimensions of the pneumostoma of the patient and is careful not to damage tissue of the pneumostoma during insertion. During the internal visual inspection the physician observes any irritation, inflammation or infection and remediates where necessary. The physician also makes a qualitative assessment of tissues surrounding the pneumostoma to determine encroachment to the pneumostoma. The physician may also use the pneumostoma inspection instrument to measure the diameter and length of the pneumostoma and the shape and/or profile of the pneumostoma. (step 206 ). These may be used to determine the size of any pneumostoma management device prescribed to the patient and the size of any instruments to be used during treatment of the pneumostoma. This step also allows the physician to monitor any tissue encroachment into the pneumostoma as indicated by change in dimensions of the pneumostoma over time.
- the physician examines the ability of gas to pass through the pneumostoma.
- the ability of gas to pass through the pneumostoma may be measured in a number of ways.
- gas flow through the pneumostoma can be measured passively by placing a device over the pneumostoma which measures airflow out of and/or into the pneumostoma during regular breathing of the patient.
- gas may be provided to the pneumostoma at a slight positive pressure from outside the chest of the patient and the rate of flow of gas into the lung through the pneumostoma may be measured.
- diagnostic gases may be introduced through the pneumostoma to assess the patency and functionality of the pneumostoma. The diagnostic gases may be used for imaging the lungs and/or measuring collateral ventilation and gas exchange.
- the physician may compare the results of the visual, functional and/or structural assessment with prior assessment results and standard assessment results to determine changes and or trends in the results (step 210 ).
- the physician may decide to treat the pneumostoma and/or surrounding tissues to maintain or enhance the pneumostoma (step 212 ).
- the physician will select from the available treatment modalities a treatment suitable to maintain and/or enhance the function of the pneumostoma in light of the assessment results. (see step 220 of FIG. 2B ).
- One or more treatment modalities may be used.
- FIG. 2B illustrates a general method for treatment of a pneumostoma.
- the physician selects a treatment modality to maintain or enhance the health and/or functionality of the pneumostoma (step 220 ).
- suction may be used to aspirate discharge or other materials from the pneumostoma.
- Irrigation/lavage may be used to introduce a liquid into the pneumostoma in order to treat the tissue or aid in the removal of material from the pneumostoma. Irrigation/lavage may be used in conjunction with suction/aspiration to remove the liquid.
- Suction and/or irrigation may also be used in conjunction with a mechanical cleaning mechanism such as soft bristles, mechanical agitation, sonic/ultrasonic agitation or the like.
- the pneumostoma may be mechanically expanded using a balloon dilator, mechanical dilator or other tools.
- the pneumostoma may additionally be treated with heat, cold, light, electromagnetic radiation, electrocautery, sound/ultrasound, and the like.
- the physician next selects a pneumostoma treatment instrument suitable to apply the treatment modality to the pneumostoma (step 222 ).
- the selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma.
- the instrument may have a configurable size, or may have a range of different adapters.
- selection of the instrument will include selecting an instrument appropriate for the treatment modality and selecting/configuring the instrument for the pneumostoma of a particular patient.
- the selected/configured instrument is introduced into the pneumostoma (step 224 ).
- the pneumostoma management device will need to be removed (step 223 ) prior to inserting the treatment device.
- the treatment modality requires contact of a target tissue with a treatment surface of the device (step 226 ).
- the instrument treats the entire pneumostoma.
- the treatment is applied for a selected time (step 228 ).
- the effect of the treatment may then be assessed (step 230 ). In some cases the effect of the treatment is assessed with the pneumostoma treatment instrument. In other cases the pneumostoma treatment instrument may be removed and replaced with a pneumostoma inspection instrument to permit the assessment.
- the treatment may then be repeated if and as necessary for the pneumostoma or additional targets within the pneumostoma (step 232 ) until the desired effects have been achieved.
- a new pneumostoma management device should be promptly and correctly positioned in the pneumostoma either by the physician, or by the patient under the observation of the physician (step 234 ).
- Particular instruments suitable for assessing and treating pneumostomas in accordance with the general method steps of FIG. 2A and 2B are described below.
- pneumostoma inspection instrument placed within the pneumostoma.
- One type of pneumostoma inspection instrument includes a light source for illuminating the interior of the pneumostoma and a visualization system for visualizing (and typically magnifying) the interior of the pneumostoma.
- the visualization system may be a direct optical system comprising one or more optical components for providing a magnified image at an object lens mounted to the instrument.
- the visualization system may include means for obtaining a video image of the pneumostoma tissues and means for displaying the image, for example a video sensor and a video display.
- a pneumostoma inspection instrument, using a light source and visualization system is referred to generally herein as a pneumoscope.
- a pneumoscope may include a short inspection tube or speculum that may be pushed into the pneumostoma.
- the speculum holds open the pneumostoma during the inspection.
- the speculum may in some cases be a detachable metal speculum which may be sterilized between uses.
- the speculum is disposable or covered with a disposable sleeve during use.
- the speculum may be provided in a range of different diameters and lengths as appropriate for a particular pneumostoma or patient.
- the physician chooses the speculum appropriate to the dimensions of the pneumostoma of the patient.
- the speculum may be provided with visible exterior markings so that the physician may gauge the depth of insertion of the speculum.
- the speculum may be provided with a flange which prevents over-insertion of the speculum—however the depth of insertion is typically under the control of the physician who should use care not to damage tissue of the pneumostoma during insertion.
- the physician may use the speculum to gauge the diameter, length and profile of the pneumostoma.
- FIGS. 3A and 3B show an example of a pneumoscope according to one embodiment of the present invention.
- FIG. 3A shows an external view of a pneumoscope 300 .
- FIG. 3B shows a sectional view of the pneumoscope positioned within a pneumostoma.
- pneumoscope 300 comprises a handle 310 and a head 320 .
- a button 312 may be provided on handle 310 by which a physician may activate the light source and/or any image capturing system.
- a disposable speculum 330 is attached to head 320 .
- Speculum 330 comprises a catch 332 at the proximal end for temporarily mounting speculum 330 to head 320 of pneumoscope 300 .
- Speculum 330 is long enough to reach the end of a pneumostoma. As shown in FIG. 3A , speculum 330 bears external markings 334 indicating how far the distal tip 336 has travelled into the pneumostoma. External markings 334 may also be used to measure the depth of a pneumostoma. Pneumoscope 300 is preferably wireless and portable for ease of use.
- handle 310 includes a light source 314 and power supply 316 .
- the distal tip 336 of speculum 330 is inserted into the pneumostoma 1 10 .
- the physician actuates light source 314 to illuminate the interior of the pneumostoma 1 10 .
- Light is directed from light source 314 to the pneumostoma 110 using an optical train 324 including e.g. fiber optics and/or lenses.
- the optical train 324 preferably provides uniform illumination of the field of view.
- the head 320 comprises optics for viewing and magnifying the interior of the pneumostoma 1 10 .
- the interior of the pneumostoma 110 may be observed by the physician through objective lens 322 within head 320 .
- speculum 330 may be open at the distal tip 336 .
- distal tip 336 may be closed so long as a transparent window is provided through which the physician may observe the interior of the pneumostoma.
- FIG. 3C shows an alternative embodiment of a pneumoscope 302 comprising a handle 340 and a head 350 .
- One or more buttons 342 may be provided on handle 340 by which a physician may activate the light source 370 and/or any image capturing system.
- a disposable cover 360 is attached to head 350 .
- Cover 360 comprises a catch 362 at the proximal end for temporarily mounting cover 360 to head 350 of pneumoscope 302 .
- Cover 360 protects an extension 352 of head 350 . Extension 352 and cover 360 are long enough to reach the end of a pneumostoma.
- Cover 360 may be provided with external markings (not shown) indicating how far the distal tip 354 has travelled into a pneumostoma.
- Pneumoscope 302 is attached to a remote light source 370 and remote display system 378 .
- Remote display system 378 may include an image capturing system to record video images of the pneumostoma.
- Light source 370 provides light which is transmitted by a fiber optic cable 372 to the distal tip 354 of extension 352 .
- a window 356 emits light to illuminate the field of view.
- a window 358 at the distal tip 354 admits light which is focused on an image sensor (not shown) which may be e.g. a CCD or CMOS sensor.
- the image sensor captures video image data which is transmitted to the display 378 .
- the surgeon may observe video images of the interior of the pneumostoma on display 378 and/or may record images of the pneumostoma for later analysis.
- one or both of the light source and display may be built into the head 350 and/or handle 340 .
- Pneumoscope 302 may be inserted into a pneumostoma in the same manner as described with respect to pneumoscope 300 and illustrated in FIG. 3B .
- FIG. 3D illustrates a general method for examining a pneumostoma with a pneumoscope.
- the physician makes a determination to observe the pneumostoma using a pneumoscope (step 380 ).
- the physician next selects and/or configures a pneumoscope suitable to observe the pneumostoma of a particular patient (step 382 ).
- the selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma.
- the pneumoscope may have a configurable size, or may have a range of different sized speculums 330 and/or covers 360 .
- selection of the pneumoscope includes selecting/configuring the pneumoscope for the pneumostoma of a particular patient.
- the pneumostoma management device will be removed from the pneumostoma (step 383 ).
- the pneumostoma should then be externally inspected (step 384 ) to determine whether there are any contraindications to use of a pneumoscope, for example any obstruction of the pneumostoma which must first be removed. If the external inspection reveals no contraindications, the pneumoscope is introduced into the pneumostoma (step 386 ).
- the physician should observe tissue of the pneumostoma through the visualization system of the pneumoscope ( 388 ) and note and/or record the appearance of the tissue.
- the physician then advances the pneumoscope into the pneumostoma (step 390 ) and repeats the observation (step 388 ) until reaching the end of the pneumostoma.
- the pneumoscope is removed (step 392 ).
- a PMD should be inserted into the pneumostoma promptly after removal of the pneumoscope either by the physician, or by the patient under the observation of the physician (step 394 ).
- inspection with the pneumoscope is made in conjunction with treatment of the pneumostoma. In such a case, the pneumoscope may be used before, after and or during the treatment to observe effects of the treatment upon the tissue of the pneumostoma.
- the pneumoscope allows the physician to visually inspect and examine the tissues of the pneumostoma.
- the physician may observe the pneumostoma and examine the tissue in the region of the chest wall, pleurodesis, and/or within the parenchymal tissue of the lung. In the event that inflamed, injured or unusual tissues are observed, it may be desirable to further assess the tissue. Further assessment of the tissue may be made, for example, by swabbing the tissue and culturing any microorganisms on the swab. Alternatively, a biopsy of tissue of the pneumostoma may be made by scraping tissue from the walls of the pneumostoma and examining cells under the microscope.
- the pneumoscope may be provided with an auxiliary lumen through which a tool may be introduced into the pneumostoma in order to scrape or swab tissue under visualization.
- Measurement of gases entering or leaving the pneumostoma may be useful for assessing the functionality of the pneumostoma.
- the ability of gas to pass through the pneumostoma may be measured in a number of ways.
- gas flow through the pneumostoma can be measured passively by placing a device over the pneumostoma which measures airflow out of and/or into the pneumostoma during regular breathing of the patient.
- gases exiting the pneumostoma are collected by a system which records the volume of gas.
- the gas may be analyzed to determine composition of the gases exiting the pneumostoma.
- it may be useful to analyze the proportion of oxygen, carbon dioxide and carbon monoxide in the gases exiting the pneumostoma as compared to in air exhaled through the natural airways or in the ambient atmosphere.
- Levels of carbon dioxide in gases exiting the pneumostoma are a useful indicator that the pneumostoma is still functioning to allow gases to exit the lung. It may also be useful to measure the presence of nitric oxide in the gases exiting the pneumostoma because nitric oxide may be indicative of inflammation of the tissues of the lung.
- Gases exiting the pneumostoma may be measured and/or analyzed with a pneumostoma management device in place.
- gas measurement/analysis is preferably performed using a gas analysis device inserted into the pneumostoma which is designed to collect gases and interface with the gas measurement/analysis equipment. See, e.g. FIGS. 4D and 4E .
- Gas analysis and measurement may be performed in a number of modes depending upon the results desired. Different systems may be used for analysis of pneumostoma function, lung function or lung imaging as required.
- FIG. 4A shows a system for measuring/analyzing gases leaving the pneumostoma.
- Gas analysis equipment may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
- a gas analysis device 400 is inserted into the pneumostoma 110 of a patient.
- Gas analysis device 400 is connected by tube 402 to gas analyzer 412 .
- the gases exhaled from the pneumostoma 110 may then be measured and/or analyzed during normal breathing or during an exercise test.
- the volume of gas exhaled may be measured by gas analyzer 412 to provide information regarding the patency/functionality of the pneumostoma.
- the exhaled gas may be also be analyzed by gas analyzer 412 to determine oxygen and carbon dioxide concentrations.
- the concentrations are compared to oxygen and carbon dioxide concentrations in the gases exhaled through the natural airways or in the ambient atmosphere. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas.
- the output of gas analyzer 412 may be provided to a computer system 414 to display the results of the gas analysis. Computer system 414 preferably records the results of the gas measurement and analysis and allows the physician to compare the results of the gas measurement/analysis with prior results for the same patient.
- a mask 416 may be provided.
- Mask 416 may be used to measure the volume of gas inhaled and exhaled by the patient through the natural airways. The volume of gas inhaled and exhaled through the natural airways may be compared to the volume of gas exiting the pneumostoma.
- a diagnostic gas 418 is introduced through the natural airways and the expiration of gases from the pneumostoma is measured.
- Computer system 414 controls valve 406 to supply the diagnostic gas 418 to the mask 416 .
- the diagnostic gas may, for example, be a gas mixture such as DLCO gas used in diffusion spirometry (which nominally consists of 10% helium, 3000 ppm carbon monoxide and the balance air). As shown in FIG.
- optional mask 416 may be used to provide a diagnostic gas mixture 418 via the natural airways.
- concentration of gases exiting the pneumostoma 110 may be compared to the concentration of gases in the diagnostic gas supply 418 .
- the time-course of exhalation of diagnostic gases through the pneumostoma may be analyzed by gas analyzer 412 to evaluate the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the remainder of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas.
- gases may be provided through the pneumostoma from outside the chest of the patient.
- Gas supply equipment may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
- the gas is preferably supplied at a controlled pressure slightly above the ambient air pressure so as not to cause injury to the pneumostoma.
- the rate of flow of gas into the lung through the pneumostoma may be measured.
- the rate of gas flow at a particular pressure may be used to assess the patency of the pneumostoma.
- diagnostic gases may be introduced through the pneumostoma for assessing collateral ventilation and gas exchange. Diagnostic gases may be helpful in measuring functional attributes of the pneumostoma and the lung.
- introduction of diagnostic gases through the pneumostoma may be useful for assessing gas diffusion between the pneumostoma and the lung.
- a diagnostic gas is introduced through the pneumostoma and the gas is measured as it is exhaled through the natural airways.
- the diagnostic gas may, for example, be a gas mixture such as DLCO gas used in diffusion spirometry (which nominally consists of 10% helium, 3000 ppm carbon monoxide and the balance air). Gases exhaled through the natural airways are analyzed to determine gas concentrations. The time course of exhalation of the diagnostic gas is indicative of factors such as pneumostoma functionality and collateral ventilation.
- the time course of exhalation of gas through the natural airways compared to introduction into the pneumostoma may be analyzed to evaluate the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the remainder of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas.
- a supply of the diagnostic gas may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
- FIG. 4B shows a schematic view of a lung assessment system using introduction of diagnostic gas 418 through a pneumostoma 110 .
- a gas analysis device 400 is inserted into the pneumostoma 110 of a patient.
- Gas analysis device 400 is connected by tube 402 to a pressure-regulated source of diagnostic gas 418 .
- a solenoid-controlled valve 406 in tube 402 controls the flow of diagnostic gas into pneumostoma 110 .
- the patient is provided with a mask 416 which allows the patient to inhale ambient air but that collects the exhaled air and passes it to gas analyzer 412 .
- a portion of the exhaled gases is collected in a sample collection system and then analyzed using discrete gas sensors and/or a gas chromatograph.
- the gas analyzer 412 and the solenoid-controlled valve 406 are connected to a computer system 420 which may be a general purpose computer.
- Computer system 420 controls solenoid-controlled valve 406 and receives data from gas analyzer 412 .
- Computer system 420 analyzes the gas concentrations in the gas exhaled by the patient and factors the relative values with inspired gas volume and other parameters to calculate factors related to collateral ventilation and pneumostoma function.
- the output of gas analyzer 412 may be provided to computer system 420 to display the results of the gas analysis.
- Computer system 420 preferably records the results of the gas measurement and analysis and allows the physician to compare the results of the gas measurement/analysis with prior results for the same patient.
- polarized Helium-3 may be utilized to enhance nuclear magnetic resonance/magnetic resonance imaging of the lung (analogous to the way contrast agents enhance X-ray imaging).
- polarized helium-3 may be produced with lasers and the magnetized pressurized gas may be stored for several days.
- the polarized helium-3 can be imaged with an MRI-like scanner which produces breath-by-breath images of lung ventilation, in real-time.
- Polarized helium-3 may thus, be used to visualize airways in static or dynamic fashion.
- Alternative gases which may be used as visualization agents include gaseous radionuclide xenon or technetium DTPA in an aerosol form.
- Introducing a controlled amount of a visualizable gas, e.g. polarized Helium-3, through the pneumostoma and imaging the diffusion of the gas into the lung over time may be utilized for quantitative evaluation of the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the parenchymal tissue of the lung. Measuring the time-course variations in diffusion of Helium-3 into the lung allows analysis of diffusion coefficients for areas of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas.
- a source of polarized Helium-3 may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
- FIG. 4C shows a schematic view of a lung assessment system using a diagnostic gas in conjunction with an imaging scanner 450 .
- Scanner 450 may be an MRI, NMR, CT or X-Ray so long as the particular diagnostic gas used may be successfully imaged with the system.
- gas analysis device 400 is inserted into the pneumostoma 110 of a patient.
- Gas analysis device 400 is connected by tube 430 to a pressure-regulated source of a visualizable gas (e.g. polarized Helium-3).
- a solenoid-controlled valve 432 in tube 430 controls the flow of diagnostic gas into pneumostoma 110 .
- the scanner 450 and the solenoid-controlled valve 432 are connected to a computer system 420 (not shown) which may be a general purpose computer.
- the computer system 420 controls solenoid-controlled valve 432 and receives data from scanner 450 .
- the computer system 420 coordinates the introduction of diagnostic gas into the patient with the patient's breathing and also with the operations of scanner 450 in order to accurately image dispersion of the diagnostic gas from the pneumostoma 110 to other parts of the lung.
- Computer system 420 analyzes the time course distribution of the diagnostic gas from the pneumostoma into the lung tissues to calculate factors related to collateral ventilation and pneumostoma function, e.g. diffusion coefficients.
- FIGS. 4D and 4E show views of the gas analysis device 400 of FIGS. 4A-4C .
- FIG. 4D shows a perspective view of the gas analysis device 400 while
- FIG. 4E shows a sectional view of gas analysis device 400 positioned within a pneumostoma.
- gas analysis device 400 is a device which can be secured into a pneumostoma for sampling gases exiting the pneumostoma and/or providing gases into the pneumostoma.
- Gas analysis device 400 can form part of a system which utilizes such gas sampling or gas provision for assessment of pneumostoma function and/or lung function.
- gas analysis device 400 is used to introduce diagnostic gas into the pneumostoma.
- gas analysis device 400 is used to collect gases exhaled from the lung for analysis by gas analyzer 412 .
- gas analysis device 400 includes a hollow tube 460 for insertion into the pneumostoma.
- Hollow tube 460 is surrounded by a flange 462 which secures tube 460 in position in the pneumostoma.
- Hollow tube 460 connects to a coupling 464 on the proximal side of flange 462 .
- Coupling 464 is configured so that tube 402 (shown in FIG. 4E ) may be readily connected and disconnected.
- Hollow tube 460 has one or more holes 466 at the distal end through which gas may pass into or out of a pneumostoma.
- Hollow tube 460 and flange 462 also provide a temporary seal which inhibits leakage of gas from around hollow tube 460 .
- FIG. 4E shows a sectional view of gas analysis device 400 of FIGS. 4A-4D in position in a pneumostoma 110 . It is preferable to minimize leakage of gases into or out of the pneumostoma.
- Flange 462 is thus provided with an adhesive coating 468 on the distal surface to provide a temporary seal between the gas analysis device 400 and the skin of the chest of the patient. Surface features may also be provided on the distal surface of flange 462 or on tube 460 to promote sealing between gas analysis device 400 and the pneumostoma. For example, a circular ridge 470 is shown in section on FIG. 4E .
- Gas analysis device 400 is preferably a disposable component that will be used only with one patient. One or more filters may be interposed between gas analysis device 400 and the gas supply and/or gas analyzer to prevent possible cross-contamination between patients.
- a principal purpose of the pneumostoma is to permit the escape of gases trapped in the lung thereby reducing the lung volume and ameliorating symptoms of COPD such as dyspnea and anoxia.
- gases should be able to enter the pneumostoma from the parenchymal tissue of the lung. High rates of air flow are not required. However, if the pneumostoma becomes completely obstructed then it will no longer permit the escape of gases trapped in the lung.
- the function of the pneumostoma may be impaired by, among other causes, the encroachment of tissues into the pneumostoma, obstruction with secretions, discharge and/or foreign objects, inflammation and/or infection.
- encroaching tissues may impair the patency and functionality of the pneumostoma.
- the pneumostoma and surrounding tissues may be treated using a number of different treatment modalities to maintain and/or enhance patency, remove obstructions, decrease inflammation and prevent infection.
- the treatment modalities include: suction, irrigation, lavage, mechanical agitation, ultrasound, infrasound, mechanical dilation, balloon dilatation, cryotherapy, and energy treatment (including e.g. UV, light, LASER, LED, IR, heat, RF and electrocautery).
- the physician may select from among the several treatment modalities a treatment modality most appropriate for the conditions observed during the pneumostoma assessment.
- the treatment modalities available for treating a pneumostoma include suction, irrigation, mechanical agitation and lavage. These treatment modalities are suitable for removing obstructions and discharge from the pneumostoma, cleaning the pneumostoma and treating the tissues of the pneumostoma. Additional methods and devices for applying suction to a pneumostoma are disclosed in applicant's U.S. Provisional Patent Application 61/084,559 titled “Aspirator For Pneumostoma Management” which is incorporated herein by reference. An aspirator may be used without irrigation for the removal of liquid/soft discharge and materials from the pneumostoma.
- FIGS. 5A-5C illustrate a device for treating a pneumostoma with suction, irrigation, mechanical irritation and/or lavage.
- a suction-irrigation device 500 includes a body 510 attached to a suction-irrigation probe 520 .
- Suction-irrigation probe 520 includes a multi-lumen tube 522 and a flange 524 .
- multi-lumen tube 522 has an outer lumen 521 and an inner lumen 523 .
- multi-lumen tube 522 has a number of side apertures 526 for releasing fluid from the outer lumen 521 .
- Multi-lumen tube 522 has a distal aperture 528 in the distal tip for applying suction and removing fluid via the inner lumen 523 .
- Distal aperture 528 may be provided with a cage or mesh covering to prevent damage to tissues and/or obstruction of distal aperture 528 .
- Multi-lumen tube 522 also supports a plurality of soft bristles 530 for mechanically agitating the surface of a pneumostoma. Although bristles are shown, other mechanical features may be used to assist the removal of material which may be adhered to the tissue of the pneumostoma, for example ribs, fingers or surface roughness.
- suction irrigation probe 520 is connected to a body 510 by a coupling 532 which mounts releasably to a mating coupling 512 on body 510 .
- Body 510 is also connected to a pressure-regulated supply of irrigation fluid and a pressure-regulated vacuum supply (not shown).
- the irrigation supply and vacuum supply are attached or connected to an irrigation conduit 514 and suction conduit 516 within body 510 .
- the couplings 532 and 512 releasably mount the suction-irrigation probe 520 to body 510 .
- the couplings 532 and 512 also put the lumens of multi-lumen tube 522 in fluid communication with the irrigation conduit 514 and suction conduit 516 within body 510 .
- the releasable couplings 532 and 512 also enable the suction-irrigation probe 520 to be removed, and either cleaned and replaced, or disposed of and replaced.
- Couplings 532 , 512 may be, for example, threaded couplings, bayonet couplings, luer locks or other connector suitable for releasable connecting lumens.
- FIG. 5C shows a sectional view of suction-irrigation device 500 with suction-irrigation probe 520 inserted into a pneumostoma 110 .
- irrigation fluid exits through side apertures 526 and is collected through distal aperture 528 .
- Bristles 530 contact the tissue of the pneumostoma 110 .
- Suction-irrigation probe 520 may be moved in and out of pneumostoma 110 so that bristles 530 dislodge any material stuck on the side of pneumostoma 110 .
- the irrigation fluid serves to move any dislodged materials into aperture 528 .
- Flange 524 serves to prevent over-insertion of suction-irrigation probe 520 and also to prevent excessive leakage of irrigation fluid from the pneumostoma.
- flange 524 may be configured to slide up and down multi-lumen tube 522 such that the depth of the distal end of probe 520 may be adjusted while the flange remains in contact with the chest of the patient.
- flange 524 may be fixed or adjustably fixed to multi-lumen tube 522 .
- Suction-irrigation device 500 may include additional features to facilitate removal of material from the pneumostoma.
- suction-irrigation device 500 may include a visualization system to permit the physician to guide suction-irrigation probe 520 and visualize the tissues inside pneumostoma 110 . See, e.g. FIGS. 3A-3C and accompanying text.
- Suction-irrigation device 500 may also include an ultrasound generator or another device to agitate bristles 530 and the irrigation fluid to aid in the mechanical removal of materials from the pneumostoma 110 .
- Suction irrigation device 500 may also include a trap for trapping any solid materials dislodged from the pneumostoma. For irrigation, a sterile but inert solution may be used.
- sterile saline or sterile water may be used.
- the irrigation fluid will typically be sterile water or saline solution.
- an antibacterial or mucolytic solution may be used.
- a small concentration of the therapeutic agent is added to the sterile water or saline.
- Suitable therapeutic agents include anti-inflammatories, antibiotics and anti-stenosis compounds.
- the irrigation fluid may also include a small concentration of an agent for maintaining the patency of the pneumostoma, for example, Paclitaxel.
- the cleaning solution should be formulated carefully to avoid injury or irritation to the lung.
- FIG. 5D illustrates a method for treatment of a pneumostoma.
- the physician makes a determination to treat the pneumostoma with one or more of suction, irrigation and/or lavage. (step 580 ).
- the physician next selects and/or configures an aspirator/irrigator suitable to treat the pneumostoma of a particular patient. (step 582 ).
- the selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma.
- the aspirator/irrigator may have a configurable size, or may have a range of different sized probes 520 .
- selection of the aspirator/irrigator includes selecting/configuring the aspirator/irrigator for the pneumostoma of a particular patient. If irrigation/lavage is to be performed, the physician should also select and/or prepare the irrigation fluid (step 584 ).
- the pneumostoma management device will be removed from the pneumostoma (step 586 ).
- the pneumostoma should then be externally inspected (step 588 ) to determine whether there are any contraindications to use of the aspirator/irrigator, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the aspirator/irrigator is introduced into the pneumostoma (step 590 ).
- the physician may then position the flange so as to prevent excess leakage from the pneumostoma (step 592 ).
- the physician will the apply suction to remove materials from the pneumostoma (step 594 ).
- the physician may also provide irrigation/lavage and or agitation to dislodge materials for removal (step 594 .)
- the physician may advance the aspirator/irrigator incrementally further into the pneumostoma and repeats the treatment (step 594 ) until reaching the end of the pneumostoma.
- the aspirator/irrigator is removed (step 596 ).
- a PMD should be inserted into the pneumostoma promptly after removal of the aspirator/irrigator either by the physician, or by the patient under the observation of the physician (step 598 ).
- treatment with the aspirator/irrigator is made in conjunction with inspection of the pneumostoma with a pneumoscope.
- the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma.
- the treatment modalities available for treating a pneumostoma include the use of sound waves. Sound waves can be used to agitate the walls of the pneumostoma to dislodge materials. Sound waves of different frequencies may be of use, including infrasound below 20 Hz, acoustic sound waves between 20 Hz and 20 KHz and ultrasound above 20 KHz. These treatment modalities are suitable for removing obstructions and discharge from the pneumostoma, cleaning the pneumostoma and treating the tissues of the pneumostoma to enhance and/or maintain patency of the pneumostoma. The amplitude, frequency and duration of sound waves supplied may be selected to achieve the desired effects.
- the amplitude, frequency and duration of the sound waves may be sufficient to kill cells, inhibit proliferation of cells or disrupt cells and connective tissue in order to enhance or maintain the patency of the pneumostoma.
- the sound waves may be selected to dislodge materials e.g. discharge, which may be adhered to the tissues of the pneumostoma.
- ultrasound may be used in conjunction with suction/irrigation to remove materials from the pneumostoma.
- FIG. 6A shows a sectional view of an ultrasound device 600 for use in a pneumostoma 110 .
- Ultrasound device 600 includes a body 610 containing an ultrasonic transducer 612 coupled by a coupling 614 to an ultrasound probe 620 .
- Ultrasonic transducer 612 is coupled to ultrasound probe 620 so that, when energized, ultrasonic transducer 612 transmits ultrasound into ultrasound probe 620 .
- Ultrasound device 600 includes within body 610 , a switch 617 , a controller 616 and power supply 618 . The physician operates switch 617 to cause controller 616 to energize ultrasonic transducer 612 .
- controller 616 energizes ultrasonic transducer 612 for a predefined and limited period of time.
- Ultrasound probe 620 is sized and configured to enter pneumostoma 110 and conduct ultrasound energy from ultrasonic transducer 612 to the walls of the pneumostoma and any materials adhered thereto.
- Ultrasound probe 620 may also include a flange 622 which serves as protection against over insertion of probe 620 .
- a biocompatible gel or liquid (not shown) may be used with ultrasound probe 620 to enhance the conduction of ultrasonic waves from ultrasound probe 620 to tissues of the pneumostoma.
- flange 622 may also be useful to create a temporary seal to retain the gel or liquid with pneumostoma 110 during the ultrasound treatment.
- ultrasound probe 620 may be provided with a channel to provide suction to remove any materials dislodged by the ultrasound.
- a separate suction/irrigation device may be utilized to remove materials from the pneumostoma after treatment with the ultrasound probe 620 .
- FIG. 6B shows a schematic view of alternate sound delivery device 650 for use in a pneumostoma 110 .
- Sound delivery device 650 includes a body 660 containing a speaker 662 which typically comprises a magnetically-driven armature or diaphragm.
- Speaker 662 generates acoustic and/or infrasound waves in chamber 664 .
- Chamber 664 is in communication via coupling 668 with sound probe 670 .
- sound probe 670 is a hollow tube for holding open the pneumostoma and delivering the sound waves into the pneumostoma. Sound probe 670 may have one or more apertures.
- a baffle may be provided around sound probe 670 to concentrate pressure waves induced by the speaker with the pneumostoma.
- sound probe 670 may be a solid probe coupled to the armature of speaker 662 or a suitable transducer.
- the sound may be generated by a speaker located within the probe which is thus located within the pneumostoma during use.
- the energy delivered by sound delivery device 650 serves to dislodge materials from the pneumostoma and/or disrupt the connective tissue of the pneumostoma.
- sound probe 670 may be provided with a channel to provide suction to remove any materials dislodged by the sound waves.
- a separate suction/irrigation device may be utilized to remove materials from the pneumostoma after treatment with the sound delivery device 650 .
- FIG. 6C illustrates a method for treatment of a pneumostoma.
- the physician makes a determination to treat the pneumostoma with one or more of acoustic sound, infrasound, and/or ultrasound.
- the physician next selects and/or configures a sound/ultrasound device suitable to treat the pneumostoma of a particular patient.
- the selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma.
- the sound/ultrasound device may have a configurable size, or may have a range of different sized probes 620 or 670 .
- selection of the sound/ultrasound device includes selecting/configuring the sound/ultrasound device for the pneumostoma of a particular patient. If a sound conducting liquid or gel is to be used, the physician should also select and/or prepare the fluid (step 684 ).
- the pneumostoma management device will be removed from the pneumostoma (step 686 ).
- the pneumostoma should then be externally inspected (step 688 ) to determine whether there are any contraindications to use of the sound/ultrasound device, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the sound/ultrasound device is introduced into the pneumostoma (step 690 ).
- the physician may then position the flange so as to prevent excess leakage from the pneumostoma (step 692 ).
- the physician will then energize the sound/ultrasound probe for a selected period of time (step 694 ).
- the physician may advance the sound/ultrasound device incrementally further into the pneumostoma and repeat the treatment (step 694 ) until reaching the end of the pneumostoma.
- the sound/ultrasound device is removed (step 696 ).
- a PMD should be inserted into the pneumostoma promptly after removal of the aspirator/irrigator either by the physician, or by the patient under the observation of the physician (step 698 ).
- treatment with the sound/ultrasound device is made in conjunction with inspection of the pneumostoma with a pneumoscope.
- the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma. It may also be desirable to clean the pneumostoma with suction/irrigation prior to reinsertion of the PMD in order to remove any materials that may have been dislodged during the treatment.
- the treatment modalities available for treating a pneumostoma include the use of mechanical dilatation. Overtime, the natural healing response of the body may cause tissues to encroach into the lumen of the pneumostoma. Additionally, the tissues bordering the pneumostoma may thicken over time reducing the permeability of the pneumostoma walls to gases. A dilator may be used to stretch the tissues of the pneumostoma to maintain the patency of the pneumostoma. Dilatation not only increases the size of the lumen of the pneumostoma but also thins the tissues surrounding the pneumostoma.
- a dilator comprises an expander which can be inserted into the pneumostoma at a first contracted size and then expanded to a desired expanded size thereby stretching the pneumostoma.
- the dilator comprises an indicator outside the body which indicates the extent to which the expander has been expanded and/or an adjustable limiter which limits expansion of the expander to a safe amount.
- FIGS. 7A-7D show views of one embodiment of mechanical dilator 700 .
- mechanical dilator 700 comprises a handle 710 , a shaft 720 and an expander 730 .
- Handle 710 includes two arms 712 a, 712 b connected by a pivot 714 .
- a spring mechanism 716 biases arms 712 a, 712 b apart.
- a screw mechanism 717 may be used to lock arms 712 a, 712 b closer together at any desired position.
- a limit mechanism 715 may be used to limit the approach of arm 712 a towards arm 712 b in order to prevent over expansion of the expander 730 .
- Handle 710 is connected to shaft 720 .
- Arm 712 a is fixedly connected to the exterior of shaft 720
- arm 712 b is pivotally connected to inner shaft 722 .
- Moving arm 712 b towards arm 712 a moves inner shaft 722 more distally relative to shaft 720 .
- Handle 710 also includes a gauge 718 marked to indicate the amount of expansion of expander 730 .
- Gauge 718 is fixed to arm 712 a .
- An indicator 719 fixed to arm 712 b moves along gauge 718 as the arms are moved towards each other thereby expanding expander 730 .
- the markings on gauge 718 correspond to the expansion of expander 730 .
- Shaft 720 is sized so as to fit into the pneumostoma.
- Shaft 720 may be provided with markings 724 on the exterior surface so the physician may determine the depth to which the distal tip of expander 730 has been inserted in the pneumostoma.
- Expander 730 includes two blades 732 a , 732 b .
- Blades 732 a , 732 b are semicircular in section so that, in the collapsed configuration, blades 732 a , 732 b form a cylinder of the same external diameter as shaft 720 .
- Blades 732 a , 732 b also form a rounded distal tip 734 in their collapsed configuration to facilitate insertion of expander 730 into the pneumostoma.
- FIG. 7B shows mechanical dilator inserted into a pneumostoma 110 (shown in section).
- the mechanical dilator 700 is inserted into the pneumostoma 110 in the collapsed configuration of FIG. 7A until it is located at the desired depth in the pneumostoma as indicated by the markings 724 .
- mechanical dilator 700 may be used to measure the diameter of a pneumostoma.
- the expander may be inserted into the pneumostoma and the handles compressed until resistance is felt.
- the indicator 719 will indicate on gauge 718 the degree of expansion of expander 730 at this point of first resistance and thus indicate the internal diameter of the pneumostoma.
- Limit mechanism 715 may then be positioned to allow only a desired amount of incremental expansion of the pneumostoma compared to the measured initial diameter of the pneumostoma.
- a fixed or adjustable flange (not shown) may be provided mounted on shaft 720 . The flange serves as mechanical stop to limit insertion of the mechanical dilator 700 at a fixed or adjustable depth.
- FIG. 7C shows a close-up view of the expander 730 in an expanded configuration.
- each of blades 732 a and 732 b are pivotably connected by linkages 736 a , 736 b to the distal end of shaft 720 .
- Each of blades 732 a , 732 b is also pivotably connected to the distal end of inner shaft 722 by linkages 738 a , 738 b , 738 c , 738 d .
- Linkages 738 a , 738 b , 738 c , 738 d are designed to fit within a slot in the interior surface of blades 732 a , 732 b when the blades are in the collapsed configuration of FIG.
- expander 730 may have 3 or more blades, each blade taking up a fractional portion of the circumference of the device and each blade having three linkages connecting the blade to the distal end of inner shaft 722 .
- blades 732 a , 732 b move outwards as shown by arrows 702 a , 702 b.
- FIG. 7D shows mechanical dilator 700 positioned in a pneumostoma 110 .
- expander 730 is positioned within the pneumostoma at the desired depth.
- Handle 712 b has been pushed towards handle 712 a until it makes contact with limit mechanism 715 .
- Handle 712 b may optionally be locked into position with screw mechanism 717 .
- Inner shaft 722 has been pushed distally relative to shaft 720 .
- Linkages 738 a , 738 , b , 738 c , 738 d have thus forced blades 732 a , 732 b away from each other causing the expander 730 to adopt the expanded position shown in FIG. 7C (see FIGS. 7B and 7C for identification of the components of expander 730 ).
- indicator 719 has moved along gauge 718 to indicate the amount of expansion of expander 730 .
- mechanical dilator 700 is preferably expanded a small amount and then locked in place as the tissues of the pneumostoma relax. Mechanical dilator 700 is then expanded another small amount and then locked in place again as the tissues of the pneumostoma relax. A number of incremental expansion steps may be performed until the desired diameter of the pneumostoma is achieved. The incremental steps can be controlled by incremental movement of limit mechanism 715 and screw mechanism 717 . In some cases, it may be desirable to expand the dilator at two or more different depths in the pneumostoma so as to expand two or more different potions of the pneumostoma. Dilator 700 may then be collapsed and withdrawn from the pneumostoma. The pneumostoma will tend to contract after dilatation so it is important to insert a pneumostoma management device into the lumen of the pneumostoma upon removal of the mechanical dilator 700 .
- FIG. 7E illustrates a method for treatment of a pneumostoma with a dilator.
- the physician makes a determination to treat the pneumostoma with a dilator.
- the physician next selects and/or configures a dilator suitable to treat the pneumostoma of a particular patient.
- the selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma.
- the dilator may have a configurable size, or a range of initial sizes.
- selection of the dilator includes selecting/configuring the dilator for the pneumostoma of a particular patient such that it may be inserted into the pneumostoma to the desired depth prior to dilation. After dilation of the pneumostoma it is preferable to insert a PMD to support the pneumostoma as soon as the dilator is removed. Therefore, it is preferable to select and prepare a larger PMD for the patient to fit the anticipated dilated pneumostoma (step 744 ).
- the original (smaller) pneumostoma management device will be removed from the pneumostoma (step 746 ).
- the pneumostoma should then be externally inspected (step 748 ) to determine whether there are any contraindications to use of the dilator, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the dilator is introduced into the pneumostoma (step 750 ).
- the physician may then expand the dilator incrementally (step 752 ).
- the physician will then allow the tissue of the pneumostoma to relax (step 754 ) and repeat the incremental expansion (step 752 ) until the desired dilation has been achieved.
- the physician may also repeat the dilation at one or more depths within the pneumostoma depending upon the length of the pneumostoma.
- the dilation is complete the dilator is removed (step 756 ).
- a new larger PMD should then be promptly inserted into the pneumostoma by the physician, or by the patient under the observation of the physician (step 758 ).
- treatment with the sound/ultrasound device is made in conjunction with inspection of the pneumostoma with a pneumoscope.
- the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma. It may also be desirable to clean the pneumostoma with suction/irrigation prior to reinsertion of the PMD in order to remove any materials that may have been dislodged during the treatment.
- FIG. 7F shows an alternative mechanical dilator 760 and FIG. 7G shows a balloon dilator 780 .
- mechanical dilator 760 comprises first handle 761 connected to inner shaft 762 which extends to the distal tip of the mechanical dilator 760 .
- a second handle 763 is connected to an outer shaft 764 which rides on inner shaft 762 .
- expander 766 At the distal end of mechanical dilator 760 is expander 766 .
- Expander 766 includes a plurality of flexible elements 767 covered by a polymer shell 768 .
- each flexible element 767 and polymer shell 768 is connected to the distal end of inner shaft 762 .
- the proximal end of each flexible element 767 and polymer shell 768 is connected to the distal end of outer shaft 764 .
- outer shaft 764 is pushed distally along inner shaft 762 (as shown by arrow 770 )
- flexible elements 767 bend or bow outwards (as shown by arrows 771 ).
- Elements 767 push on polymer shell 768 causing it to also bow outwards (in the direction of arrows 771 ).
- mechanical dilator 760 transitions from the collapsed configuration to the expanded configuration by pushing handle 763 distally relative to handle 761 .
- Both outer shaft 764 and inner shaft 762 have markings 765 on the exterior surface so the physician may assess the depth of insertion of mechanical dilator 760 and the diameter of expansion of mechanical dilator 760 .
- Mechanical dilator 760 may be used in the same way as dilator 700 of FIGS. 7A-7D , either for dilating the pneumostoma or assessing the diameter of the pneumostoma.
- Mechanical dilator 760 may additionally be provided with a locking device to hold it in an expanded position and/or a limit device to control expansion of the expander 766 .
- FIG. 7G shows a balloon dilator 780 .
- mechanical dilator 780 comprises first handle 781 connected to a hollow shaft 782 which extends to the distal tip of the balloon dilator 780 .
- balloon 786 At the distal end of mechanical dilator 780 is balloon 786 .
- Balloon 786 is sealed to the hollow shaft at the proximal end 787 and distal end 788 of balloon 786 .
- An aperture in hollow shaft 782 communicates between the lumen of the hollow shaft 782 and the interior of balloon 786 .
- a syringe 792 is connected to the proximal end of hollow shaft 782 .
- Balloon dilator 780 may be used in the same way as dilator 700 of FIGS. 7A-7D , either for dilating the pneumostoma or assessing the diameter of the pneumostoma.
- Balloon 786 may be formed of a relatively inelastic material. In such case, injection of the liquid into the balloon will expand the balloon to a preset size. This ensures that the balloon does not stretch the pneumostoma more than desired. Moreover, the balloon can be expanded at high pressure without risk of over-expansion. However, a number of different balloon dilators may be required having different sizes in order to treat different pneumostomas or to incrementally expand a single pneumostoma. In alternative embodiments, a relatively elastic material may be used to make balloon 786 . In such case, the balloon will have a larger diameter for larger amounts of liquid allowing broader application. However, the pressure applied by the balloon to the tissue will be lower than for an inelastic balloon.
- the treatment modalities available for treating a pneumostoma include the application of heat (thermotherapy) or cold (cryotherapy).
- Thermotherapy and cryotherapy can be used to affect physical characteristics of tissues and cell proliferation and also to treat infection.
- the tissues of the pneumostoma tend to encroach into the lumen of the pneumostoma thereby impairing the function of the pneumostoma.
- One way to reduce tissue encroachment is through the use of thermotherapy or cryotherapy thereby maintaining or enhancing the patency of the pneumostoma.
- a pneumostoma treatment device may be used to heat the tissue in others the pneumostoma treatment device may be used to cool the tissue to achieve the desired effects.
- thermotherapy a surface of a pneumostoma treatment device is brought into contact with a target tissue of the pneumostoma.
- the surface of the pneumostoma treatment device is then heated to raise the temperature of the target tissue (e.g. by electrical heating, laser heating, or by circulating a heated medium).
- Other methods of thermotherapy include application of focused ultrasound, infrared light, radio or microwave-frequency radiation to the target tissue to induce the desired temperature rise in the target tissue.
- thermotherapy treatment device may direct energy at the tissue to heat the target tissue.
- the energy may be supplied as ultrasound, electrical energy, electromagnetic energy (for example IR or laser energy).
- the treatment is applied for a selected period of time. After the treatment the tissue is reassessed and treated again as necessary.
- the treatment may be applied to the pneumostoma tissue using a range of treatment devices and modalities as described in more detail below.
- the temperature and duration of the heat treatment are selected to affect physical characteristics of tissues, reduce cell proliferation and/or treat infection but not to kill tissues of the pneumostoma.
- Methods of cryotherapy include placing the target tissues in thermal contact with a cooled device or medium to lower the temperature of the target tissue.
- Cryotherapy may be used in two modes.
- the first mode of cryotherapy is cryogenic ablation in which cryotherapy is used to freeze tissue.
- a device is used to lower the temperature of the target cells to temperatures below freezing for short periods of time.
- the cells in the frozen tissue die and the tissue is removed.
- tissue ablation it is a disadvantage of tissue ablation that the cell necrosis stimulates the healing response.
- the healing response causes cell proliferation and generation of more cells in the form of scar tissue.
- cryogenic ablation may ultimately lead to greater tissue encroachment rather than less tissue encroachment.
- Cryogenic ablation may however still be useful for treating regions where tissue is encroaching into the pneumostoma.
- a second mode of cryotherapy is cryogenic cooling in which cells are cooled below physiologic temperatures without freezing the cells.
- a device is used to lower the temperature of the target cells to temperatures between normal physiologic temperatures and a temperature above freezing for short periods of time.
- Cryogenic cooling has been found to reduce hyperplasia in blood vessels. See e.g. U.S. Pat. No. 6,811,550 entitled “Safety Cryotherapy Catheter” to Holland et al.
- Cryogenic cooling may also be used to his mode of cryotherapy to treat larger areas of the pneumostoma including up to the entire pneumostoma.
- the temperature and duration of the cryotherapy are selected to affect physical characteristics of tissues, reduce cell proliferation and/or treat infection but not to kill tissues of the pneumostoma.
- FIGS. 8A-8C show a catheter which may be used for cryotherapy or thermotherapy of a pneumostoma tissues.
- catheter 800 includes a shaft 802 , a balloon 804 and a flange 806 .
- Flange 806 slides on the exterior of shaft 802 and acts as a mechanical stop for insertion of shaft 802 into a pneumostoma.
- the positioning of flange 806 on shaft 802 allows the physician to control the depth of balloon 804 and thus the location of the treatment area.
- the shaft 802 is provided with external markings 805 to indicate the distance between the treatment area and flange 806 thereby facilitating application of the treatment to the desired target tissues.
- shaft 802 has two lumens in inner lumen 808 and outer lumen 810 .
- shaft 802 may be coated with an insulating layer 803 so that treatment is limited to the region of the balloon 804 . The balloon may then be moved to different locations in the pneumostoma to treat different areas.
- shaft 802 is not insulated and is also designed to treat the tissues of the pneumostoma in addition to the balloon. In such cases, it is preferable that treatment is performed at a single position (because to do otherwise would treat areas along the shaft 802 multiple times).
- FIG. 8C at the proximal end of shaft 802 are an inlet 809 which communicates with inner lumen 808 and an outlet 811 which communicates with outer lumen 810 .
- catheter 800 is introduced in to the pneumostoma 110 to a depth limited by flange 806 as shown in FIG. 8C .
- Cryotherapy catheter 800 is connected to a cryotherapy coolant system 819 which supplies a temperature-controlled coolant fluid to cryotherapy catheter 800 .
- a coolant fluid is introduced through inlet 809 into inner lumen 808 .
- the coolant passes through inner lumen 808 to the distal end of cryogenic catheter 800 .
- the coolant passes through an aperture out of inner lumen 808 into the balloon 804 .
- the coolant inflates balloon 804 to bring it into contact with the tissue of the pneumostoma 110 .
- the coolant circulates around balloon 804 and cools the surface of balloon 804 to the desired temperature.
- a temperature sensor may be included in the distal tip of cryotherapy catheter 800 in order to monitor the temperature of the balloon.
- temperature regulation is performed by regulating the temperature of the coolant supplied by the cryotherapy coolant system.
- the coolant fluid is preferably a non-toxic liquid such as saline.
- liquids other than saline may be used and in some cases the coolant fluid may be a temperature-controlled gas.
- One system for supplying coolant is described in U.S. Pat. No. 6,432,102 entitled “Cryosurgical Fluid Supply” to Joye et al. If thermotherapy of the tissues is desired, a fluid heated to above body-temperature may be used in place of the coolant.
- FIG. 8D shows an alternative cryotherapy probe 820 .
- Cryotherapy probe 820 includes a shaft 821 and tip 822 .
- Tip 822 is of fixed size and is preferably made of a heat conductive material.
- Tip 822 may be made in whole or in part of a biocompatible metal, for example surgical steel.
- Tip 822 may be made in one piece with shaft 821 or may be made separately and joined to shaft 821 .
- shaft 821 (shown in FIG. 8D ) includes two lumens 824 , 826 for supplying coolant to tip 822 (in FIG. 8D ).
- Tip 822 has a cavity 828 in which the coolant circulates.
- cryotherapy probe 820 At the proximal end of cryotherapy probe 820 is an inlet 834 which communicates with lumen 824 and an outlet 836 which communicates with lumen 826 .
- shaft 820 may be coated with an insulating layer 823 so that treatment is limited to the region of the tip 822 .
- Shaft 821 may be coated with an insulating material 823 in order that the cryotherapy treatment is localized to the region of tip 822 . The tip 822 may then be moved to different locations in the pneumostoma to treat different areas.
- the size of tip 822 may differ between different cryotherapy probes 820 .
- a physician may have a range of cryotherapy probes available and choose the cryotherapy probe based upon the anatomy of the pneumostoma and the size and location of the tissues to be treated.
- Cryotherapy probe 820 may optionally be provided with a flange 830 positionable along shaft 821 in order to limit insertion of tip 822 into the pneumostoma and thereby control the location of tip 822 and the location of the cryotherapy treatment site.
- cryotherapy probe 820 is introduced into a pneumostoma to a position indicated by the markings on the exterior of the shaft 821 or position of the flange 830 . Tip 822 is brought into thermal contact with the pneumostoma tissues to be treated.
- Cryotherapy probe 820 is connected to a cryotherapy coolant system 819 .
- a coolant fluid is introduced through inlet 834 into lumen 824 .
- the coolant passes through lumen 824 to the distal end of cryotherapy probe 820 .
- the coolant passes through an aperture out of lumen 824 into the cavity 828 .
- the coolant circulates around cavity 828 and cools the surface of tip 822 to the desired temperature.
- a temperature sensor may be included in the tip 822 of cryotherapy probe 820 in order to monitor the temperature of the tip.
- temperature regulation is performed by regulating the temperature of the coolant supplied by the cryotherapy coolant system.
- a heated fluid may be circulated through the probe in place of the coolant.
- the treatment modalities available for treating a pneumostoma include the application of energy in the form of electromagnetic radiation, for example, infrared, ultraviolet, visible light, RF, microwaves.
- energy treatment can be used to affect physical characteristics of tissues and cell proliferation and also to treat infection.
- the tissues of the pneumostoma tend to encroach into the lumen of the pneumostoma and/or thicken the walls of the pneumostoma thereby impairing the function of the pneumostoma.
- One way to reduce tissue encroachment and/or thickness is through the application of energy to the tissues, either to kill the cells or to reduce their proliferation thereby maintaining or enhancing the patency of the pneumostoma.
- a pneumostoma treatment device may be used to direct energy to particular localized regions of the pneumostoma tissue, in other embodiments, the pneumostoma treatment device may apply energy equally in all directions.
- the electromagnetic radiation may be selected to kill or damage bacteria to reduce infection while minimizing damage to the cells of the pneumostoma. Some frequencies of visible light, for example, have been shown to kill certain bacteria without causing significant damage to human cells.
- FIG. 9A illustrates a pneumostoma treatment device 900 for treatment of pneumostoma tissues with electromagnetic radiation.
- the device includes a shaft 902 having at its distal end a treatment head 904 .
- the treatment head has a tapered or rounded tip 920 to facilitate introduction into the pneumostoma.
- the treatment head 904 may generate electromagnetic radiation in situ, or the electromagnetic radiation may be transmitted from an external source to the treatment head 904 .
- the treatment head may in some cases have a window 905 which is either open or covered with a material transparent to the electromagnetic radiation to be transmitted. In other cases the entire treatment head 904 may be enclosed in a material which is transparent to the delivered electromagnetic radiation.
- the pneumostoma treatment device 900 has a coupling 912 for connecting the pneumostoma treatment device 900 to a power source which may provide the electromagnetic radiation directly or provide electrical power to create electromagnetic radiation in the treatment head 904 .
- Coupling 912 may be connected to shaft 910 by a flexible cable 914 .
- the proximal end of shaft 902 may also provide access to lumens 916 which communicate with apertures 918 adjacent treatment head 904 .
- Lumens 916 and apertures 918 optionally provide suction, irrigation and/or cooling to the region adjacent treatment head 904 as necessary and/or desirable for a particular treatment modality.
- the shaft 902 and treatment head 904 are of suitable diameter for insertion into a pneumostoma. Typically the shaft 902 and treatment head 904 will be less than approximately 10 mm in diameter. In some cases the shaft and treatment head may be approximately 5 mm in diameter.
- the shaft 902 is flexible enough to allow insertion of the treatment head 904 into a pneumostoma even when the pneumostoma is not entirely straight. The shaft 902 should however be stiff enough that it can provide adequate force to push the treatment head 904 to the correct location in the pneumostoma.
- the pneumostoma treatment device carries a flange 906 which can slide on shaft 902 .
- the flange 906 has a locking collar 908 to fix the flange 906 at an adjustable position along the shaft 902 , other locking means may be used, for example, a suture, tape glue or mechanical lock.
- the physician will typically adjust the location of the flange 906 along the shaft 902 so that when the treatment head 904 and shaft 902 are inserted to the desired depth into a pneumostoma, the flange contacts the chest of the patient and prevent further insertion. Correct pre-positioning of the flange 906 on shaft 902 serves to guide treatment depth and protect against over insertion.
- the shaft 902 may also be provided with external markings 910 so that the physician may determine the correct location for flange 906 and the corresponding depth of treatment head 904 .
- FIG. 9B shows a sectional view of pneumostoma treatment device 900 inserted into a pneumostoma 110 .
- flange 906 is in contact with the skin 114 of the chest 100 of the patient and thus acts as a mechanical stop to prevent further insertion.
- Flange 906 may additionally be provided with an adhesive (not shown) to temporarily secure the flange 906 to the skin 114 of the chest 100 of the patient thereby securing the treatment head 904 at the desired depth within the pneumostoma 110 .
- Coupling 912 connects controller 922 via cable 914 to the proximal end of shaft 902 and via shaft 902 to treatment head 904 .
- Controller 922 may be used to control the provision of electromagnetic radiation by treatment head 904 . Controller may control one or more of: the location, intensity, wavelength and/or duration of the application of the electromagnetic radiation as directed by a physician.
- the treatment head 904 may be designed so that it delivers electromagnetic radiation equally in all directions thereby treating uniformly all of the tissues adjacent the treatment head.
- treatment head 904 may be designed such that it applies the electromagnetic radiation in a directional manner—this adds additional complexity in that a mechanism needs to be provided for aligning the electromagnetic radiation with the target tissues.
- the directional solution allows for different tissues within the pneumostoma to be treated differently and also different regions to be treated differently from other regions.
- Directionality may be provided, for example, using scanning optics to aim a beam of electromagnetic radiation provided by controller 922 through a fiber optic cable.
- FIG. 9C shows a sectional view of a pneumostoma treatment device 930 for treatment of pneumostoma tissues with electromagnetic radiation.
- the device includes a shaft 932 having at its distal end a treatment head 934 .
- the shaft 932 carries a flange 936 which can slide on shaft 932 .
- One or more lumens 946 passes along the length of shaft 932 to one or more aperture 948 adjacent treatment head 934 .
- Lumens 946 and apertures 948 optionally provide suction, irrigation and/or cooling to the region adjacent treatment head 934 as necessary and/or desirable to enhance treatment or protect tissue during treatment.
- the pneumostoma treatment device 930 has a coupling 942 for connecting the pneumostoma treatment device 930 to a power source 940 which provides electrical power through cable 944 to create electromagnetic radiation in the treatment head 934 .
- the treatment head 934 generates electromagnetic radiation in situ.
- the treatment head 934 is enclosed in a material which is transparent to the delivered electromagnetic radiation.
- the treatment head 934 radiates electromagnetic radiation in all directions uniformly from source 935 located within head 934 .
- Source 935 generates the desired electromagnetic radiation from electrical power provided by power source 940 .
- the source may be for example, a source of IR, UV visible light, X-rays or other electromagnetic radiation with which it is desired to treat the tissue of the pneumostoma.
- Particular devices suitable for use as source 935 include for example incandescent light sources, LEDs, fluorescent lamps and miniature X-ray sources.
- the source may be provided with additional features to ensure uniformity of distribution of the selected electromagnetic radiation including, for example a collimator, diffuser, and or reflector.
- FIG. 9D shows a sectional view of a pneumostoma treatment device 950 for treatment of pneumostoma tissues with electromagnetic radiation.
- the device includes a shaft 952 having at its distal end a treatment head 954 .
- the shaft 952 carries a flange 956 which can slide on shaft 952 .
- Flange 956 may be locked to shaft 952 and secured to the chest of the patient so that head 954 may be secured in a fixed relation to the pneumostoma during operation of pneumostoma treatment device 950 .
- the pneumostoma treatment device 950 has a coupling 962 for connecting the pneumostoma treatment device 950 to a controller 960 which provides light and power through cable 964 to treatment head 954 .
- the treatment head 954 does not generate electromagnetic radiation in situ. Instead, the electromagnetic radiation is generated by controller 960 and transmitted through an optical fiber 953 to treatment head 954 .
- the treatment head 954 is enclosed in a material which is transparent to the delivered electromagnetic radiation.
- the treatment head 954 includes scanning optics 958 which direct the electromagnetic radiation in a particular direction under the control of controller 960 .
- Controller 960 generates the desired electromagnetic radiation, transmits it to head 954 which directs it to a particular region of tissue of the pneumostoma.
- Controller 960 is connected to a computer system 964 which provides the physician with an interface 966 to operate controller 960 and control head 954 to treat selected target tissues within a pneumostoma.
- Controller 960 may generate one or more selectable frequencies of electromagnetic radiation. Controller 960 may, for example include a tunable laser source cable of generating coherent light over a range of different frequencies. The light frequency and intensity may be selected based upon the effect desired. For example, in some case the light frequency and intensity may be selected to ablate certain target tissues in the pneumostoma. Tissue ablation may be used to generate pores in the wall of the pneumostoma to enhance patency of the pneumostoma and/or restore pathways for gas to exit the pneumostoma.
- the scanning optics may also receive light received back from the tissue, which light may pass back down the fiber optic to controller 960 .
- the received light may be analyzed using tissue spectroscopy and/or tomography techniques to determine properties of the particular tissue from which the light is received.
- the head 954 can be used to analyze the tissue of the pneumostoma in addition to, or instead of, treating the tissue.
- Tissue scanning may be used in order to select target tissues for e.g. ablation to enhance the selectivity of treatment and reduce damage to sensitive tissue.
- tissue scanning may be used to ensure that tissue ablation avoids blood vessels in proximity to the pneumostoma when forming pores to restore or enhance the exit of gas through the pneumostoma.
- the pneumostoma may also be used as a port for analysis of compounds in the bloodstream. For example analysis of blood gases, and/or glucose concentration.
- the analysis can be performed by scanning the thin tissues of the pneumostoma and analyzing the light received from the tissues. Information in the received light at different frequencies and in a number of modes (for example scattering, reflectance, absorption and fluorescence) may be used to derive detailed information regarding the tissues of the pneumostoma and blood in vessels immediately adjacent the pneumostoma
Abstract
A pneumostoma assessment and treatment system includes methods and devices for aftercare of a pneumostoma and for additional patient care utilizing a pneumostoma. The system utilizes a number of modalities to assess the health and functionality of the pneumostoma, the lungs and/or the patient as a whole. In response to an assessment of the health and functionality of the pneumostoma, lungs and patient, the tissues of pneumostoma may be treated with a treatment device and utilizing one or more different modalities to preserve or enhance the health and function of the pneumostoma and/or treat other conditions of the patient.
Description
- This application claims priority to all of the following applications including: U.S. Provisional Application No. 61/029,830, filed Feb. 19, 2008, entitled “ENHANCED PNEUMOSTOMA MANAGEMENT DEVICE AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06013US0);
- U.S. Provisional Application No. 61/032,877, filed Feb. 29, 2008, entitled “PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06001US0);
- U.S. Provisional Application No. 61/038,371, filed Mar. 20, 2008, entitled “SURGICAL PROCEDURE AND INSTRUMENT TO CREATE A PNEUMOSTOMA AND TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06000US0);
- U.S. Provisional Application No. 61/082,892, filed Jul. 23, 2008, entitled “PNEUMOSTOMA MANAGEMENT SYSTEM HAVING A COSMETIC AND/OR PROTECTIVE COVER” (Attorney Docket No. LUNG1-06008US0);
- U.S. Provisional Application No. 61/083,573, filed Jul. 25, 2008, entitled “DEVICES AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT THROUGH A PNEUMOSTOMA” (Attorney Docket No. LUNG1-06003US0);
- U.S. Provisional Application No. 61/084,559, filed Jul. 29, 2008, entitled “ASPIRATOR FOR PNEUMOSTOMA MANAGEMENT” (Attorney Docket No. LUNG1-06011US0);
- U.S. Provisional Application No. 61/088,118, filed Aug. 12, 2008, entitled “FLEXIBLE PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06004US0);
- U.S. Provisional Application No. 61/143,298, filed Jan. 8, 2009, entitled “METHODS AND APPARATUS FOR THE CRYOTHERAPY CREATION OR RE-CREATION OF PNEUMOSTOMY” (Attorney Docket No. LUNG1-06006US0); and
- U.S. Provisional Application No. 61/151,581, filed Feb. 11, 2009, entitled “SURGICAL INSTRUMENTS AND PROCEDURES TO CREATE A PNEUMOSTOMA AND TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06002US0).
- All of the afore-mentioned applications are incorporated herein by reference in their entireties.
- This application is related to all of the above provisional applications and all the patent applications that claim priority thereto including:
- This application is related to all of the following applications including U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “ENHANCED PNEUMOSTOMA MANAGEMENT DEVICE AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06013US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06001US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “PNEUMOSTOMA MANAGEMENT METHOD FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06001US2);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “TWO-PHASE SURGICAL PROCEDURE FOR CREATING A PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06000US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “ACCELERATED TWO-PHASE SURGICAL PROCEDURE FOR CREATING A PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06000US2);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “SINGLE-PHASE SURGICAL PROCEDURE FOR CREATING A PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06000US3);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “PERCUTANEOUS SINGLE-PHASE SURGICAL PROCEDURE FOR CREATING A PNEUMSOTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06000US4);
- U.S. patent application Ser. No. 12/______, filed Feb. 13, 2009, entitled “PNEUMOSTOMA MANAGEMENT SYSTEM HAVING A COSTMETIC AND/OR PROTECTIVE COVER” (Attorney Docket No. LUNG1-06008US1)
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “DEVICES AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT THROUGH A PNEUMOSTOMA” (Attorney Docket No. LUNG1-06003US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “ASPIRATOR FOR PNEUMOSTOMA MANAGEMENT” (Attorney Docket No. LUNG1-06011US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “ASPIRATOR AND METHOD FOR PNEUMOSTOMA MANAGEMENT” (Attorney Docket No. LUNG1-06011US2);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “FLEXIBLE PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06004US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “SURGICAL INSTRUMENTS FOR CREATING A PNEUMOSTOMA AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06002US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “ONE-PIECE PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06017US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “PNEUMOSTOMA MANAGEMENT SYSTEM WITH SECRETION MANAGEMENT FEATURES FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06019US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “MULTI-LAYER PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULJMONARY DISEASE” (Attorney Docket No. LUNG1-06022US1);
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “VARIABLE LENGTH PNEUMOSTOMA MANAGEMENT SYSTEM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” (Attorney Docket No. LUNG1-06023US1); and
- U.S. patent application Ser. No. 12/______, filed Feb. 18, 2009, entitled “SELF-SEALING DEVICE AND METHOD FOR DELIVERY OF A THERAPEUTIC AGENT THROUGH A PNEUMOSTOMA” (Attorney Docket No. LUNG1-06025US1).
- All of the afore-mentioned applications are incorporated herein by reference in their entireties. This patent application also incorporates by reference all patents, applications, and articles discussed and/or cited herein.
- In the United States alone, approximately 14 million people suffer from some form of Chronic Obstructive Pulmonary Disease (COPD). However an additional ten million adults have evidence of impaired lung function indicating that COPD may be significantly underdiagnosed. The cost of COPD to the nation in 2002 was estimated to be $32.1 billion. Medicare expenses for COPD beneficiaries were nearly 2.5 times that of the expenditures for all other patients. Direct medical services accounted for $18.0 billion, and indirect cost of morbidity and premature mortality was $14.1 billion. COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020.
- Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease of the airways that is characterized by a gradual loss of lung function. In the United States, the term COPD includes chronic bronchitis, chronic obstructive bronchitis, and emphysema, or combinations of these conditions. In emphysema the alveoli walls of the lung tissue are progressively weakened and lose their elastic recoil. The breakdown of lung tissue causes progressive loss of elastic recoil and the loss of radial support of the airways which traps residual air in the lung. This increases the work of exhaling and leads to hyperinflation of the lung. When the lungs become hyperinflated, forced expiration cannot reduce the residual volume of the lungs because the force exerted to empty the lungs collapses the small airways and blocks air from being exhaled. As the disease progresses, the inspiratory capacity and air exchange surface area of the lungs is reduced until air exchange becomes seriously impaired and the individual can only take short shallow labored breaths (dyspnea).
- The symptoms of COPD can range from the chronic cough and sputum production of chronic bronchitis to the severe disabling shortness of breath of emphysema. In some individuals, chronic cough and sputum production are the first signs that they are at risk for developing the airflow obstruction and shortness of breath characteristic of COPD. With continued exposure to cigarettes or noxious particles, the disease progresses and individuals with COPD increasingly lose their ability to breathe. Acute infections or certain weather conditions may temporarily worsen symptoms (exacerbations), occasionally where hospitalization may be required. In others, shortness of breath may be the first indication of the disease. The diagnosis of COPD is confirmed by the presence of airway obstruction on testing with spirometry. Ultimately, severe emphysema may lead to severe dyspnea, severe limitation of daily activities, illness and death.
- There is no cure for COPD or pulmonary emphysema, only various treatments for ameliorating the symptoms. The goal of current treatments is to help people live with the disease more comfortably and to prevent the progression of the disease. The current options include: self-care (e.g., quitting smoking), therapeutic agents (such as bronchodilators which do not address emphysema physiology), long-term oxygen therapy, and surgery (lung transplantation and lung volume reduction surgery). Lung Volume Reduction Surgery (LVRS) is an invasive procedure primarily for patients who have a localized (heterogeneous) version of emphysema; in which, the most diseased area of the lung is surgically removed to allow the remaining tissue to work more efficiently. Patients with diffuse emphysema cannot be treated with LVRS, and typically only have lung transplantation as an end-stage option. However, many patients are not candidates for such a taxing procedure.
- A number of less-invasive surgical methods have been proposed for ameliorating the symptoms of COPD. In one approach new windows are opened inside the lung to allow air to more easily escape from the diseased tissue into the natural airways. These windows are kept open with permanently implanted stents. Other approaches attempt to seal off and shrink portions of the hyperinflated lung using chemical treatments and/or implantable plugs. However, these proposals remain significantly invasive and are still in clinical trails. None of the surgical approaches to treatment of COPD has been widely adopted. Therefore, a large unmet need remains for a medical procedure that can sufficiently alleviate the debilitating effects of COPD and emphysema and is accepted by physicians and patients.
- In view of the disadvantages of the state of the art, Applicants have developed a method for treating COPD in which an artificial passageway is made through the chest wall into the lung. An anastomosis is formed between the artificial passageway and the lung by pleurodesis between the visceral and parietal membranes surrounding the passageway as it enters the lung. The pleurodesis creates an adhesion between the pleural membrane surrounding the passageway which prevents air from entering the pleural cavity and causing a pneumothorax (deflation of the lung due to air pressure in the pleural cavity). Pleurodesis results from a fibrotic healing response between the pleural membranes and may be localized to the vicinity of the passageway. The artificial passageway through the chest wall also becomes epithelialized. The result is a stable artificial aperture through the chest wall which communicates with the parenchymal tissue of the lung.
- The artificial aperture into the lung through the chest is referred to herein as a pneumostoma. The pneumostoma provides an extra pathway that allows air to exit the lung while bypassing the natural airways which have been impaired by COPD and emphysema. By providing this ventilation bypass, the pneumostoma allows the stale air trapped in the lung to escape from the lung thereby shrinking the lung (reducing hyperinflation). By shrinking the lung, the ventilation bypass reduces breathing effort, reduces expiratory pressures, reduces dyspnea, and allows more fresh air to be drawn in through the natural airways and increases the effectiveness of all of the tissues of the lung for gas exchange. Increasing the effectiveness of gas exchange allows for increased absorption of oxygen into the bloodstream and also increased removal of carbon dioxide. Reducing the amount of carbon dioxide retained in the lung reduces hypercapnia which also reduces dyspnea. The pneumostoma thereby achieves the advantages of lung volume reduction surgery without surgically removing or sealing off a portion of the lung or transplanting a lung.
- The present invention provides methods and devices for assessing, and treating the health and functionality of a pneumostoma. Utilizing the methods and devices of the present invention a physician can enhance the health, patency and/or effectiveness of a pneumostoma thereby enhancing the remediation of COPD. Other objects, features and advantages of the invention are apparent from drawings and detailed description to follow.
- The above and further features, advantages and benefits of the present invention are apparent upon consideration of the present description taken in conjunction with the accompanying drawings.
-
FIG. 1A shows the chest of a patient indicating alternative locations for a pneumostoma that may be managed using the devices and methods of the present invention. -
FIG. 1B shows a sectional view of the chest illustrating the relationship between the pneumostoma, lung and natural airways. -
FIG. 1C shows a detailed sectional view of a pneumostoma. -
FIG. 1D shows a perspective view of a pneumostoma management device. -
FIG. 1E shows the chest of a patient showing the pneumostoma management device positioned at alternative pneumostoma locations. -
FIG. 1F shows a detailed sectional view of a pneumostoma management device positioned inside a pneumostoma. -
FIG. 2A is a flow chart illustrating general steps for follow-up care and assessment of a patient having a pneumostoma according to an embodiment of the invention. -
FIG. 2B is a flow chart illustrating general steps for follow-up care and treatment of a patient having a pneumostoma according to an embodiment of the invention. -
FIG. 3A shows an exterior view of an instrument for internal inspection of a pneumostoma according to an embodiment of the invention. -
FIG. 3B shows a sectional view of the instrument for internal inspection of a pneumostoma ofFIG. 3A positioned within a pneumostoma. -
FIG. 3C shows an exterior view of an alternative instrument for internal inspection of a pneumostoma according to an embodiment of the invention. -
FIG. 3D is a flow chart illustrating steps for examination of a pneumostoma with a pneumoscope according to an embodiment of the invention. -
FIG. 4A shows a view of a spirometry system for assessing the functionality of a pneumostoma according to an embodiment of the present invention. -
FIG. 4B shows a view of a gas analysis system for assessing the functionality of a pneumostoma according to an embodiment of the present invention. -
FIG. 4C shows a view of lung imaging system for imaging gas diffusion from a pneumostoma according to an embodiment of the present invention. -
FIG. 4D and 4E show views of a diagnostic device for delivering diagnostic gas to a pneumostoma or sampling gas from a pneumostoma according to embodiments of the present invention. -
FIGS. 5A-5C show views of a device for cleaning and treating the pneumostoma according to an embodiment of the invention. -
FIG. 5D is a flow chart illustrating steps for treatment of a pneumostoma with suction, irrigation and/or lavage according to an embodiment of the invention. -
FIG. 6A shows a view of an ultrasound device for cleaning or treating the pneumostoma according to an embodiment of the invention. -
FIG. 6B shows a view of a sound-wave therapy device for cleaning or treating the pneumostoma according to an embodiment of the invention. -
FIG. 6C is a flow chart illustrating steps for treatment of a pneumostoma with sound and/or ultrasound according to an embodiment of the invention. -
FIGS. 7A-7D show views of a mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention. -
FIG. 7E is a flow chart illustrating steps for treatment of a pneumostoma with a mechanical instrument for dilating the pneumostoma according to an embodiment of the invention. -
FIG. 7F shows an alternative mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention. -
FIG. 7G shows an alternative mechanical instrument for dilating the pneumostoma or a portion of the pneumostoma according to an embodiment of the present invention. -
FIGS. 8A-8C show views of a thermotherapy device for treating tissues of a pneumostoma according to an embodiment of the present invention. -
FIGS. 8D-8E show views of an alternate thermotherapy device for treating tissues of a pneumostoma according to an embodiment of the present invention. -
FIGS. 9A-9B show views of an electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention. -
FIG. 9C shows a view of an alternate electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention. -
FIG. 9D shows a view of an alternate electromagnetic treatment device for treating tissues of the pneumostoma according to an embodiment of the present invention. - The following description is of the best modes presently contemplated for practicing various embodiments of the present invention. The description is not to be taken in a limiting sense but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be ascertained with reference to the claims. In the description of the invention that follows, like numerals or reference designators are used to refer to like parts or elements throughout. In addition, the first digit of a reference number identifies the drawing in which the reference number first appears.
-
FIG. 1A shows the chest of a patient identifying alternative locations for creating a pneumostoma that may be managed using the system of the present invention. Afirst pneumostoma 110 is shown on the front of thechest 100 over the right lung 101 (shown in dashed lines). The pneumostoma is preferably positioned over the third intercostal space on the mid-clavicular line. Thus thepneumostoma 110 is located on the front of the chest between the third and fourth ribs. Although thepneumostoma 110 is preferably located between two ribs, in alternative procedures a pneumostoma can also be prepared using a minithoracotomy with a rib resection. - In
FIG. 1A asecond pneumostoma 112 is illustrated in a lateral position entering the left lung 103 (shown in dashed lines). Thepneumostoma 112 is preferably positioned over the fourth or fifth intercostal space under theleft arm 104. In general, one pneumostoma per lung is created; however, more or less than one pneumostoma per lung may be created depending upon the needs of the patient. In most humans, the lobes of the lung are not completely separate and air may pass between the lobes. The upper lobe is the preferred location for a pneumostoma as the upper lobe tends to move less during breathing. However depending upon the patient, it may be desirable to position a pneumostoma in any one of the lobes of the lung including the lower lobes. - A pneumostoma is surgically created by forming an artificial channel through the chest wall and joining that channel with an opening through the visceral membrane of the lung into parenchymal tissue of the lung to form an anastomosis. The anastomosis is joined and sealed by sealing the channel from the pleural cavity using adhesives, mechanical sealing and/or pleurodesis.
-
FIG. 1B shows a sectional view ofchest 100 illustrating the position of thepneumostoma 110. Theparenchymal tissue 132 of thelung 130 is comprised principally ofalveoli 134. Thealveoli 134 are the thin walled air-filled sacs in which gas exchange takes place. Air flows into the lungs through the natural airways including thetrachea 136,carina 137, andbronchi 138. Inside the lungs, the bronchi branch into a multiplicity of smaller vessels referred to as bronchioles (not shown). Typically, there are more than one million bronchioles in each lung. Each bronchiole connects a cluster of alveoli to the natural airways. As illustrated inFIG. 1B ,pneumostoma 110 comprises a channel through thethoracic wall 106 of thechest 100 between tworibs 107.Pneumostoma 110 opens at anaperture 126 through theskin 114 ofchest 100. -
FIG. 1C shows a detailed sectional view of thepneumostoma 110. As illustrated inFIG. 1C ,pneumostoma 110 comprises achannel 120 through thethoracic wall 106 of thechest 100 between theribs 107. Thechannel 120 is joined tocavity 122 in theparenchymal tissue 132 oflung 130. Thecavity 122 will typically conform to the shape of the device inserted into thepneumostoma 110. An adhesion orpleurodesis 124 surrounds thechannel 120 where it enters thelung 130. Thethoracic wall 106 is lined with theparietal membrane 108. The surface of thelung 130 is covered with a continuous sac called thevisceral membrane 138. Theparietal membrane 108 andvisceral membrane 138 are often referred to collectively as the pleural membranes. Between theparietal membrane 108 andvisceral membrane 138 is the pleural cavity (pleural space) 140. The pleural cavity usually only contains a thin film of fluid that serves as a lubricant between the lungs and the chest wall. Inpleurodesis 124 the pleural membranes are fused and/or adhered to one another eliminating the space between the pleural membranes in that region. - An important feature of the pneumostoma is the seal or
adhesion 124 surrounding thechannel 120 where it enters thelung 130 which may be formed by pleurodesis. Pleurodesis creates a fusion oradhesion 124 of theparietal membrane 108 andvisceral membrane 138. A pleurodesis may be a complete pleurodesis in which the entirepleural cavity 140 is removed by fusion of thevisceral membrane 138 with theparietal membrane 108 over the entire surface of thelung 130. However, as shown inFIG. 1C , theadhesion 124 is preferably localized to the region surrounding thechannel 120. Theadhesion 124 surrounding thechannel 120 prevents air from entering thepleural cavity 140. If air is permitted to enterpleural cavity 140, a pneumothorax will result and the lung may collapse. -
Adhesion 124 can be created between the visceral pleura of the lung and the inner wall of the thoracic cavity using chemical methods including introducing into the pleural space irritants such as antibiotics (e.g. Doxycycline or Quinacrine), antibiotics (e.g. iodopovidone or silver nitrate), anticancer therapeutic agents (e.g. Bleomycin, Mitoxantrone or Cisplatin), cytokines (e.g. interferon alpha-2β and Transforming growth factor-β); pyrogens (e.g. Corynebacterium parvum, Staphylococcus aureus superantigen or OK432); connective tissue proteins (e.g. fibrin or collagen) and minerals (e.g. talc slurry). Pleurodesis can also be performed using surgical methods including pleurectomy. For example, the pleural space may be mechanically abraded during thoracoscopy or thoracotomy. This procedure is called dry abrasion pleurodesis. A pleurodesis may also be formed using radiotherapy methods, including radioactive gold or external radiation. These methods cause an inflammatory response and or fibrosis, healing, and fusion of the pleural membranes. Alternatively, a seal can be created in an acute manner between the pleural membranes using biocompatible glues, meshes or mechanical means such as clamps, staples, clips and/or sutures. The adhesive or mechanical seal may develop cause pleurodesis over time. A range of biocompatible glues are available that may be used on the lung, including light-activatable glues, fibrin glues, cyanoacrylates and two part polymerizing glues. - When formed,
pneumostoma 110 provides an extra pathway for exhaled air to exit thelung 130 reducing residual volume and intra-thoracic pressure without the air passing through the major natural airways such as thebronchi 138 andtrachea 136. Collateral ventilation is particularly prevalent in an emphysemous lung because of the deterioration of lung tissue caused by COPD. Collateral ventilation is the term given to leakage of air through the connective tissue between the alveoli 134. Collateral ventilation may include leakage of air through pathways that include the interalveolar pores of Kohn, bronchiole-alveolar communications of Lambert, and interbronchiolar pathways of Martin. This air typically becomes trapped in the lung and contributes to hyperinflation. In lungs that have been damaged by COPD and emphysema, the resistance to flow in collateral channels (not shown) of theparenchymal tissue 132 is reduced allowing collateral ventilation to increase. Air fromalveoli 134 ofparenchymal tissue 132 that passes into collateral pathways oflung 130 is collected incavity 122 ofpneumostoma 110.Pneumostoma 110 thus makes use of collateral ventilation to collect air incavity 122 and vent the air outside the body viachannel 120 reducing residual volume and intra-thoracic pressure and bypassing the natural airways which have been impaired by COPD and emphysema.Cavity 122 will typically conform/adapt to the size and shape of the device inserted into the pneumostoma. - By providing this ventilation bypass, the pneumostoma allows stale air trapped in the
parenchymal tissue 132 to escape from thelung 130. This reduces the residual volume and intra-thoracic pressure. The lower intra-thoracic pressure reduces the dynamic collapse of airways during exhalation. By allowing the airways to remain patent during exhalation, labored breathing (dyspnea) and residual volume (hyperinflation) are both reduced.Pneumostoma 110 not only provides an extra pathway that allows air to exit thelung 130 but also allows more fresh air to be drawn in through the natural airways. This increases the effectiveness of all of the tissues of thelung 130 and improves gas exchange.Pneumostoma 110 thus achieves many of the advantages sought by lung volume reduction surgery without surgically removing a portion of the lung or sealing off a portion of the lung. - Methods and instruments for forming the channel, opening, anastomosis and pleurodesis are disclosed in applicant's pending and issued patents and applications including those related cases incorporated by reference above.
- As described above, a pneumostoma may be created to treat the symptoms of chronic obstructive pulmonary disease. A patient is typically provided with a pneumostoma management system to protect the pneumostoma and keeps the pneumostoma open on a day-to-day basis. In general terms a pneumostoma management device (“PMD”) comprises a tube which is inserted into the pneumostoma and an external component which is secured to the skin of the patient to keep the tube in place. Gases escape from the lung through the tube and are vented external to the patient. The pneumostoma management device may, in some, but not all cases, include a filter which only permits gases to enter or exit the tube. The pneumostoma management device may, in some, but not all cases, include a one-way valve which allows gases to exit the lung but not enter the lung through the tube.
FIGS. 1D , 1E and 1F show an example of pneumostoma management device (“PMD”) 150.FIG. 1D shows a perspective view ofPMD 150.FIG. 1E shows a view of the chest of apatient showing PMD 150 positioned in pneumostomas.FIG. 1F shows a sectional view ofPMD 150 positioned withinpneumostoma 110. - Referring to
FIG. 1D ,PMD 150 includes avent tube 152, aflange 154 and afilter 156.Filter 156 prevents liquid and solid discharge from leaking out of the PMD and such discharge is trapped inside the pneumostoma or vent tube until the PMD is removed and replaced.Filter 156 also prevents the entry of contaminants into the pneumostoma.Filter 156 is preferably a hydrophobic filter to prevent leakage of fluids into or out of the pneumostoma.Flange 154 has an adhesive coating 162 (not shown) on the distal side. Theadhesive coating 162 temporarily securesflange 154 to theskin 114 of the patient.Flange 154 also prevents over insertion ofvent tube 152 by providing a mechanical stop to further insertion. - As shown in
FIGS. 1E and IF, during use, thevent tube 152 ofPMD 150 is pushed into the pneumostoma 1 10. The vent tube is configured to fit into a pneumostoma to keep the pneumostoma open. Gases from the lung enter anopening 158 in the distal end ofvent tube 152.Vent tube 152 is sized so as to pass through the thoracic wall into a portion of thepneumostoma 110 within thelung 130 as shown inFIG. 1F . However, venttube 152 but is not so long that it causes damage to theparenchymal tissue 132 of thelung 130.Vent tube 152 is preferably rounded over to provide anatraumatic tip 166 at the distal end. A patient is provided with a PMD having avent tube 152 of the appropriate length for their pneumostoma. When the patient exhales, the pressure inside the chest is above atmospheric pressure and gases are consequently pushed through the central lumen ofvent tube 152 and out throughfilter 156. Additional details and variations of pneumostoma management devices are described in applicant's pending and issued patents and applications including those related cases incorporated by reference above. - The patient is typically responsible for day-to-day management of the pneumostoma including replacement of the PMD and whatever daily cleaning and skin care may be required. In preferred embodiments, the PMD is a disposable unit which is changed on a daily basis or as needed. While changing the PMD, the patient and/or caregiver can clean the skin surrounding the pneumostoma and observe the condition of the pneumostoma.
- A patient with a pneumostoma is also under the care of a physician and undergoes periodic checkups to monitor the condition of their lungs and of the pneumostoma. Moreover, the patient is advised to visit the physician if certain conditions are observed. The patient therefore visits the physician for regular follow-up visits and as indicated by observed conditions. The patient will also preferably be enrolled in a pulmonary rehabilitation program which will include: medical evaluation and management including monitoring patient compliance with pneumostoma care procedures; setting short term and long-term exercise goals; therapy programs (including smoking cessation if necessary); evaluation; and exercise. The rehabilitation program can also monitor the pneumostoma and refer the patient for assessment and treatment of the pneumostoma where indicated.
- The present invention provides a number of methods and devices for pneumostoma assessment and treatment. Such assessment and treatment is typically carried by a medical professional, for example a physician, nurse, respiratory therapist and/or medical assistant (this patent will use the term physician to include other medical care providers).
FIG. 2A shows general assessment steps that may be performed when a patient visits a physician. The physician will typically assess the lung function of the patient (step 200). The physician will also assess each pneumostoma of the patient. The assessment of the pneumostoma may include one or more of an external visual inspection of the pneumostoma (step 202), an internal visual inspection of the pneumostoma (step 204); physical measurement of the pneumostoma (step 206), and a functional assessment of the pneumostoma (step 208). The results of the assessments may be compared with standard results and with prior assessments of the patient (step 210) to determine trends and variations in the lung/pneumostoma function. Based on the assessment of the lung function and pneumostoma, the physician determines whether any follow-up assessments and/or treatments are required (step 212). - The assessment of lung function (step 200) is performed as is typically done for COPD and emphysema patients. Such assessment may utilize one or more of: patient questionnaire/self reporting, spirometry (pre-/post-bronchodilator), pulmonary function test (lung volumes), diffusion capacity (DLLO), and arterial blood gas measurement.
- In the external visual inspection (step 202) the physician examines the opening to the pneumostoma and the skin of the chest surrounding the pneumostoma. The physician observes any irritation, inflammation or infection and remediates where necessary. In the internal visual inspection (step 204) the physician examines the inside of the pneumostoma. The physician may use a pneumostoma inspection instrument. The pneumostoma inspection instrument includes a short inspection tube that may be pushed into the pneumostoma and that provides illumination and magnification for observation of the interior of the pneumostoma. The observation may be achieved using a direct optical train or a video device which displays images on a video display. The pneumostoma inspection instrument is typically provided with a range of inspection tubes of different diameters and lengths. The physician chooses the inspection tube appropriate to the dimensions of the pneumostoma of the patient and is careful not to damage tissue of the pneumostoma during insertion. During the internal visual inspection the physician observes any irritation, inflammation or infection and remediates where necessary. The physician also makes a qualitative assessment of tissues surrounding the pneumostoma to determine encroachment to the pneumostoma. The physician may also use the pneumostoma inspection instrument to measure the diameter and length of the pneumostoma and the shape and/or profile of the pneumostoma. (step 206). These may be used to determine the size of any pneumostoma management device prescribed to the patient and the size of any instruments to be used during treatment of the pneumostoma. This step also allows the physician to monitor any tissue encroachment into the pneumostoma as indicated by change in dimensions of the pneumostoma over time.
- In the functional assessment of the pneumostoma (step 208) the physician examines the ability of gas to pass through the pneumostoma. The ability of gas to pass through the pneumostoma may be measured in a number of ways. First, gas flow through the pneumostoma can be measured passively by placing a device over the pneumostoma which measures airflow out of and/or into the pneumostoma during regular breathing of the patient. Alternatively, gas may be provided to the pneumostoma at a slight positive pressure from outside the chest of the patient and the rate of flow of gas into the lung through the pneumostoma may be measured. Alternatively, as discussed below, diagnostic gases may be introduced through the pneumostoma to assess the patency and functionality of the pneumostoma. The diagnostic gases may be used for imaging the lungs and/or measuring collateral ventilation and gas exchange. The physician may compare the results of the visual, functional and/or structural assessment with prior assessment results and standard assessment results to determine changes and or trends in the results (step 210).
- Based upon the results of the visual, functional and/or structural assessment of the pneumostoma and any trends in such results, the physician may decide to treat the pneumostoma and/or surrounding tissues to maintain or enhance the pneumostoma (step 212). The physician will select from the available treatment modalities a treatment suitable to maintain and/or enhance the function of the pneumostoma in light of the assessment results. (see
step 220 ofFIG. 2B ). One or more treatment modalities may be used. -
FIG. 2B illustrates a general method for treatment of a pneumostoma. First, based on the assessment results, the physician selects a treatment modality to maintain or enhance the health and/or functionality of the pneumostoma (step 220). For example, suction may be used to aspirate discharge or other materials from the pneumostoma. Irrigation/lavage may be used to introduce a liquid into the pneumostoma in order to treat the tissue or aid in the removal of material from the pneumostoma. Irrigation/lavage may be used in conjunction with suction/aspiration to remove the liquid. Suction and/or irrigation may also be used in conjunction with a mechanical cleaning mechanism such as soft bristles, mechanical agitation, sonic/ultrasonic agitation or the like. The pneumostoma may be mechanically expanded using a balloon dilator, mechanical dilator or other tools. The pneumostoma may additionally be treated with heat, cold, light, electromagnetic radiation, electrocautery, sound/ultrasound, and the like. - The physician next selects a pneumostoma treatment instrument suitable to apply the treatment modality to the pneumostoma (step 222). The selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma. As pneumostomas may vary in size, the instrument may have a configurable size, or may have a range of different adapters. Thus selection of the instrument will include selecting an instrument appropriate for the treatment modality and selecting/configuring the instrument for the pneumostoma of a particular patient.
- The selected/configured instrument is introduced into the pneumostoma (step 224). In most cases, the pneumostoma management device will need to be removed (step 223) prior to inserting the treatment device. In some cases, the treatment modality requires contact of a target tissue with a treatment surface of the device (step 226). In other cases, the instrument treats the entire pneumostoma. The treatment is applied for a selected time (step 228). The effect of the treatment may then be assessed (step 230). In some cases the effect of the treatment is assessed with the pneumostoma treatment instrument. In other cases the pneumostoma treatment instrument may be removed and replaced with a pneumostoma inspection instrument to permit the assessment. The treatment may then be repeated if and as necessary for the pneumostoma or additional targets within the pneumostoma (step 232) until the desired effects have been achieved. After the treatment is over a new pneumostoma management device should be promptly and correctly positioned in the pneumostoma either by the physician, or by the patient under the observation of the physician (step 234). Particular instruments suitable for assessing and treating pneumostomas in accordance with the general method steps of
FIG. 2A and 2B are described below. - To observe the interior of the pneumostoma the physician uses a pneumostoma inspection instrument placed within the pneumostoma. One type of pneumostoma inspection instrument includes a light source for illuminating the interior of the pneumostoma and a visualization system for visualizing (and typically magnifying) the interior of the pneumostoma. The visualization system may be a direct optical system comprising one or more optical components for providing a magnified image at an object lens mounted to the instrument. Alternatively, the visualization system may include means for obtaining a video image of the pneumostoma tissues and means for displaying the image, for example a video sensor and a video display. Such a pneumostoma inspection instrument, using a light source and visualization system, is referred to generally herein as a pneumoscope.
- A pneumoscope may include a short inspection tube or speculum that may be pushed into the pneumostoma. The speculum holds open the pneumostoma during the inspection. The speculum may in some cases be a detachable metal speculum which may be sterilized between uses. Preferably, however, the speculum is disposable or covered with a disposable sleeve during use. The speculum may be provided in a range of different diameters and lengths as appropriate for a particular pneumostoma or patient. The physician chooses the speculum appropriate to the dimensions of the pneumostoma of the patient. The speculum may be provided with visible exterior markings so that the physician may gauge the depth of insertion of the speculum. The speculum may be provided with a flange which prevents over-insertion of the speculum—however the depth of insertion is typically under the control of the physician who should use care not to damage tissue of the pneumostoma during insertion. The physician may use the speculum to gauge the diameter, length and profile of the pneumostoma.
-
FIGS. 3A and 3B show an example of a pneumoscope according to one embodiment of the present invention.FIG. 3A shows an external view of apneumoscope 300.FIG. 3B shows a sectional view of the pneumoscope positioned within a pneumostoma. As shown inFIG. 3A ,pneumoscope 300 comprises ahandle 310 and ahead 320. Abutton 312 may be provided onhandle 310 by which a physician may activate the light source and/or any image capturing system. Adisposable speculum 330 is attached to head 320.Speculum 330 comprises acatch 332 at the proximal end for temporarily mountingspeculum 330 to head 320 ofpneumoscope 300.Speculum 330 is long enough to reach the end of a pneumostoma. As shown inFIG. 3A ,speculum 330 bearsexternal markings 334 indicating how far thedistal tip 336 has travelled into the pneumostoma.External markings 334 may also be used to measure the depth of a pneumostoma.Pneumoscope 300 is preferably wireless and portable for ease of use. - As shown in
FIG. 3B , handle 310 includes alight source 314 andpower supply 316. In use, thedistal tip 336 ofspeculum 330 is inserted into the pneumostoma 1 10. The physician actuateslight source 314 to illuminate the interior of the pneumostoma 1 10. Light is directed fromlight source 314 to thepneumostoma 110 using anoptical train 324 including e.g. fiber optics and/or lenses. Theoptical train 324 preferably provides uniform illumination of the field of view. In the embodiment ofFIG. 3A , thehead 320 comprises optics for viewing and magnifying the interior of the pneumostoma 1 10. The interior of thepneumostoma 110 may be observed by the physician throughobjective lens 322 withinhead 320. As shown inFIG. 3B ,speculum 330 may be open at thedistal tip 336. In alternative embodiments,distal tip 336 may be closed so long as a transparent window is provided through which the physician may observe the interior of the pneumostoma. -
FIG. 3C shows an alternative embodiment of apneumoscope 302 comprising ahandle 340 and ahead 350. One ormore buttons 342 may be provided onhandle 340 by which a physician may activate thelight source 370 and/or any image capturing system. Adisposable cover 360 is attached to head 350. Cover 360 comprises acatch 362 at the proximal end for temporarily mountingcover 360 to head 350 ofpneumoscope 302. Cover 360 protects anextension 352 ofhead 350.Extension 352 and cover 360 are long enough to reach the end of a pneumostoma. Cover 360 may be provided with external markings (not shown) indicating how far thedistal tip 354 has travelled into a pneumostoma.Pneumoscope 302 is attached to a remotelight source 370 andremote display system 378.Remote display system 378 may include an image capturing system to record video images of the pneumostoma. -
Light source 370 provides light which is transmitted by afiber optic cable 372 to thedistal tip 354 ofextension 352. Awindow 356 emits light to illuminate the field of view. Awindow 358 at thedistal tip 354 admits light which is focused on an image sensor (not shown) which may be e.g. a CCD or CMOS sensor. The image sensor captures video image data which is transmitted to thedisplay 378. The surgeon may observe video images of the interior of the pneumostoma ondisplay 378 and/or may record images of the pneumostoma for later analysis. In alternative embodiments, one or both of the light source and display may be built into thehead 350 and/or handle 340.Pneumoscope 302 may be inserted into a pneumostoma in the same manner as described with respect topneumoscope 300 and illustrated inFIG. 3B . -
FIG. 3D illustrates a general method for examining a pneumostoma with a pneumoscope. First, based on, for example, information from the patient or observation of the pneumostoma, the physician makes a determination to observe the pneumostoma using a pneumoscope (step 380). The physician next selects and/or configures a pneumoscope suitable to observe the pneumostoma of a particular patient (step 382). The selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma. As pneumostomas may vary in size, the pneumoscope may have a configurable size, or may have a range of differentsized speculums 330 and/or covers 360. Thus selection of the pneumoscope includes selecting/configuring the pneumoscope for the pneumostoma of a particular patient. - After the pneumoscope is ready, the pneumostoma management device will be removed from the pneumostoma (step 383). The pneumostoma should then be externally inspected (step 384) to determine whether there are any contraindications to use of a pneumoscope, for example any obstruction of the pneumostoma which must first be removed. If the external inspection reveals no contraindications, the pneumoscope is introduced into the pneumostoma (step 386). The physician should observe tissue of the pneumostoma through the visualization system of the pneumoscope (388) and note and/or record the appearance of the tissue. The physician then advances the pneumoscope into the pneumostoma (step 390) and repeats the observation (step 388) until reaching the end of the pneumostoma. When the inspection is completed the pneumoscope is removed (step 392). A PMD should be inserted into the pneumostoma promptly after removal of the pneumoscope either by the physician, or by the patient under the observation of the physician (step 394). In some cases, inspection with the pneumoscope is made in conjunction with treatment of the pneumostoma. In such a case, the pneumoscope may be used before, after and or during the treatment to observe effects of the treatment upon the tissue of the pneumostoma.
- The pneumoscope allows the physician to visually inspect and examine the tissues of the pneumostoma. The physician may observe the pneumostoma and examine the tissue in the region of the chest wall, pleurodesis, and/or within the parenchymal tissue of the lung. In the event that inflamed, injured or unusual tissues are observed, it may be desirable to further assess the tissue. Further assessment of the tissue may be made, for example, by swabbing the tissue and culturing any microorganisms on the swab. Alternatively, a biopsy of tissue of the pneumostoma may be made by scraping tissue from the walls of the pneumostoma and examining cells under the microscope. In some embodiments, the pneumoscope may be provided with an auxiliary lumen through which a tool may be introduced into the pneumostoma in order to scrape or swab tissue under visualization.
- Measurement of gases entering or leaving the pneumostoma may be useful for assessing the functionality of the pneumostoma. The ability of gas to pass through the pneumostoma may be measured in a number of ways. First, gas flow through the pneumostoma can be measured passively by placing a device over the pneumostoma which measures airflow out of and/or into the pneumostoma during regular breathing of the patient. Essentially, gases exiting the pneumostoma are collected by a system which records the volume of gas.
- Additionally, the gas may be analyzed to determine composition of the gases exiting the pneumostoma. In particular it may be useful to analyze the proportion of oxygen, carbon dioxide and carbon monoxide in the gases exiting the pneumostoma as compared to in air exhaled through the natural airways or in the ambient atmosphere. Levels of carbon dioxide in gases exiting the pneumostoma are a useful indicator that the pneumostoma is still functioning to allow gases to exit the lung. It may also be useful to measure the presence of nitric oxide in the gases exiting the pneumostoma because nitric oxide may be indicative of inflammation of the tissues of the lung.
- Gases exiting the pneumostoma may be measured and/or analyzed with a pneumostoma management device in place. However it is preferable to avoid any confounding effects due to the PMD, for example obstruction of the pneumostoma by the PMD, the filter of the PMD or accumulated discharge in the PMD. Therefore gas measurement/analysis is preferably performed using a gas analysis device inserted into the pneumostoma which is designed to collect gases and interface with the gas measurement/analysis equipment. See, e.g.
FIGS. 4D and 4E . Gas analysis and measurement may be performed in a number of modes depending upon the results desired. Different systems may be used for analysis of pneumostoma function, lung function or lung imaging as required. - Systems for supplying gases, to a patient and analyzing gases received from a patient are already in use for supplying gases to be inhaled through the natural airways and analyzing gases exhaled through the natural airways. For example a system for analyzing expiratory gases is described in U.S. Pat. No. 6,506,608 titled “Method And Apparatus For Respiratory Gas Analysis Employing Enhanced Measurement Of Expired Gas Mass” to Mault. A system for supplying and analyzing diagnostic gases is described in U.S. Pat. No. 5,022,406 title “Module For Determining Diffusing Capacity Of The Lungs For Carbon Monoxide And Method” to Tomlinson et al. A review of DLCO spirometry can be found in Macintyre et al., “Standardisation Of The Single-Breath Determination Of Carbon Monoxide Uptake In The Lung,” Eur. Respir. J. 26 (4): 720-35 (2005) and reference cited therein. A system for supplying and imaging hyperpolarized noble gases in the lungs is described in U.S. Patent Publication 2005/0174114 title “Method And System For Rapid Magnetic Resonance Imaging Of Gases With Reduced Diffusion-Induced Signal Loss” to Mugler III et al. A review of diffusion imaging of the lung can be found in Mayo et al., “Hyperpolarized Helium 3 Diffusion Imaging Of The Lung,” Radiology 222:8-11 (2202) and reference cited therein. The above articles, patents and applications are incorporated herein by reference. These and other such systems may be adapted as described herein to supply and analyze gases utilizing the pneumostoma and thereby provide information regarding lung function, pneumostoma function and collateral ventilation not previously available.
-
FIG. 4A shows a system for measuring/analyzing gases leaving the pneumostoma. Gas analysis equipment may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein. As shown inFIG. 4A , agas analysis device 400 is inserted into thepneumostoma 110 of a patient.Gas analysis device 400 is connected bytube 402 togas analyzer 412. The gases exhaled from thepneumostoma 110 may then be measured and/or analyzed during normal breathing or during an exercise test. The volume of gas exhaled may be measured bygas analyzer 412 to provide information regarding the patency/functionality of the pneumostoma. The exhaled gas may be also be analyzed bygas analyzer 412 to determine oxygen and carbon dioxide concentrations. In some cases, the concentrations are compared to oxygen and carbon dioxide concentrations in the gases exhaled through the natural airways or in the ambient atmosphere. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas. The output ofgas analyzer 412 may be provided to acomputer system 414 to display the results of the gas analysis.Computer system 414 preferably records the results of the gas measurement and analysis and allows the physician to compare the results of the gas measurement/analysis with prior results for the same patient. - Optionally, a
mask 416 may be provided.Mask 416 may be used to measure the volume of gas inhaled and exhaled by the patient through the natural airways. The volume of gas inhaled and exhaled through the natural airways may be compared to the volume of gas exiting the pneumostoma. Optionally, adiagnostic gas 418 is introduced through the natural airways and the expiration of gases from the pneumostoma is measured.Computer system 414controls valve 406 to supply thediagnostic gas 418 to themask 416. The diagnostic gas may, for example, be a gas mixture such as DLCO gas used in diffusion spirometry (which nominally consists of 10% helium, 3000 ppm carbon monoxide and the balance air). As shown inFIG. 4A ,optional mask 416 may be used to provide adiagnostic gas mixture 418 via the natural airways. The concentration of gases exiting thepneumostoma 110 may be compared to the concentration of gases in thediagnostic gas supply 418. The time-course of exhalation of diagnostic gases through the pneumostoma may be analyzed bygas analyzer 412 to evaluate the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the remainder of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas. - Alternatively, gases may be provided through the pneumostoma from outside the chest of the patient. Gas supply equipment may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein. The gas is preferably supplied at a controlled pressure slightly above the ambient air pressure so as not to cause injury to the pneumostoma. In a simple case, the rate of flow of gas into the lung through the pneumostoma may be measured. The rate of gas flow at a particular pressure may be used to assess the patency of the pneumostoma. Alternatively, diagnostic gases may be introduced through the pneumostoma for assessing collateral ventilation and gas exchange. Diagnostic gases may be helpful in measuring functional attributes of the pneumostoma and the lung. In particular, introduction of diagnostic gases through the pneumostoma may be useful for assessing gas diffusion between the pneumostoma and the lung.
- In one example, a diagnostic gas is introduced through the pneumostoma and the gas is measured as it is exhaled through the natural airways. The diagnostic gas may, for example, be a gas mixture such as DLCO gas used in diffusion spirometry (which nominally consists of 10% helium, 3000 ppm carbon monoxide and the balance air). Gases exhaled through the natural airways are analyzed to determine gas concentrations. The time course of exhalation of the diagnostic gas is indicative of factors such as pneumostoma functionality and collateral ventilation. The time course of exhalation of gas through the natural airways compared to introduction into the pneumostoma may be analyzed to evaluate the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the remainder of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas. A supply of the diagnostic gas may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
-
FIG. 4B shows a schematic view of a lung assessment system using introduction ofdiagnostic gas 418 through apneumostoma 110. As shown inFIG. 4B agas analysis device 400 is inserted into thepneumostoma 110 of a patient.Gas analysis device 400 is connected bytube 402 to a pressure-regulated source ofdiagnostic gas 418. A solenoid-controlledvalve 406 intube 402 controls the flow of diagnostic gas intopneumostoma 110. The patient is provided with amask 416 which allows the patient to inhale ambient air but that collects the exhaled air and passes it togas analyzer 412. During exhalation, a portion of the exhaled gases is collected in a sample collection system and then analyzed using discrete gas sensors and/or a gas chromatograph. Thegas analyzer 412 and the solenoid-controlledvalve 406 are connected to acomputer system 420 which may be a general purpose computer.Computer system 420 controls solenoid-controlledvalve 406 and receives data fromgas analyzer 412.Computer system 420 analyzes the gas concentrations in the gas exhaled by the patient and factors the relative values with inspired gas volume and other parameters to calculate factors related to collateral ventilation and pneumostoma function. The output ofgas analyzer 412 may be provided tocomputer system 420 to display the results of the gas analysis.Computer system 420 preferably records the results of the gas measurement and analysis and allows the physician to compare the results of the gas measurement/analysis with prior results for the same patient. - Introduction of diagnostic gases through a pneumostoma may also be used to enhance imaging the lung with a CT scan or NMR scan. For example polarized Helium-3 may be utilized to enhance nuclear magnetic resonance/magnetic resonance imaging of the lung (analogous to the way contrast agents enhance X-ray imaging). For example, polarized helium-3 may be produced with lasers and the magnetized pressurized gas may be stored for several days. When introduced into the lung, the polarized helium-3 can be imaged with an MRI-like scanner which produces breath-by-breath images of lung ventilation, in real-time. Polarized helium-3 may thus, be used to visualize airways in static or dynamic fashion. Alternative gases which may be used as visualization agents include gaseous radionuclide xenon or technetium DTPA in an aerosol form.
- Introducing a controlled amount of a visualizable gas, e.g. polarized Helium-3, through the pneumostoma and imaging the diffusion of the gas into the lung over time may be utilized for quantitative evaluation of the function of the pneumostoma and the prevalence of collateral ventilation pathways connecting the pneumostoma to the parenchymal tissue of the lung. Measuring the time-course variations in diffusion of Helium-3 into the lung allows analysis of diffusion coefficients for areas of the lung. Such evaluation may be useful in determining the effectiveness of a pneumostoma and the location and/or desirability of additional pneumostomas. A source of polarized Helium-3 may be connected to a PMD and/or pneumostoma using one of the several techniques and mechanisms described herein.
-
FIG. 4C shows a schematic view of a lung assessment system using a diagnostic gas in conjunction with animaging scanner 450.Scanner 450 may be an MRI, NMR, CT or X-Ray so long as the particular diagnostic gas used may be successfully imaged with the system. As shown inFIG. 4B ,gas analysis device 400 is inserted into thepneumostoma 110 of a patient.Gas analysis device 400 is connected bytube 430 to a pressure-regulated source of a visualizable gas (e.g. polarized Helium-3). A solenoid-controlledvalve 432 intube 430 controls the flow of diagnostic gas intopneumostoma 110. Thescanner 450 and the solenoid-controlledvalve 432 are connected to a computer system 420 (not shown) which may be a general purpose computer. The computer system 420 (not shown) controls solenoid-controlledvalve 432 and receives data fromscanner 450. Thecomputer system 420 coordinates the introduction of diagnostic gas into the patient with the patient's breathing and also with the operations ofscanner 450 in order to accurately image dispersion of the diagnostic gas from thepneumostoma 110 to other parts of the lung.Computer system 420 analyzes the time course distribution of the diagnostic gas from the pneumostoma into the lung tissues to calculate factors related to collateral ventilation and pneumostoma function, e.g. diffusion coefficients. -
FIGS. 4D and 4E show views of thegas analysis device 400 ofFIGS. 4A-4C .FIG. 4D shows a perspective view of thegas analysis device 400 whileFIG. 4E shows a sectional view ofgas analysis device 400 positioned within a pneumostoma. In general terms,gas analysis device 400 is a device which can be secured into a pneumostoma for sampling gases exiting the pneumostoma and/or providing gases into the pneumostoma.Gas analysis device 400 can form part of a system which utilizes such gas sampling or gas provision for assessment of pneumostoma function and/or lung function. As used inFIGS. 4A and 4C ,gas analysis device 400 is used to introduce diagnostic gas into the pneumostoma. As used inFIG. 4B ,gas analysis device 400 is used to collect gases exhaled from the lung for analysis bygas analyzer 412. - Referring to
FIG. 4D ,gas analysis device 400 includes ahollow tube 460 for insertion into the pneumostoma.Hollow tube 460 is surrounded by aflange 462 which securestube 460 in position in the pneumostoma.Hollow tube 460 connects to acoupling 464 on the proximal side offlange 462. Coupling 464 is configured so that tube 402 (shown inFIG. 4E ) may be readily connected and disconnected.Hollow tube 460 has one ormore holes 466 at the distal end through which gas may pass into or out of a pneumostoma.Hollow tube 460 andflange 462 also provide a temporary seal which inhibits leakage of gas from aroundhollow tube 460. -
FIG. 4E shows a sectional view ofgas analysis device 400 ofFIGS. 4A-4D in position in apneumostoma 110. It is preferable to minimize leakage of gases into or out of the pneumostoma.Flange 462 is thus provided with anadhesive coating 468 on the distal surface to provide a temporary seal between thegas analysis device 400 and the skin of the chest of the patient. Surface features may also be provided on the distal surface offlange 462 or ontube 460 to promote sealing betweengas analysis device 400 and the pneumostoma. For example, acircular ridge 470 is shown in section onFIG. 4E .Gas analysis device 400 is preferably a disposable component that will be used only with one patient. One or more filters may be interposed betweengas analysis device 400 and the gas supply and/or gas analyzer to prevent possible cross-contamination between patients. - Based upon the assessment of the pneumostoma, it may be necessary or desirable to treat the pneumostoma in order to preserve and/or enhance the health and/or functionality of the pneumostoma. A principal purpose of the pneumostoma is to permit the escape of gases trapped in the lung thereby reducing the lung volume and ameliorating symptoms of COPD such as dyspnea and anoxia. To serve this purpose gases should be able to enter the pneumostoma from the parenchymal tissue of the lung. High rates of air flow are not required. However, if the pneumostoma becomes completely obstructed then it will no longer permit the escape of gases trapped in the lung. The function of the pneumostoma may be impaired by, among other causes, the encroachment of tissues into the pneumostoma, obstruction with secretions, discharge and/or foreign objects, inflammation and/or infection. For example, encroaching tissues may impair the patency and functionality of the pneumostoma.
- The pneumostoma and surrounding tissues may be treated using a number of different treatment modalities to maintain and/or enhance patency, remove obstructions, decrease inflammation and prevent infection. The treatment modalities include: suction, irrigation, lavage, mechanical agitation, ultrasound, infrasound, mechanical dilation, balloon dilatation, cryotherapy, and energy treatment (including e.g. UV, light, LASER, LED, IR, heat, RF and electrocautery). The physician may select from among the several treatment modalities a treatment modality most appropriate for the conditions observed during the pneumostoma assessment.
- The treatment modalities available for treating a pneumostoma include suction, irrigation, mechanical agitation and lavage. These treatment modalities are suitable for removing obstructions and discharge from the pneumostoma, cleaning the pneumostoma and treating the tissues of the pneumostoma. Additional methods and devices for applying suction to a pneumostoma are disclosed in applicant's U.S. Provisional Patent Application 61/084,559 titled “Aspirator For Pneumostoma Management” which is incorporated herein by reference. An aspirator may be used without irrigation for the removal of liquid/soft discharge and materials from the pneumostoma.
-
FIGS. 5A-5C illustrate a device for treating a pneumostoma with suction, irrigation, mechanical irritation and/or lavage. As shown inFIG. 5A , a suction-irrigation device 500 includes abody 510 attached to a suction-irrigation probe 520. Suction-irrigation probe 520 includes amulti-lumen tube 522 and aflange 524. As shown in the sectional viewFIG. 5B of suction-irrigation probe 520,multi-lumen tube 522 has anouter lumen 521 and aninner lumen 523. Referring again toFIG. 5A ,multi-lumen tube 522 has a number ofside apertures 526 for releasing fluid from theouter lumen 521.Multi-lumen tube 522 has adistal aperture 528 in the distal tip for applying suction and removing fluid via theinner lumen 523.Distal aperture 528 may be provided with a cage or mesh covering to prevent damage to tissues and/or obstruction ofdistal aperture 528.Multi-lumen tube 522 also supports a plurality ofsoft bristles 530 for mechanically agitating the surface of a pneumostoma. Although bristles are shown, other mechanical features may be used to assist the removal of material which may be adhered to the tissue of the pneumostoma, for example ribs, fingers or surface roughness. - Referring now to
FIG. 5C ,suction irrigation probe 520 is connected to abody 510 by acoupling 532 which mounts releasably to amating coupling 512 onbody 510.Body 510 is also connected to a pressure-regulated supply of irrigation fluid and a pressure-regulated vacuum supply (not shown). The irrigation supply and vacuum supply are attached or connected to anirrigation conduit 514 andsuction conduit 516 withinbody 510. Thecouplings irrigation probe 520 tobody 510. Thecouplings multi-lumen tube 522 in fluid communication with theirrigation conduit 514 andsuction conduit 516 withinbody 510. Thereleasable couplings irrigation probe 520 to be removed, and either cleaned and replaced, or disposed of and replaced.Couplings -
FIG. 5C shows a sectional view of suction-irrigation device 500 with suction-irrigation probe 520 inserted into apneumostoma 110. As shown inFIG. 5C , irrigation fluid exits throughside apertures 526 and is collected throughdistal aperture 528.Bristles 530 contact the tissue of thepneumostoma 110. Suction-irrigation probe 520 may be moved in and out ofpneumostoma 110 so that bristles 530 dislodge any material stuck on the side ofpneumostoma 110. The irrigation fluid serves to move any dislodged materials intoaperture 528.Flange 524 serves to prevent over-insertion of suction-irrigation probe 520 and also to prevent excessive leakage of irrigation fluid from the pneumostoma. In some embodiments,flange 524 may be configured to slide up and downmulti-lumen tube 522 such that the depth of the distal end ofprobe 520 may be adjusted while the flange remains in contact with the chest of the patient. In other embodiments,flange 524 may be fixed or adjustably fixed tomulti-lumen tube 522. - Suction-
irrigation device 500 may include additional features to facilitate removal of material from the pneumostoma. For example, suction-irrigation device 500 may include a visualization system to permit the physician to guide suction-irrigation probe 520 and visualize the tissues insidepneumostoma 110. See, e.g.FIGS. 3A-3C and accompanying text. Suction-irrigation device 500 may also include an ultrasound generator or another device to agitatebristles 530 and the irrigation fluid to aid in the mechanical removal of materials from thepneumostoma 110.Suction irrigation device 500 may also include a trap for trapping any solid materials dislodged from the pneumostoma. For irrigation, a sterile but inert solution may be used. For example, sterile saline or sterile water may be used. The irrigation fluid will typically be sterile water or saline solution. In some cases, it may be desirable to use a medicated irrigation fluid. For example, an antibacterial or mucolytic solution may be used. In such cases a small concentration of the therapeutic agent is added to the sterile water or saline. Suitable therapeutic agents include anti-inflammatories, antibiotics and anti-stenosis compounds. The irrigation fluid may also include a small concentration of an agent for maintaining the patency of the pneumostoma, for example, Paclitaxel. The cleaning solution should be formulated carefully to avoid injury or irritation to the lung. -
FIG. 5D illustrates a method for treatment of a pneumostoma. First, based on, for example, information from the patient or observation of the pneumostoma, the physician makes a determination to treat the pneumostoma with one or more of suction, irrigation and/or lavage. (step 580). The physician next selects and/or configures an aspirator/irrigator suitable to treat the pneumostoma of a particular patient. (step 582). The selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma. As pneumostomas may vary in size, the aspirator/irrigator may have a configurable size, or may have a range of differentsized probes 520. Thus selection of the aspirator/irrigator includes selecting/configuring the aspirator/irrigator for the pneumostoma of a particular patient. If irrigation/lavage is to be performed, the physician should also select and/or prepare the irrigation fluid (step 584). - After the aspirator/irrigator and optional irrigation fluid is ready, the pneumostoma management device will be removed from the pneumostoma (step 586). The pneumostoma should then be externally inspected (step 588) to determine whether there are any contraindications to use of the aspirator/irrigator, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the aspirator/irrigator is introduced into the pneumostoma (step 590). The physician may then position the flange so as to prevent excess leakage from the pneumostoma (step 592). The physician will the apply suction to remove materials from the pneumostoma (step 594). While suction is applied the physician may also provide irrigation/lavage and or agitation to dislodge materials for removal (
step 594.) The physician may advance the aspirator/irrigator incrementally further into the pneumostoma and repeats the treatment (step 594) until reaching the end of the pneumostoma. When the treatment is completed the aspirator/irrigator is removed (step 596). A PMD should be inserted into the pneumostoma promptly after removal of the aspirator/irrigator either by the physician, or by the patient under the observation of the physician (step 598). In some cases, treatment with the aspirator/irrigator is made in conjunction with inspection of the pneumostoma with a pneumoscope. In such case, the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma. - The treatment modalities available for treating a pneumostoma include the use of sound waves. Sound waves can be used to agitate the walls of the pneumostoma to dislodge materials. Sound waves of different frequencies may be of use, including infrasound below 20 Hz, acoustic sound waves between 20 Hz and 20 KHz and ultrasound above 20 KHz. These treatment modalities are suitable for removing obstructions and discharge from the pneumostoma, cleaning the pneumostoma and treating the tissues of the pneumostoma to enhance and/or maintain patency of the pneumostoma. The amplitude, frequency and duration of sound waves supplied may be selected to achieve the desired effects. In some cases the amplitude, frequency and duration of the sound waves may be sufficient to kill cells, inhibit proliferation of cells or disrupt cells and connective tissue in order to enhance or maintain the patency of the pneumostoma. In other cases, the sound waves may be selected to dislodge materials e.g. discharge, which may be adhered to the tissues of the pneumostoma. In some embodiments, ultrasound may be used in conjunction with suction/irrigation to remove materials from the pneumostoma.
-
FIG. 6A shows a sectional view of anultrasound device 600 for use in apneumostoma 110.Ultrasound device 600 includes abody 610 containing anultrasonic transducer 612 coupled by acoupling 614 to anultrasound probe 620.Ultrasonic transducer 612 is coupled toultrasound probe 620 so that, when energized,ultrasonic transducer 612 transmits ultrasound intoultrasound probe 620.Ultrasound device 600 includes withinbody 610, aswitch 617, acontroller 616 andpower supply 618. The physician operatesswitch 617 to causecontroller 616 to energizeultrasonic transducer 612. In preferred embodiments,controller 616 energizesultrasonic transducer 612 for a predefined and limited period of time. -
Ultrasound probe 620 is sized and configured to enterpneumostoma 110 and conduct ultrasound energy fromultrasonic transducer 612 to the walls of the pneumostoma and any materials adhered thereto.Ultrasound probe 620 may also include aflange 622 which serves as protection against over insertion ofprobe 620. A biocompatible gel or liquid (not shown) may be used withultrasound probe 620 to enhance the conduction of ultrasonic waves fromultrasound probe 620 to tissues of the pneumostoma. In such case,flange 622 may also be useful to create a temporary seal to retain the gel or liquid withpneumostoma 110 during the ultrasound treatment. In some embodiments,ultrasound probe 620 may be provided with a channel to provide suction to remove any materials dislodged by the ultrasound. Alternatively, a separate suction/irrigation device may be utilized to remove materials from the pneumostoma after treatment with theultrasound probe 620. -
FIG. 6B shows a schematic view of alternatesound delivery device 650 for use in apneumostoma 110.Sound delivery device 650 includes abody 660 containing aspeaker 662 which typically comprises a magnetically-driven armature or diaphragm.Speaker 662 generates acoustic and/or infrasound waves inchamber 664.Chamber 664 is in communication viacoupling 668 withsound probe 670. As shown inFIG. 6B ,sound probe 670 is a hollow tube for holding open the pneumostoma and delivering the sound waves into the pneumostoma.Sound probe 670 may have one or more apertures. A baffle may be provided aroundsound probe 670 to concentrate pressure waves induced by the speaker with the pneumostoma. Alternatively,sound probe 670 may be a solid probe coupled to the armature ofspeaker 662 or a suitable transducer. In alternative embodiments, the sound may be generated by a speaker located within the probe which is thus located within the pneumostoma during use. The energy delivered bysound delivery device 650 serves to dislodge materials from the pneumostoma and/or disrupt the connective tissue of the pneumostoma. In some embodiments,sound probe 670 may be provided with a channel to provide suction to remove any materials dislodged by the sound waves. Alternatively, a separate suction/irrigation device may be utilized to remove materials from the pneumostoma after treatment with thesound delivery device 650. -
FIG. 6C illustrates a method for treatment of a pneumostoma. First, based on, for example, information from the patient or observation of the pneumostoma, the physician makes a determination to treat the pneumostoma with one or more of acoustic sound, infrasound, and/or ultrasound. (step 680). The physician next selects and/or configures a sound/ultrasound device suitable to treat the pneumostoma of a particular patient. (step 682). The selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma. As pneumostomas may vary in size, the sound/ultrasound device may have a configurable size, or may have a range of differentsized probes - After the sound/ultrasound device and optional sound-conducting fluid is ready, the pneumostoma management device will be removed from the pneumostoma (step 686). The pneumostoma should then be externally inspected (step 688) to determine whether there are any contraindications to use of the sound/ultrasound device, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the sound/ultrasound device is introduced into the pneumostoma (step 690). The physician may then position the flange so as to prevent excess leakage from the pneumostoma (step 692). The physician will then energize the sound/ultrasound probe for a selected period of time (step 694). The physician may advance the sound/ultrasound device incrementally further into the pneumostoma and repeat the treatment (step 694) until reaching the end of the pneumostoma. When the treatment is completed the sound/ultrasound device is removed (step 696). A PMD should be inserted into the pneumostoma promptly after removal of the aspirator/irrigator either by the physician, or by the patient under the observation of the physician (step 698).
- In some cases, treatment with the sound/ultrasound device is made in conjunction with inspection of the pneumostoma with a pneumoscope. In such case, the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma. It may also be desirable to clean the pneumostoma with suction/irrigation prior to reinsertion of the PMD in order to remove any materials that may have been dislodged during the treatment.
- The treatment modalities available for treating a pneumostoma include the use of mechanical dilatation. Overtime, the natural healing response of the body may cause tissues to encroach into the lumen of the pneumostoma. Additionally, the tissues bordering the pneumostoma may thicken over time reducing the permeability of the pneumostoma walls to gases. A dilator may be used to stretch the tissues of the pneumostoma to maintain the patency of the pneumostoma. Dilatation not only increases the size of the lumen of the pneumostoma but also thins the tissues surrounding the pneumostoma. This thinning of the tissues bordering the pneumostoma in the lung may enhance the ability of air to enter the pneumostoma from the parenchymal tissue of the lung thereby enhancing the functionality of the pneumostoma. In embodiments, a dilator comprises an expander which can be inserted into the pneumostoma at a first contracted size and then expanded to a desired expanded size thereby stretching the pneumostoma. In preferred embodiments the dilator comprises an indicator outside the body which indicates the extent to which the expander has been expanded and/or an adjustable limiter which limits expansion of the expander to a safe amount.
-
FIGS. 7A-7D show views of one embodiment ofmechanical dilator 700. As shown inFIG. 7A ,mechanical dilator 700 comprises ahandle 710, ashaft 720 and anexpander 730. Handle 710 includes twoarms pivot 714. Aspring mechanism 716biases arms screw mechanism 717 may be used to lockarms limit mechanism 715 may be used to limit the approach ofarm 712a towardsarm 712b in order to prevent over expansion of theexpander 730. Handle 710 is connected toshaft 720.Arm 712a, is fixedly connected to the exterior ofshaft 720,arm 712 b is pivotally connected toinner shaft 722. Movingarm 712 b towardsarm 712 a movesinner shaft 722 more distally relative toshaft 720. Handle 710 also includes agauge 718 marked to indicate the amount of expansion ofexpander 730.Gauge 718 is fixed to arm 712 a. Anindicator 719 fixed toarm 712 b moves alonggauge 718 as the arms are moved towards each other thereby expandingexpander 730. The markings ongauge 718 correspond to the expansion ofexpander 730. -
Shaft 720 is sized so as to fit into the pneumostoma.Shaft 720 may be provided withmarkings 724 on the exterior surface so the physician may determine the depth to which the distal tip ofexpander 730 has been inserted in the pneumostoma.Expander 730 includes twoblades Blades blades shaft 720.Blades distal tip 734 in their collapsed configuration to facilitate insertion ofexpander 730 into the pneumostoma. -
FIG. 7B shows mechanical dilator inserted into a pneumostoma 110 (shown in section). As shown inFIG. 7B , themechanical dilator 700 is inserted into thepneumostoma 110 in the collapsed configuration ofFIG. 7A until it is located at the desired depth in the pneumostoma as indicated by themarkings 724. In some situations,mechanical dilator 700 may be used to measure the diameter of a pneumostoma. The expander may be inserted into the pneumostoma and the handles compressed until resistance is felt. Theindicator 719 will indicate ongauge 718 the degree of expansion ofexpander 730 at this point of first resistance and thus indicate the internal diameter of the pneumostoma.Limit mechanism 715 may then be positioned to allow only a desired amount of incremental expansion of the pneumostoma compared to the measured initial diameter of the pneumostoma. In alternative embodiments, a fixed or adjustable flange (not shown) may be provided mounted onshaft 720. The flange serves as mechanical stop to limit insertion of themechanical dilator 700 at a fixed or adjustable depth. -
FIG. 7C shows a close-up view of theexpander 730 in an expanded configuration. As shown inFIG. 7C , each ofblades linkages shaft 720. Each ofblades inner shaft 722 bylinkages Linkages blades FIG. 7A . In alternative embodiments,expander 730 may have 3 or more blades, each blade taking up a fractional portion of the circumference of the device and each blade having three linkages connecting the blade to the distal end ofinner shaft 722. Asinner shaft 722 moves in the direction ofarrow 704,blades arrows -
FIG. 7D showsmechanical dilator 700 positioned in apneumostoma 110. As shown inFIG. 7D ,expander 730 is positioned within the pneumostoma at the desired depth. Handle 712 b has been pushed towardshandle 712 a until it makes contact withlimit mechanism 715. Handle 712 b may optionally be locked into position withscrew mechanism 717.Inner shaft 722 has been pushed distally relative toshaft 720.Linkages 738 a, 738, b, 738 c, 738 d have thus forcedblades expander 730 to adopt the expanded position shown inFIG. 7C (seeFIGS. 7B and 7C for identification of the components of expander 730). Note thatindicator 719 has moved alonggauge 718 to indicate the amount of expansion ofexpander 730. - In practice,
mechanical dilator 700 is preferably expanded a small amount and then locked in place as the tissues of the pneumostoma relax.Mechanical dilator 700 is then expanded another small amount and then locked in place again as the tissues of the pneumostoma relax. A number of incremental expansion steps may be performed until the desired diameter of the pneumostoma is achieved. The incremental steps can be controlled by incremental movement oflimit mechanism 715 andscrew mechanism 717. In some cases, it may be desirable to expand the dilator at two or more different depths in the pneumostoma so as to expand two or more different potions of the pneumostoma.Dilator 700 may then be collapsed and withdrawn from the pneumostoma. The pneumostoma will tend to contract after dilatation so it is important to insert a pneumostoma management device into the lumen of the pneumostoma upon removal of themechanical dilator 700. -
FIG. 7E illustrates a method for treatment of a pneumostoma with a dilator. First, based on, for example, information from the patient or observation of the pneumostoma, the physician makes a determination to treat the pneumostoma with a dilator. (step 740). The physician next selects and/or configures a dilator suitable to treat the pneumostoma of a particular patient. (step 742). The selected instrument is preferably sized such that it can be introduced into the pneumostoma and placed at a desired depth in the pneumostoma. As pneumostomas may vary in size, the dilator may have a configurable size, or a range of initial sizes. Thus selection of the dilator includes selecting/configuring the dilator for the pneumostoma of a particular patient such that it may be inserted into the pneumostoma to the desired depth prior to dilation. After dilation of the pneumostoma it is preferable to insert a PMD to support the pneumostoma as soon as the dilator is removed. Therefore, it is preferable to select and prepare a larger PMD for the patient to fit the anticipated dilated pneumostoma (step 744). - After the dilator and replacement PMD are, the original (smaller) pneumostoma management device will be removed from the pneumostoma (step 746). The pneumostoma should then be externally inspected (step 748) to determine whether there are any contraindications to use of the dilator, for example any obstruction of the pneumostoma which must first be removed. If the visual inspection reveals no contraindications, the dilator is introduced into the pneumostoma (step 750). The physician may then expand the dilator incrementally (step 752). The physician will then allow the tissue of the pneumostoma to relax (step 754) and repeat the incremental expansion (step 752) until the desired dilation has been achieved. The physician may also repeat the dilation at one or more depths within the pneumostoma depending upon the length of the pneumostoma. When the dilation is complete the dilator is removed (step 756). A new larger PMD should then be promptly inserted into the pneumostoma by the physician, or by the patient under the observation of the physician (step 758).
- In some cases, treatment with the sound/ultrasound device is made in conjunction with inspection of the pneumostoma with a pneumoscope. In such case, the pneumoscope may be used before and after treatment to observe effects of the treatment upon the tissue of the pneumostoma and to ensure all deleterious materials have been removed from the pneumostoma. It may also be desirable to clean the pneumostoma with suction/irrigation prior to reinsertion of the PMD in order to remove any materials that may have been dislodged during the treatment.
- Alternative means may be used to dilate the pneumostoma in alternative embodiments.
FIG. 7F shows an alternativemechanical dilator 760 andFIG. 7G shows aballoon dilator 780. Referring toFIG. 7F ,mechanical dilator 760 comprisesfirst handle 761 connected toinner shaft 762 which extends to the distal tip of themechanical dilator 760. Asecond handle 763 is connected to anouter shaft 764 which rides oninner shaft 762. At the distal end ofmechanical dilator 760 isexpander 766.Expander 766 includes a plurality offlexible elements 767 covered by apolymer shell 768. The distal end of eachflexible element 767 andpolymer shell 768 is connected to the distal end ofinner shaft 762. The proximal end of eachflexible element 767 andpolymer shell 768 is connected to the distal end ofouter shaft 764. Whenouter shaft 764 is pushed distally along inner shaft 762 (as shown by arrow 770),flexible elements 767 bend or bow outwards (as shown by arrows 771).Elements 767 push onpolymer shell 768 causing it to also bow outwards (in the direction of arrows 771). Thusmechanical dilator 760 transitions from the collapsed configuration to the expanded configuration by pushinghandle 763 distally relative to handle 761. Bothouter shaft 764 andinner shaft 762 havemarkings 765 on the exterior surface so the physician may assess the depth of insertion ofmechanical dilator 760 and the diameter of expansion ofmechanical dilator 760.Mechanical dilator 760 may be used in the same way asdilator 700 ofFIGS. 7A-7D , either for dilating the pneumostoma or assessing the diameter of the pneumostoma.Mechanical dilator 760 may additionally be provided with a locking device to hold it in an expanded position and/or a limit device to control expansion of theexpander 766. -
FIG. 7G shows aballoon dilator 780. Referring toFIG. 7F ,mechanical dilator 780 comprisesfirst handle 781 connected to ahollow shaft 782 which extends to the distal tip of theballoon dilator 780. At the distal end ofmechanical dilator 780 isballoon 786.Balloon 786 is sealed to the hollow shaft at theproximal end 787 anddistal end 788 ofballoon 786. An aperture inhollow shaft 782 communicates between the lumen of thehollow shaft 782 and the interior ofballoon 786. Asyringe 792 is connected to the proximal end ofhollow shaft 782. Whensyringe 792 is compressed (as shown by arrow 790), a liquid such as sterile saline is pushed throughhollow shaft 782 intoballoon 786 causingballoon 786 to inflate (as shown by arrows 791). Thusballoon dilator 780 transitions from the collapsed configuration to the expanded configuration by compressingsyringe 792.Hollow shaft 782 hasmarkings 785 on the exterior surface so the physician may assess the depth of insertion ofballoon dilator 780.Syringe 792 hasexterior markings 795 so that the physician may assess the volume ofballoon 786 and hence the diameter to which it has been expanded.Balloon dilator 780 may be used in the same way asdilator 700 ofFIGS. 7A-7D , either for dilating the pneumostoma or assessing the diameter of the pneumostoma. -
Balloon 786 may be formed of a relatively inelastic material. In such case, injection of the liquid into the balloon will expand the balloon to a preset size. This ensures that the balloon does not stretch the pneumostoma more than desired. Moreover, the balloon can be expanded at high pressure without risk of over-expansion. However, a number of different balloon dilators may be required having different sizes in order to treat different pneumostomas or to incrementally expand a single pneumostoma. In alternative embodiments, a relatively elastic material may be used to makeballoon 786. In such case, the balloon will have a larger diameter for larger amounts of liquid allowing broader application. However, the pressure applied by the balloon to the tissue will be lower than for an inelastic balloon. - The treatment modalities available for treating a pneumostoma include the application of heat (thermotherapy) or cold (cryotherapy). Thermotherapy and cryotherapy can be used to affect physical characteristics of tissues and cell proliferation and also to treat infection. For example, the tissues of the pneumostoma tend to encroach into the lumen of the pneumostoma thereby impairing the function of the pneumostoma. One way to reduce tissue encroachment is through the use of thermotherapy or cryotherapy thereby maintaining or enhancing the patency of the pneumostoma. In some embodiments a pneumostoma treatment device may be used to heat the tissue in others the pneumostoma treatment device may be used to cool the tissue to achieve the desired effects.
- In one method of thermotherapy, a surface of a pneumostoma treatment device is brought into contact with a target tissue of the pneumostoma. The surface of the pneumostoma treatment device is then heated to raise the temperature of the target tissue (e.g. by electrical heating, laser heating, or by circulating a heated medium). Other methods of thermotherapy include application of focused ultrasound, infrared light, radio or microwave-frequency radiation to the target tissue to induce the desired temperature rise in the target tissue. For example, thermotherapy treatment device may direct energy at the tissue to heat the target tissue. The energy may be supplied as ultrasound, electrical energy, electromagnetic energy (for example IR or laser energy). The treatment is applied for a selected period of time. After the treatment the tissue is reassessed and treated again as necessary. The treatment may be applied to the pneumostoma tissue using a range of treatment devices and modalities as described in more detail below. In preferred embodiments, the temperature and duration of the heat treatment are selected to affect physical characteristics of tissues, reduce cell proliferation and/or treat infection but not to kill tissues of the pneumostoma.
- Methods of cryotherapy include placing the target tissues in thermal contact with a cooled device or medium to lower the temperature of the target tissue. Cryotherapy may be used in two modes. The first mode of cryotherapy is cryogenic ablation in which cryotherapy is used to freeze tissue. A device is used to lower the temperature of the target cells to temperatures below freezing for short periods of time. The cells in the frozen tissue die and the tissue is removed. However, it is a disadvantage of tissue ablation that the cell necrosis stimulates the healing response. The healing response causes cell proliferation and generation of more cells in the form of scar tissue. As a result, cryogenic ablation may ultimately lead to greater tissue encroachment rather than less tissue encroachment. Cryogenic ablation may however still be useful for treating regions where tissue is encroaching into the pneumostoma.
- A second mode of cryotherapy is cryogenic cooling in which cells are cooled below physiologic temperatures without freezing the cells. A device is used to lower the temperature of the target cells to temperatures between normal physiologic temperatures and a temperature above freezing for short periods of time. Cryogenic cooling has been found to reduce hyperplasia in blood vessels. See e.g. U.S. Pat. No. 6,811,550 entitled “Safety Cryotherapy Catheter” to Holland et al. Cryogenic cooling may also be used to his mode of cryotherapy to treat larger areas of the pneumostoma including up to the entire pneumostoma. In preferred embodiments, the temperature and duration of the cryotherapy are selected to affect physical characteristics of tissues, reduce cell proliferation and/or treat infection but not to kill tissues of the pneumostoma.
-
FIGS. 8A-8C show a catheter which may be used for cryotherapy or thermotherapy of a pneumostoma tissues. As shown inFIG. 8A ,catheter 800 includes ashaft 802, aballoon 804 and aflange 806.Flange 806 slides on the exterior ofshaft 802 and acts as a mechanical stop for insertion ofshaft 802 into a pneumostoma. The positioning offlange 806 onshaft 802 allows the physician to control the depth ofballoon 804 and thus the location of the treatment area. Theshaft 802 is provided withexternal markings 805 to indicate the distance between the treatment area andflange 806 thereby facilitating application of the treatment to the desired target tissues. - As shown in
FIG. 8B ,shaft 802 has two lumens ininner lumen 808 andouter lumen 810. In someembodiments shaft 802 may be coated with an insulatinglayer 803 so that treatment is limited to the region of theballoon 804. The balloon may then be moved to different locations in the pneumostoma to treat different areas. In other embodiments,shaft 802 is not insulated and is also designed to treat the tissues of the pneumostoma in addition to the balloon. In such cases, it is preferable that treatment is performed at a single position (because to do otherwise would treat areas along theshaft 802 multiple times). As shown inFIG. 8C , at the proximal end ofshaft 802 are aninlet 809 which communicates withinner lumen 808 and anoutlet 811 which communicates withouter lumen 810. - As used for cryotherapy,
catheter 800 is introduced in to thepneumostoma 110 to a depth limited byflange 806 as shown inFIG. 8C .Cryotherapy catheter 800 is connected to acryotherapy coolant system 819 which supplies a temperature-controlled coolant fluid tocryotherapy catheter 800. A coolant fluid is introduced throughinlet 809 intoinner lumen 808. The coolant passes throughinner lumen 808 to the distal end ofcryogenic catheter 800. The coolant passes through an aperture out ofinner lumen 808 into theballoon 804. The coolant inflatesballoon 804 to bring it into contact with the tissue of thepneumostoma 110. The coolant circulates aroundballoon 804 and cools the surface ofballoon 804 to the desired temperature. The coolant then returns through theouter lumen 810 and exits the catheter via theoutlet 811. In some embodiments, a temperature sensor may be included in the distal tip ofcryotherapy catheter 800 in order to monitor the temperature of the balloon. However, in other embodiments, temperature regulation is performed by regulating the temperature of the coolant supplied by the cryotherapy coolant system. - The coolant fluid is preferably a non-toxic liquid such as saline. However, liquids other than saline may be used and in some cases the coolant fluid may be a temperature-controlled gas. One system for supplying coolant is described in U.S. Pat. No. 6,432,102 entitled “Cryosurgical Fluid Supply” to Joye et al. If thermotherapy of the tissues is desired, a fluid heated to above body-temperature may be used in place of the coolant.
-
FIG. 8D shows analternative cryotherapy probe 820.Cryotherapy probe 820 includes ashaft 821 andtip 822.Tip 822 is of fixed size and is preferably made of a heat conductive material.Tip 822 may be made in whole or in part of a biocompatible metal, for example surgical steel.Tip 822 may be made in one piece withshaft 821 or may be made separately and joined toshaft 821. As shown inFIG. 8E , shaft 821 (shown inFIG. 8D ) includes twolumens FIG. 8D ).Tip 822 has acavity 828 in which the coolant circulates. At the proximal end ofcryotherapy probe 820 is aninlet 834 which communicates withlumen 824 and anoutlet 836 which communicates withlumen 826. In some embodiments,shaft 820 may be coated with an insulatinglayer 823 so that treatment is limited to the region of thetip 822.Shaft 821 may be coated with an insulatingmaterial 823 in order that the cryotherapy treatment is localized to the region oftip 822. Thetip 822 may then be moved to different locations in the pneumostoma to treat different areas. - The size of
tip 822 may differ between different cryotherapy probes 820. A physician may have a range of cryotherapy probes available and choose the cryotherapy probe based upon the anatomy of the pneumostoma and the size and location of the tissues to be treated.Cryotherapy probe 820 may optionally be provided with aflange 830 positionable alongshaft 821 in order to limit insertion oftip 822 into the pneumostoma and thereby control the location oftip 822 and the location of the cryotherapy treatment site. - In use,
cryotherapy probe 820 is introduced into a pneumostoma to a position indicated by the markings on the exterior of theshaft 821 or position of theflange 830.Tip 822 is brought into thermal contact with the pneumostoma tissues to be treated.Cryotherapy probe 820 is connected to acryotherapy coolant system 819. A coolant fluid is introduced throughinlet 834 intolumen 824. The coolant passes throughlumen 824 to the distal end ofcryotherapy probe 820. The coolant passes through an aperture out oflumen 824 into thecavity 828. The coolant circulates aroundcavity 828 and cools the surface oftip 822 to the desired temperature. The coolant then returns throughlumen 826 and exits the probe via theoutlet 836. In some embodiments a temperature sensor may be included in thetip 822 ofcryotherapy probe 820 in order to monitor the temperature of the tip. However, in other embodiments, temperature regulation is performed by regulating the temperature of the coolant supplied by the cryotherapy coolant system. For thermotherapy, a heated fluid may be circulated through the probe in place of the coolant. - The treatment modalities available for treating a pneumostoma include the application of energy in the form of electromagnetic radiation, for example, infrared, ultraviolet, visible light, RF, microwaves. Such energy treatment can be used to affect physical characteristics of tissues and cell proliferation and also to treat infection. For example, the tissues of the pneumostoma tend to encroach into the lumen of the pneumostoma and/or thicken the walls of the pneumostoma thereby impairing the function of the pneumostoma. One way to reduce tissue encroachment and/or thickness is through the application of energy to the tissues, either to kill the cells or to reduce their proliferation thereby maintaining or enhancing the patency of the pneumostoma. In some embodiments a pneumostoma treatment device may be used to direct energy to particular localized regions of the pneumostoma tissue, in other embodiments, the pneumostoma treatment device may apply energy equally in all directions. In other embodiments, the electromagnetic radiation may be selected to kill or damage bacteria to reduce infection while minimizing damage to the cells of the pneumostoma. Some frequencies of visible light, for example, have been shown to kill certain bacteria without causing significant damage to human cells.
-
FIG. 9A illustrates apneumostoma treatment device 900 for treatment of pneumostoma tissues with electromagnetic radiation. The device includes ashaft 902 having at its distal end atreatment head 904. The treatment head has a tapered or roundedtip 920 to facilitate introduction into the pneumostoma. Thetreatment head 904 may generate electromagnetic radiation in situ, or the electromagnetic radiation may be transmitted from an external source to thetreatment head 904. The treatment head may in some cases have awindow 905 which is either open or covered with a material transparent to the electromagnetic radiation to be transmitted. In other cases theentire treatment head 904 may be enclosed in a material which is transparent to the delivered electromagnetic radiation. - At the proximal end the
pneumostoma treatment device 900 has acoupling 912 for connecting thepneumostoma treatment device 900 to a power source which may provide the electromagnetic radiation directly or provide electrical power to create electromagnetic radiation in thetreatment head 904. Coupling 912 may be connected toshaft 910 by aflexible cable 914. The proximal end ofshaft 902 may also provide access tolumens 916 which communicate withapertures 918adjacent treatment head 904.Lumens 916 andapertures 918 optionally provide suction, irrigation and/or cooling to the regionadjacent treatment head 904 as necessary and/or desirable for a particular treatment modality. - The
shaft 902 andtreatment head 904 are of suitable diameter for insertion into a pneumostoma. Typically theshaft 902 andtreatment head 904 will be less than approximately 10 mm in diameter. In some cases the shaft and treatment head may be approximately 5 mm in diameter. Theshaft 902 is flexible enough to allow insertion of thetreatment head 904 into a pneumostoma even when the pneumostoma is not entirely straight. Theshaft 902 should however be stiff enough that it can provide adequate force to push thetreatment head 904 to the correct location in the pneumostoma. - The pneumostoma treatment device carries a
flange 906 which can slide onshaft 902. Theflange 906 has alocking collar 908 to fix theflange 906 at an adjustable position along theshaft 902, other locking means may be used, for example, a suture, tape glue or mechanical lock. The physician will typically adjust the location of theflange 906 along theshaft 902 so that when thetreatment head 904 andshaft 902 are inserted to the desired depth into a pneumostoma, the flange contacts the chest of the patient and prevent further insertion. Correct pre-positioning of theflange 906 onshaft 902 serves to guide treatment depth and protect against over insertion. Theshaft 902 may also be provided withexternal markings 910 so that the physician may determine the correct location forflange 906 and the corresponding depth oftreatment head 904. -
FIG. 9B shows a sectional view ofpneumostoma treatment device 900 inserted into apneumostoma 110. Note thatflange 906 is in contact with theskin 114 of thechest 100 of the patient and thus acts as a mechanical stop to prevent further insertion.Flange 906 may additionally be provided with an adhesive (not shown) to temporarily secure theflange 906 to theskin 114 of thechest 100 of the patient thereby securing thetreatment head 904 at the desired depth within thepneumostoma 110. Coupling 912 connectscontroller 922 viacable 914 to the proximal end ofshaft 902 and viashaft 902 totreatment head 904.Controller 922 may be used to control the provision of electromagnetic radiation bytreatment head 904. Controller may control one or more of: the location, intensity, wavelength and/or duration of the application of the electromagnetic radiation as directed by a physician. - The
treatment head 904 may be designed so that it delivers electromagnetic radiation equally in all directions thereby treating uniformly all of the tissues adjacent the treatment head. In alternativeembodiments treatment head 904 may be designed such that it applies the electromagnetic radiation in a directional manner—this adds additional complexity in that a mechanism needs to be provided for aligning the electromagnetic radiation with the target tissues. However, the directional solution allows for different tissues within the pneumostoma to be treated differently and also different regions to be treated differently from other regions. Directionality may be provided, for example, using scanning optics to aim a beam of electromagnetic radiation provided bycontroller 922 through a fiber optic cable. -
FIG. 9C shows a sectional view of apneumostoma treatment device 930 for treatment of pneumostoma tissues with electromagnetic radiation. The device includes ashaft 932 having at its distal end atreatment head 934. Theshaft 932 carries aflange 936 which can slide onshaft 932. One ormore lumens 946 passes along the length ofshaft 932 to one ormore aperture 948adjacent treatment head 934.Lumens 946 andapertures 948 optionally provide suction, irrigation and/or cooling to the regionadjacent treatment head 934 as necessary and/or desirable to enhance treatment or protect tissue during treatment. At the proximal end thepneumostoma treatment device 930 has acoupling 942 for connecting thepneumostoma treatment device 930 to apower source 940 which provides electrical power throughcable 944 to create electromagnetic radiation in thetreatment head 934. - In the embodiment shown in
FIG. 9C , thetreatment head 934 generates electromagnetic radiation in situ. Thetreatment head 934 is enclosed in a material which is transparent to the delivered electromagnetic radiation. As shown inFIG. 9C thetreatment head 934 radiates electromagnetic radiation in all directions uniformly fromsource 935 located withinhead 934.Source 935, generates the desired electromagnetic radiation from electrical power provided bypower source 940. The source may be for example, a source of IR, UV visible light, X-rays or other electromagnetic radiation with which it is desired to treat the tissue of the pneumostoma. Particular devices suitable for use assource 935 include for example incandescent light sources, LEDs, fluorescent lamps and miniature X-ray sources. The source may be provided with additional features to ensure uniformity of distribution of the selected electromagnetic radiation including, for example a collimator, diffuser, and or reflector. -
FIG. 9D shows a sectional view of apneumostoma treatment device 950 for treatment of pneumostoma tissues with electromagnetic radiation. The device includes ashaft 952 having at its distal end atreatment head 954. Theshaft 952 carries aflange 956 which can slide onshaft 952.Flange 956 may be locked toshaft 952 and secured to the chest of the patient so thathead 954 may be secured in a fixed relation to the pneumostoma during operation ofpneumostoma treatment device 950. At the proximal end thepneumostoma treatment device 950 has acoupling 962 for connecting thepneumostoma treatment device 950 to acontroller 960 which provides light and power throughcable 964 totreatment head 954. - In the embodiment shown in
FIG. 9D , thetreatment head 954 does not generate electromagnetic radiation in situ. Instead, the electromagnetic radiation is generated bycontroller 960 and transmitted through anoptical fiber 953 totreatment head 954. Thetreatment head 954 is enclosed in a material which is transparent to the delivered electromagnetic radiation. As shown inFIG. 9D , thetreatment head 954 includesscanning optics 958 which direct the electromagnetic radiation in a particular direction under the control ofcontroller 960.Controller 960 generates the desired electromagnetic radiation, transmits it to head 954 which directs it to a particular region of tissue of the pneumostoma.Controller 960 is connected to acomputer system 964 which provides the physician with aninterface 966 to operatecontroller 960 andcontrol head 954 to treat selected target tissues within a pneumostoma. -
Controller 960 may generate one or more selectable frequencies of electromagnetic radiation.Controller 960 may, for example include a tunable laser source cable of generating coherent light over a range of different frequencies. The light frequency and intensity may be selected based upon the effect desired. For example, in some case the light frequency and intensity may be selected to ablate certain target tissues in the pneumostoma. Tissue ablation may be used to generate pores in the wall of the pneumostoma to enhance patency of the pneumostoma and/or restore pathways for gas to exit the pneumostoma. - In some embodiments, the scanning optics may also receive light received back from the tissue, which light may pass back down the fiber optic to
controller 960. The received light may be analyzed using tissue spectroscopy and/or tomography techniques to determine properties of the particular tissue from which the light is received. In such way thehead 954 can be used to analyze the tissue of the pneumostoma in addition to, or instead of, treating the tissue. Tissue scanning may be used in order to select target tissues for e.g. ablation to enhance the selectivity of treatment and reduce damage to sensitive tissue. For example, tissue scanning may be used to ensure that tissue ablation avoids blood vessels in proximity to the pneumostoma when forming pores to restore or enhance the exit of gas through the pneumostoma. - Because of the proximity of blood vessels to the surface of the pneumostoma, the pneumostoma may also be used as a port for analysis of compounds in the bloodstream. For example analysis of blood gases, and/or glucose concentration. The analysis can be performed by scanning the thin tissues of the pneumostoma and analyzing the light received from the tissues. Information in the received light at different frequencies and in a number of modes (for example scattering, reflectance, absorption and fluorescence) may be used to derive detailed information regarding the tissues of the pneumostoma and blood in vessels immediately adjacent the pneumostoma
- The foregoing description of preferred embodiments of the present invention has been provided for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many embodiments were chosen and described in order to best explain the principles of the invention and its practical application, thereby enabling others skilled in the art to understand the invention for various embodiments and with various modifications that are suited to the particular use contemplated. Embodiments of the present invention may use some or all of the features shown in the various disclosed embodiments where such features are not structurally or functionally incompatible. It is intended that the scope of the invention be defined by the claims and their equivalents.
Claims (25)
1. A method for treating a pneumostoma into a lung of a patient comprising;
(a) removing a pneumostoma management device from the pneumostoma;
(b) inserting the treatment part of a pneumostoma treatment instrument into the pneumostoma;
(c) treating the pneumostoma with the treatment part so as to maintain and/or enhance escape of gases from the lung through the pneumostoma;
(d) removing the treatment part of the pneumostoma treatment instrument from the pneumostoma; and
(e) inserting a pneumostoma management device into the pneumostoma.
2. The method of claim 1 , wherein the method steps are performed in the order of (a), (b), (c), (d) then (e).
3. The method of claim 1 , further comprising:
(f) selecting a pneumostoma treatment instrument for treating the pneumostoma prior to step (b).
4. The method of claim 1 , further comprising:
(f) determining a dimension of the pneumostoma; and
(g) configuring the pneumostoma treatment instrument based on the dimension of the pneumostoma prior to step (b).
5. The method of claim 1 , further comprising:
(f) selecting a portion of a tissue of the pneumostoma being less than all of the tissue of the pneumostoma to treat with the treatment part;
wherein step (b) comprises inserting the treatment part of the pneumostoma treatment instrument into the pneumostoma so as to treat a portion of tissue of the pneumostoma selected in step (f); and,
wherein step (c) comprises treating the portion of tissue of the pneumostoma selected in step (f) with the pneumostoma treatment part so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma without treating other tissue of the pneumostoma with the treatment part.
6. The method of claim 1 , further comprising the step of:
(f) applying one or more of suction and irrigation to the pneumostoma.
7. The method of claim 1 , further comprising the step of
(f) applying one or more of suction and irrigation to the pneumostoma after step (c) and before step (e).
8. The method of claim 1 , wherein the pneumostoma treatment device comprises an energy source and wherein the method comprises:
(c) applying energy to the pneumostoma with the treatment part so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma.
9. The method of claim 1 , wherein the pneumostoma treatment device comprises an electromagnetic energy source and wherein the method comprises:
(c) applying electromagnetic energy to the pneumostoma with the treatment part so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma.
10. The method of claim 1 , wherein the pneumostoma treatment device comprises a sound source, wherein the sound source supplies one or more of infrasound, acoustic sound and infrasound and wherein the method comprises:
(c) applying sound to the pneumostoma with the treatment part so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma.
11. The method of claim 1 , wherein the pneumostoma treatment part comprises a temperature-controlled surface and wherein the method comprises:
(b) inserting the treatment part of the pneumostoma treatment instrument into the pneumostoma so as to bring the temperature-controlled surface into contact with a tissue of the pneumostoma; and
(c) treating the tissue of the pneumostoma with the treatment part by changing the temperature of the tissue away from body temperature for a selected period of time so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma.
12. The method of claim 1 , wherein the pneumostoma treatment part comprises a temperature-controlled surface and wherein the method comprises:
(b) inserting the treatment part of the pneumostoma treatment instrument into the pneumostoma so as to bring the temperature-controlled surface into contact with a tissue of the pneumostoma; and
(c) treating the tissue of the pneumostoma with the temperature-controlled surface of the treatment part by cooling the tissue to a temperature lower than body temperature for a selected period of time so as to maintain and/or enhance the escape of gases from the lung through the pneumostoma.
13. A method for treating a tissue of a surgically-created passage which passes through a thoracic wall, parietal membrane and visceral membrane into a lung of a patient and through which gasses may escape from the lung, the parietal membrane being sealed to the visceral membrane surrounding the passage, wherein the method comprises;
(a) selecting a treatment device having a treatment probe;
(b) inserting the treatment probe of the treatment device into the passage;
(c) treating a tissue of the passage with the treatment probe;
(d) removing the treatment probe from the passage; and
(e) inserting a tube into the passage through which gases may escape the lung via the chest wall.
14. The method of claim 13 , wherein step (c) comprises treating a tissue of the passage with the treatment probe to enhance escape of gases from the lung through the passage.
15. The method of claim 13 , wherein the method steps are performed in the order (a) (b) (c) (d) (e).
16. The method of claim 13 , further comprising:
(f) determining a dimension of the passage; and
(g) configuring the treatment device based on the dimension of the passage prior to step (b).
17. The method of claim 13 , further comprising:
(f) selecting a tissue of the passage being less than all of the tissue of the passage to treat with the treatment device; and
wherein step (c) comprises selectively treating the portion of a tissue of the passage selected in step (f) with the treatment probe without treating other tissues of the passage with the treatment part.
18. The method of claim 13 , further comprising the step of
(f) applying one or more of suction and irrigation to the passage after step (b) and before step (e).
19. The method of claim 13 , wherein the treatment device comprises a means for transmitting energy and wherein the method comprises:
(c) applying energy to a tissue of the passage with the treatment probe.
20. The method of claim 13 , wherein the treatment probe comprises a coolable surface and wherein the method comprises:
(b) inserting the treatment probe into the passage so as to bring the coolable surface into contact with a tissue of the passage; and
(c) treating the tissue of the passage with the coolable surface of the treatment part by cooling the tissue to a temperature lower than body temperature for a selected period of time.
21. A method for treating a tissue of a stoma which passes through a thoracic wall, parietal membrane and visceral membrane into a lung of a patient and through which gasses may escape from the lung, the parietal membrane being sealed to the visceral membrane surrounding a passage, wherein the method comprises;
(a) selecting a treatment device having a treatment probe;
(b) measuring a dimension of the stoma;
(c) configuring the treatment probe in response to the dimension of the stoma;
(d) inserting the treatment probe into the stoma;
(e) treating a tissue of the stoma with the treatment probe so as to promote the escape of gases from the lung through the stoma; and
(f) removing the treatment probe from the stoma.
22. The method of claim 21 further comprising:
(g) selecting some but not all of the tissue of the stoma to treat with the treatment probe so as to promote the escape of gases from the lung through the stoma; and
wherein step (c) comprises selectively treating the some but not all of the tissue of the stoma selected in step (g) with the treatment probe so as to promote the escape of gases from the lung through the stoma.
23. The method of claim 21 , further comprising the step of
(g) removing a material from the stoma.
24. The method of claim 21 , further comprising:
(g) inserting a tube into the stoma through which gases may escape the lung via the chest wall.
25. The method of claim 21 , wherein the treatment device comprises a means for transmitting energy and wherein the method comprises:
(c) applying energy to a tissue of the stoma with the treatment probe.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/388,459 US20090205665A1 (en) | 2008-02-19 | 2009-02-18 | Methods and devices for follow-up care and treatment of a pneumostoma |
US12/796,409 US8475389B2 (en) | 2008-02-19 | 2010-06-08 | Methods and devices for assessment of pneumostoma function |
US13/027,024 US20110180064A1 (en) | 2008-02-19 | 2011-02-14 | Methods and devices for follow-up care and treatment of a pneumstoma |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2983008P | 2008-02-19 | 2008-02-19 | |
US3287708P | 2008-02-29 | 2008-02-29 | |
US3837108P | 2008-03-20 | 2008-03-20 | |
US8289208P | 2008-07-23 | 2008-07-23 | |
US8357308P | 2008-07-25 | 2008-07-25 | |
US8455908P | 2008-07-29 | 2008-07-29 | |
US8811808P | 2008-08-12 | 2008-08-12 | |
US14329809P | 2009-01-08 | 2009-01-08 | |
US15158109P | 2009-02-11 | 2009-02-11 | |
US12/388,459 US20090205665A1 (en) | 2008-02-19 | 2009-02-18 | Methods and devices for follow-up care and treatment of a pneumostoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/796,409 Continuation-In-Part US8475389B2 (en) | 2008-02-19 | 2010-06-08 | Methods and devices for assessment of pneumostoma function |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090205665A1 true US20090205665A1 (en) | 2009-08-20 |
Family
ID=40953964
Family Applications (23)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/388,441 Expired - Fee Related US8491602B2 (en) | 2008-02-19 | 2009-02-18 | Single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,470 Expired - Fee Related US8021320B2 (en) | 2008-02-19 | 2009-02-18 | Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma |
US12/388,451 Abandoned US20090205645A1 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management method for the treatment of chronic obstructive pulmonary disease |
US12/388,467 Expired - Fee Related US8347880B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease |
US12/388,438 Abandoned US20090205643A1 (en) | 2008-02-19 | 2009-02-18 | Accelerated two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,465 Expired - Fee Related US7909803B2 (en) | 2008-02-19 | 2009-02-18 | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US12/388,462 Expired - Fee Related US7927324B2 (en) | 2008-02-19 | 2009-02-18 | Aspirator and method for pneumostoma management |
US12/388,455 Abandoned US20090205658A1 (en) | 2008-02-19 | 2009-02-18 | Devices and methods for delivery of a therapeutic agent through a pneumostoma |
US12/388,446 Abandoned US20090209909A1 (en) | 2008-02-19 | 2009-02-18 | Percutaneous single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,453 Expired - Fee Related US8252003B2 (en) | 2008-02-19 | 2009-02-18 | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
US12/388,468 Expired - Fee Related US8365722B2 (en) | 2008-02-19 | 2009-02-18 | Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,466 Expired - Fee Related US8453638B2 (en) | 2008-02-19 | 2009-02-18 | One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,461 Expired - Fee Related US8348906B2 (en) | 2008-02-19 | 2009-02-18 | Aspirator for pneumostoma management |
US12/388,460 Expired - Fee Related US8464708B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system having a cosmetic and/or protective cover |
US12/388,469 Expired - Fee Related US8474449B2 (en) | 2008-02-19 | 2009-02-18 | Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease |
US12/388,459 Abandoned US20090205665A1 (en) | 2008-02-19 | 2009-02-18 | Methods and devices for follow-up care and treatment of a pneumostoma |
US12/388,447 Expired - Fee Related US8453637B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system for treatment of chronic obstructive pulmonary disease |
US12/388,458 Expired - Fee Related US8430094B2 (en) | 2008-02-19 | 2009-02-18 | Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,435 Abandoned US20090209856A1 (en) | 2008-02-19 | 2009-02-18 | Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US13/012,962 Expired - Fee Related US8231581B2 (en) | 2008-02-19 | 2011-01-25 | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US13/213,279 Expired - Fee Related US8273051B2 (en) | 2008-02-19 | 2011-08-19 | Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma |
US13/543,588 Expired - Fee Related US8506577B2 (en) | 2008-02-19 | 2012-07-06 | Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US13/851,545 Abandoned US20130218134A1 (en) | 2008-02-19 | 2013-03-27 | Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
Family Applications Before (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/388,441 Expired - Fee Related US8491602B2 (en) | 2008-02-19 | 2009-02-18 | Single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,470 Expired - Fee Related US8021320B2 (en) | 2008-02-19 | 2009-02-18 | Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma |
US12/388,451 Abandoned US20090205645A1 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management method for the treatment of chronic obstructive pulmonary disease |
US12/388,467 Expired - Fee Related US8347880B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease |
US12/388,438 Abandoned US20090205643A1 (en) | 2008-02-19 | 2009-02-18 | Accelerated two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,465 Expired - Fee Related US7909803B2 (en) | 2008-02-19 | 2009-02-18 | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US12/388,462 Expired - Fee Related US7927324B2 (en) | 2008-02-19 | 2009-02-18 | Aspirator and method for pneumostoma management |
US12/388,455 Abandoned US20090205658A1 (en) | 2008-02-19 | 2009-02-18 | Devices and methods for delivery of a therapeutic agent through a pneumostoma |
US12/388,446 Abandoned US20090209909A1 (en) | 2008-02-19 | 2009-02-18 | Percutaneous single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US12/388,453 Expired - Fee Related US8252003B2 (en) | 2008-02-19 | 2009-02-18 | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
US12/388,468 Expired - Fee Related US8365722B2 (en) | 2008-02-19 | 2009-02-18 | Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,466 Expired - Fee Related US8453638B2 (en) | 2008-02-19 | 2009-02-18 | One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,461 Expired - Fee Related US8348906B2 (en) | 2008-02-19 | 2009-02-18 | Aspirator for pneumostoma management |
US12/388,460 Expired - Fee Related US8464708B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system having a cosmetic and/or protective cover |
US12/388,469 Expired - Fee Related US8474449B2 (en) | 2008-02-19 | 2009-02-18 | Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/388,447 Expired - Fee Related US8453637B2 (en) | 2008-02-19 | 2009-02-18 | Pneumostoma management system for treatment of chronic obstructive pulmonary disease |
US12/388,458 Expired - Fee Related US8430094B2 (en) | 2008-02-19 | 2009-02-18 | Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US12/388,435 Abandoned US20090209856A1 (en) | 2008-02-19 | 2009-02-18 | Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US13/012,962 Expired - Fee Related US8231581B2 (en) | 2008-02-19 | 2011-01-25 | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US13/213,279 Expired - Fee Related US8273051B2 (en) | 2008-02-19 | 2011-08-19 | Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma |
US13/543,588 Expired - Fee Related US8506577B2 (en) | 2008-02-19 | 2012-07-06 | Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US13/851,545 Abandoned US20130218134A1 (en) | 2008-02-19 | 2013-03-27 | Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
Country Status (8)
Country | Link |
---|---|
US (23) | US8491602B2 (en) |
EP (3) | EP2242527A4 (en) |
JP (2) | JP2011512232A (en) |
CN (1) | CN102006904A (en) |
AU (1) | AU2009215579A1 (en) |
BR (1) | BRPI0908784A2 (en) |
CA (1) | CA2752159A1 (en) |
WO (4) | WO2009105432A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080077038A1 (en) * | 2004-11-02 | 2008-03-27 | Children's Hospital Of Philadelphia | Respiratory Volume/Flow Gating, Monitoring, and Spirometry System for Mri |
US7909803B2 (en) | 2008-02-19 | 2011-03-22 | Portaero, Inc. | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US20110112408A1 (en) * | 2009-11-10 | 2011-05-12 | Lior Greenstein | Optical Speculum |
US20120174675A1 (en) * | 2009-09-18 | 2012-07-12 | B-K Medical Aps | Ultrasound Probe |
US8323230B2 (en) | 2003-07-15 | 2012-12-04 | Portaero, Inc. | Methods and devices to accelerate wound healing in thoracic anastomosis applications |
US8336540B2 (en) | 2008-02-19 | 2012-12-25 | Portaero, Inc. | Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease |
US8347881B2 (en) | 2009-01-08 | 2013-01-08 | Portaero, Inc. | Pneumostoma management device with integrated patency sensor and method |
US8475389B2 (en) | 2008-02-19 | 2013-07-02 | Portaero, Inc. | Methods and devices for assessment of pneumostoma function |
US8518053B2 (en) | 2009-02-11 | 2013-08-27 | Portaero, Inc. | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
US9271640B2 (en) | 2009-11-10 | 2016-03-01 | Illumigyn Ltd. | Optical speculum |
US20160166320A1 (en) * | 2014-12-11 | 2016-06-16 | Boston Scientific Scimed, Inc. | Medical device and methods of use |
US9877644B2 (en) | 2009-11-10 | 2018-01-30 | Illumigyn Ltd. | Optical speculum |
US10058332B2 (en) | 2012-08-01 | 2018-08-28 | Terumo Kabushiki Kaisha | Method for treatment of chronic obstructive pulmonary disease |
US11344356B2 (en) | 2018-02-28 | 2022-05-31 | Medtronic Cryocath Lp | Apparatus and method for targeted bronchial denervation by cryo-ablation |
US11369424B2 (en) * | 2018-10-10 | 2022-06-28 | Korust Co., Ltd. | Ultrasound apparatus of body cavity insertable type having separable sealing cover |
WO2022248456A1 (en) * | 2021-05-26 | 2022-12-01 | Universität Rostock | Cleaning element for cleaning tissues and/or implants |
US11666370B2 (en) | 2020-07-27 | 2023-06-06 | Medtronic, Inc. | Apparatus and method for targeted temporary bronchial nerve modulation by cryo-ablation for prevention and treatment of acute respiratory distress syndromes |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572588B1 (en) | 2000-03-10 | 2003-06-03 | Venetec International, Inc. | Medical anchoring system |
US7524809B2 (en) * | 2004-02-27 | 2009-04-28 | The Procter & Gamble Company | Multiple use fabric conditioning composition with improved perfume |
US9138560B2 (en) | 2006-01-12 | 2015-09-22 | Venetec International, Inc. | Universal catheter securement device |
EP2012858A2 (en) | 2006-04-10 | 2009-01-14 | Aeiomed, INC. | Apparatus and methods for administration of positive airway pressure therapies |
US8603029B2 (en) | 2007-10-10 | 2013-12-10 | Hospi Corporation | Apparatuses and methods for medication administration |
WO2009153926A1 (en) * | 2008-06-18 | 2009-12-23 | 株式会社ニコン | Template manufacturing method, template inspecting method and inspecting apparatus, nanoimprint apparatus, nanoimprint system, and device manufacturing method |
WO2010002393A1 (en) | 2008-06-30 | 2010-01-07 | Venetec International, Inc. | Anchoring system for a medical article |
WO2013116670A1 (en) * | 2012-02-01 | 2013-08-08 | Hospi Corporation | Valved enteral administration assembly |
US8882678B2 (en) * | 2009-03-13 | 2014-11-11 | Atrium Medical Corporation | Pleural drainage system and method of use |
US10226614B2 (en) * | 2009-03-19 | 2019-03-12 | Illinois Tool Works Inc. | One-way check valve |
CN102802712A (en) * | 2009-06-26 | 2012-11-28 | 皇家飞利浦电子股份有限公司 | A hyperpolarized contrast agent dispenser for magnetic resonance imaging |
WO2011060197A1 (en) * | 2009-11-11 | 2011-05-19 | Venetec International, Inc. | Stabilizing device for an extension set |
US20120302909A1 (en) * | 2009-11-11 | 2012-11-29 | Mayse Martin L | Methods and systems for screening subjects |
EP3569376B1 (en) | 2010-01-20 | 2022-12-14 | 3M Innovative Properties Company | Method for making foam wound insert with regions of higher and lower densities |
EP2566561B1 (en) * | 2010-05-07 | 2019-04-24 | Care Fusion 2200, Inc. | Improved catheter design for use in treating pleural diseases |
CN103118602B (en) | 2010-06-11 | 2016-04-27 | 随行医疗技术公司 | For getting involved and closed system and method through the apex of the heart |
US9161778B2 (en) | 2010-06-11 | 2015-10-20 | Entourage Medical Technologies, Inc. | System and method for transapical access and closure |
US9421032B2 (en) * | 2010-06-16 | 2016-08-23 | Covidien Lp | Seal port with blood collector |
JP3193069U (en) | 2010-09-02 | 2014-09-18 | シプノーズ リミテッド | Nasal administration device |
US9579097B2 (en) | 2010-09-20 | 2017-02-28 | Entourage Medical Technologies, Inc. | Method for tensioning a surgical closure |
US8777900B2 (en) * | 2010-12-14 | 2014-07-15 | Kimberly-Clark Worldwide, Inc. | Ambulatory enteral feeding system |
WO2012094230A2 (en) * | 2011-01-03 | 2012-07-12 | Somnetics Global Pte. Ltd. | Positive airway pressure therapy apparatus and methods |
TWM420333U (en) * | 2011-07-01 | 2012-01-11 | Avita Corp | Body fluid collecting apparatus |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US8496632B2 (en) * | 2011-08-25 | 2013-07-30 | Ethicon Endo-Surgery, Inc. | Surgical access device with adjustable cannula |
US8486045B2 (en) * | 2011-08-25 | 2013-07-16 | Ethicon Endo-Surgery, Inc. | Surgical access device with adjustable cannula |
US8439881B2 (en) * | 2011-08-25 | 2013-05-14 | Ethicon Endo-Surgery, Inc. | Surgical access device with adjustable cannula |
US8491545B2 (en) * | 2011-08-25 | 2013-07-23 | Ethicon Endo-Surgery, Inc. | Surgical access device with adjustable cannula |
US8496633B2 (en) * | 2011-08-25 | 2013-07-30 | Ethicon Endo-Surgery, Inc. | Surgical access device with adjustable cannula |
WO2013039713A2 (en) * | 2011-09-14 | 2013-03-21 | 3M Innovative Properties Company | Positive pressure medical dressings with valve and kits containing same |
EP2583642A1 (en) * | 2011-10-21 | 2013-04-24 | Universitätsspital Basel | Implantable stoma ring |
WO2013111057A1 (en) * | 2012-01-24 | 2013-08-01 | Kimberly-Clark Worldwide, Inc. | Drainage catheter system with cuff |
US9078990B1 (en) * | 2012-02-03 | 2015-07-14 | Andrew Thomas Obst | Devices and methods for treatment of fistulas and complex wounds |
US9888870B2 (en) | 2012-02-16 | 2018-02-13 | Board Of Regents Of The University Of Nebraska | System and method for monitoring pleural fluid |
USD780547S1 (en) | 2013-08-08 | 2017-03-07 | Carter J. Kovarik | Pick up device with flexible shaft portion |
US9832980B2 (en) | 2012-02-22 | 2017-12-05 | Carter J. Kovarik | Selectively bendable remote gripping tool |
US11083475B2 (en) | 2012-02-22 | 2021-08-10 | Carter J. Kovarik | Medical device to remove an obstruction from a body lumen, vessel or organ |
US10226266B2 (en) | 2012-02-22 | 2019-03-12 | Carter J. Kovarik | Selectively bendable remote gripping tool |
US9901245B2 (en) | 2012-02-22 | 2018-02-27 | Carter J. Kovarik | Selectively bendable remote gripping tool |
US9592066B2 (en) | 2012-02-22 | 2017-03-14 | Carter J. Kovarik | Selectively bendable remote gripping tool |
US9233015B2 (en) | 2012-06-15 | 2016-01-12 | Trivascular, Inc. | Endovascular delivery system with an improved radiopaque marker scheme |
US9402968B2 (en) | 2012-07-11 | 2016-08-02 | Mercy Medical Research Institute, Inc. | Colorectal delivery device |
JP2014028023A (en) * | 2012-07-31 | 2014-02-13 | Terumo Corp | Tube |
EP2695581B1 (en) | 2012-08-07 | 2019-03-13 | Critical Innovations, LLC | Device for simultaneously documenting and treating tension pneumothorax and/or hemothorax |
US20150297873A1 (en) * | 2012-08-22 | 2015-10-22 | Clemson University Research Foundation | Percutaneous tube stabilization device |
GB2510321B (en) * | 2012-11-12 | 2018-01-31 | Biosurgical S L | Agitation apparatus |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
SI2928531T1 (en) | 2012-12-04 | 2017-07-31 | Ino Therapeutics LLC Perryville III Corporate Park | Cannula for minimizing dilution of dosing during nitric oxide delivery |
US9795756B2 (en) | 2012-12-04 | 2017-10-24 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
US10039898B2 (en) * | 2013-01-08 | 2018-08-07 | Biosense Webster (Israel) Ltd. | Catheter sheath introducer with directional retention damper |
DE102013203116A1 (en) * | 2013-02-26 | 2014-08-28 | Robert Bosch Gmbh | Abrasive device |
EP2967516A4 (en) | 2013-03-15 | 2016-11-16 | Prabhat K Ahluwalia | Content inflation and delivery system |
MX2015009906A (en) | 2013-03-15 | 2016-11-08 | Bard Inc C R | Securement device having an integral strap and dressing. |
US8920381B2 (en) * | 2013-04-12 | 2014-12-30 | Medtronic Minimed, Inc. | Infusion set with improved bore configuration |
CN103263703A (en) * | 2013-05-03 | 2013-08-28 | 江苏亚华生物科技工程有限公司 | Tension pneumothorax puncture component |
US9144635B1 (en) | 2013-07-01 | 2015-09-29 | Ibiz Innovations, Llc | Easily disinfected bulb-syringe |
AU2014342300A1 (en) | 2013-10-29 | 2016-05-19 | Entourage Medical Technologies, Inc. | System for providing surgical access |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10046147B2 (en) | 2013-12-26 | 2018-08-14 | Critical Innovations, LLC | Percutaneous access pathway system and method |
CN104874084B (en) * | 2014-02-28 | 2019-07-05 | 北京谊安医疗系统股份有限公司 | Outlet valve and ventilator with it |
EP3124968B8 (en) * | 2014-03-26 | 2018-07-04 | PHC Holdings Corporation | Exhalation measuring device and method for controlling exhalation measuring device |
US20150273156A1 (en) * | 2014-03-26 | 2015-10-01 | Boston Scientific Scimed, Inc. | Devices for systemic drug delivery and related methods of use |
WO2015153500A1 (en) * | 2014-03-31 | 2015-10-08 | Spiration, Inc. | Simulated valve device for airway |
US9693854B2 (en) * | 2014-03-31 | 2017-07-04 | Boston Scientific Scimed, Inc. | Devices for forming collateral channels and related methods of use |
CA2939137A1 (en) * | 2014-04-30 | 2015-11-05 | Soffio Medical Inc. | Methods and devices for treating a hyper-inflated lung |
WO2015180732A1 (en) * | 2014-05-28 | 2015-12-03 | Coloplast A/S | An ostomy wafer |
EP3148485B1 (en) * | 2014-05-28 | 2021-05-26 | Coloplast A/S | An ostomy wafer |
US20150343139A1 (en) * | 2014-05-30 | 2015-12-03 | Boston Scientific Scimed, Inc. | Implantable pumps and related methods of use |
US10206686B2 (en) * | 2014-06-10 | 2019-02-19 | Ethicon Llc | Bronchus sealants and methods of sealing bronchial tubes |
TWI549702B (en) * | 2014-07-22 | 2016-09-21 | 國立臺灣大學 | Medical supply composed of biodegradable adhesive material |
WO2016037144A2 (en) | 2014-09-04 | 2016-03-10 | AtaCor Medical, Inc. | Cardiac pacing lead delivery system |
US9636505B2 (en) | 2014-11-24 | 2017-05-02 | AtaCor Medical, Inc. | Cardiac pacing sensing and control |
US10328268B2 (en) | 2014-09-04 | 2019-06-25 | AtaCor Medical, Inc. | Cardiac pacing |
US10743960B2 (en) | 2014-09-04 | 2020-08-18 | AtaCor Medical, Inc. | Cardiac arrhythmia treatment devices and delivery |
TWI552781B (en) * | 2014-09-30 | 2016-10-11 | Liquid suction and discharge filter | |
EP3215198B1 (en) | 2014-11-03 | 2021-04-28 | Fistula Solution Corporation | Containment devices for treatment of intestinal fistulas and complex wounds |
US11426302B2 (en) | 2014-11-03 | 2022-08-30 | Fistula Solution Corporation | Containment devices for treatment of intestinal fistulas and complex wounds |
US11097109B2 (en) | 2014-11-24 | 2021-08-24 | AtaCor Medical, Inc. | Cardiac pacing sensing and control |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
CN107530181B (en) * | 2015-03-16 | 2020-11-13 | 科洛普拉斯特公司 | Ostomy appliance |
US10758712B2 (en) * | 2015-04-06 | 2020-09-01 | Santacruz Technology Llc | Medical device for treating abscesses |
AU2016259243B2 (en) * | 2015-05-01 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for protecting umbilical stumps |
US9717293B2 (en) | 2015-06-11 | 2017-08-01 | Michelle P. LIM | Magnetic fastener for a garment |
US9827135B2 (en) | 2015-09-15 | 2017-11-28 | Savage Medical, Inc. | Devices and methods for anchoring a sheath in a tissue cavity |
US10632284B2 (en) * | 2015-10-02 | 2020-04-28 | Rabie Stephan | Catheter port |
WO2017075595A1 (en) * | 2015-10-30 | 2017-05-04 | Soffio Medical Inc. | Devices for access to hyper-inflated lung |
WO2017095311A1 (en) * | 2015-12-02 | 2017-06-08 | Atos Medical Ab | Device for securely loading and mounting a tubular device in a flexible wall |
BE1023204B1 (en) * | 2016-03-18 | 2016-12-20 | Nougimmo Sprl | Assembly to handle a container |
US10286121B2 (en) | 2016-04-11 | 2019-05-14 | Ulus Landon HUNT | Device for drawing and expelling a liquid or powder |
JP7274147B2 (en) * | 2016-11-22 | 2023-05-16 | アルフレッド ヘルス | Surgical system and method of use |
US10987128B2 (en) | 2017-03-22 | 2021-04-27 | Covidien Lp | Cannula assembly |
US11083490B2 (en) * | 2017-09-21 | 2021-08-10 | Covidien Lp | Systems and methods for large tissue specimen removal |
US10814119B2 (en) | 2017-09-22 | 2020-10-27 | Critical Innovations, LLC | Percutaneous access pathway system |
US11419658B2 (en) * | 2017-11-06 | 2022-08-23 | Uptake Medical Technology Inc. | Method for treating emphysema with condensable thermal vapor |
EP3485826A1 (en) * | 2017-11-20 | 2019-05-22 | Universität Regensburg - Universitätsklinikum | Needle assembly for relieving a pneumothorax |
FR3077013B1 (en) * | 2018-01-24 | 2023-12-15 | Aptar France Sas | FLUID PRODUCT DISTRIBUTION DEVICE. |
CN108452422A (en) * | 2018-03-22 | 2018-08-28 | 四川省肿瘤医院 | A kind of autogenous cutting humidification cover |
WO2019204499A1 (en) * | 2018-04-17 | 2019-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Airway visualization system |
CN109157718A (en) * | 2018-07-26 | 2019-01-08 | 合肥康居人智能科技有限公司 | A kind of oxygen-absorption atomizing integral type oxygenerator atomization bite |
AU2019389110A1 (en) * | 2018-11-30 | 2021-06-03 | Quick Tube Medical, Llc | Method and apparatus for treating tension pneumothorax using a rapid deployment chest port |
US11207097B2 (en) | 2019-02-13 | 2021-12-28 | Andrew Thomas Obst | Fluid management device for medical tubes and drainage incisions |
US20220039643A1 (en) * | 2019-03-14 | 2022-02-10 | Medivators Inc. | Endoscope cleaning and flushing accessory |
EP3976167A1 (en) | 2019-05-29 | 2022-04-06 | Atacor Medical, Inc. | Implantable electrical leads and associated delivery systems |
US11523932B2 (en) | 2019-06-26 | 2022-12-13 | Andrew Thomas Obst | Enteric fistula, rectovaginal fistula, and ostomy effluent containment system, and devices and methods thereof |
RU2757523C2 (en) * | 2020-01-17 | 2021-10-18 | Владимир Иванович Попов | Device for the treatment of open pneumothorax |
US11638606B2 (en) | 2020-04-15 | 2023-05-02 | Bard Peripheral Vascular, Inc. | Bipolar electrosurgical pleura sealing device, system, and method of operating same |
US11666771B2 (en) | 2020-05-29 | 2023-06-06 | AtaCor Medical, Inc. | Implantable electrical leads and associated delivery systems |
RU2751651C1 (en) * | 2020-07-17 | 2021-07-15 | Федеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский Томский государственный университет» | Hardware and software complex for physiotherapeutic training and prevention of respiratory diseases based on artificial lung ventilation apparatus |
USD981567S1 (en) * | 2020-12-18 | 2023-03-21 | Hamilton Medical Ag | Part of an artificial lung ventilation apparatus |
US20230012749A1 (en) * | 2021-07-13 | 2023-01-19 | Moldoveanu Designs LLC | Chest wound system |
EP4166178A1 (en) * | 2021-10-15 | 2023-04-19 | innotrach ApS | Tracheotomy apparatus and tracheostomy system |
Citations (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4799494A (en) * | 1986-10-22 | 1989-01-24 | Wang Ko P | Percutaneous aspiration lung biopsy needle assembly |
US4813929A (en) * | 1987-02-19 | 1989-03-21 | Neal Semrad | Chest tube device and method of inserting device |
US5004456A (en) * | 1989-03-10 | 1991-04-02 | Arrow International Investment Corporation | In-dwelling catheter |
US5078689A (en) * | 1990-05-14 | 1992-01-07 | Keller Alan M | Device for removing body fluids |
US5389077A (en) * | 1993-03-03 | 1995-02-14 | Uresil Corporation | Minimally invasive body cavity penetrating instruments |
US5401262A (en) * | 1990-07-20 | 1995-03-28 | Atrium Medical Corporation | Fluid recovery system |
US5403264A (en) * | 1992-09-04 | 1995-04-04 | Ethicon, Inc. | Endoscopic closure inspection device |
US5484401A (en) * | 1992-11-04 | 1996-01-16 | Denver Biomaterials, Inc. | Treatment method for pleural effusion |
US5496297A (en) * | 1993-02-22 | 1996-03-05 | Coloplast A/S | Ostomy coupling |
US5501678A (en) * | 1991-08-30 | 1996-03-26 | Coloplast A/S | Adapter for use in connection with ostomy equipment |
US5501677A (en) * | 1993-06-25 | 1996-03-26 | Jensen; Ole R. | Two-piece ostomy appliance and low-profile coupling ring assembly |
US5616131A (en) * | 1992-09-23 | 1997-04-01 | Lasersurge, Inc. | Apparatus and method for anchoring surgical instrumentation |
US5728066A (en) * | 1995-12-13 | 1998-03-17 | Daneshvar; Yousef | Injection systems and methods |
US5730735A (en) * | 1996-03-12 | 1998-03-24 | Hollister Incorporated | Convex ostomy faceplate with floating flange and finger recess |
US5738661A (en) * | 1995-06-16 | 1998-04-14 | Larice; Gennaro | Medical device for holding a feeding tube and use thereof |
US5897531A (en) * | 1994-01-07 | 1999-04-27 | Amirana; Omar | Adhesive surgical retaining device |
US6174323B1 (en) * | 1998-06-05 | 2001-01-16 | Broncus Technologies, Inc. | Method and assembly for lung volume reduction |
US6197010B1 (en) * | 1998-06-11 | 2001-03-06 | Hollister Incorporated | Ostomy appliance faceplate with concealed coupling ring flange |
US6200333B1 (en) * | 1997-04-07 | 2001-03-13 | Broncus Technologies, Inc. | Bronchial stenter |
US6334441B1 (en) * | 1998-11-23 | 2002-01-01 | Mallinckrodt Medical, Inc. | Phonation valve for breathing tube |
US6358269B1 (en) * | 1998-11-02 | 2002-03-19 | Ralph Aye | Method of treating peripheral bronchopleural fistulas |
US20020042564A1 (en) * | 1999-08-05 | 2002-04-11 | Cooper Joel D. | Devices for creating collateral channels in the lungs |
US20030013935A1 (en) * | 2001-07-10 | 2003-01-16 | Spiration, Inc. | Constriction device viewable under X ray fluoroscopy |
US20030018344A1 (en) * | 2001-07-19 | 2003-01-23 | Olympus Optical Co., Ltd. | Medical device and method of embolizing bronchus or bronchiole |
US6514290B1 (en) * | 2000-03-31 | 2003-02-04 | Broncus Technologies, Inc. | Lung elastic recoil restoring or tissue compressing device and method |
US6517519B1 (en) * | 1999-08-13 | 2003-02-11 | The Johns Hopkins University | Device and method for rapid chest tube insertion |
US6520183B2 (en) * | 2001-06-11 | 2003-02-18 | Memorial Sloan-Kettering Cancer Center | Double endobronchial catheter for one lung isolation anesthesia and surgery |
US6527761B1 (en) * | 2000-10-27 | 2003-03-04 | Pulmonx, Inc. | Methods and devices for obstructing and aspirating lung tissue segments |
US20030050648A1 (en) * | 2001-09-11 | 2003-03-13 | Spiration, Inc. | Removable lung reduction devices, systems, and methods |
US20030055331A1 (en) * | 2001-09-11 | 2003-03-20 | Pulmonx | Methods of endobronchial diagnosis using imaging |
US20030051733A1 (en) * | 2001-09-10 | 2003-03-20 | Pulmonx | Method and apparatus for endobronchial diagnosis |
US20030065339A1 (en) * | 2001-10-02 | 2003-04-03 | Spiration, Inc. | Constriction device including reinforced suture holes |
US20030069488A1 (en) * | 2001-07-10 | 2003-04-10 | Spiration, Inc. | Constriction device including fixation structure |
US6550475B1 (en) * | 1998-03-11 | 2003-04-22 | Oldfield Family Holdings Pty. Limited | Endotracheal tube for selective bronchial occlusion |
US20030078469A1 (en) * | 2001-10-18 | 2003-04-24 | Spiration, Inc. | Constriction device including tear resistant structures |
US20040010289A1 (en) * | 2000-10-17 | 2004-01-15 | Broncus Technologies, Inc. | Control system and process for application of energy to airway walls and other mediums |
US20040010209A1 (en) * | 2002-07-15 | 2004-01-15 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
US6679264B1 (en) * | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US6682506B1 (en) * | 1998-12-22 | 2004-01-27 | Francis Navarro | Device for maintaining at least a tube |
US20040024356A1 (en) * | 2002-07-31 | 2004-02-05 | Don Tanaka | Long term oxygen therapy system |
US20040031494A1 (en) * | 1998-06-10 | 2004-02-19 | Broncus Technologies, Inc. | Methods of treating asthma |
US6695791B2 (en) * | 2002-01-04 | 2004-02-24 | Spiration, Inc. | System and method for capturing body tissue samples |
US20040040555A1 (en) * | 2002-08-28 | 2004-03-04 | Don Tanaka | Collateral ventilation bypass trap system |
US6702812B2 (en) * | 1996-09-20 | 2004-03-09 | Ioan Cosmescu | Multifunctional telescopic monopolar/bipolar surgical device and method therefor |
US20040047855A1 (en) * | 2002-06-17 | 2004-03-11 | Bistech, Inc., A Delaware Corporation | Compositions and methods for reducing lung volume |
US6709401B2 (en) * | 1999-07-02 | 2004-03-23 | Pulmonx | Methods, systems, and kits for lung volume reduction |
US20040055606A1 (en) * | 2001-03-02 | 2004-03-25 | Emphasys Medical, Inc. | Bronchial flow control devices with membrane seal |
US20040059263A1 (en) * | 2002-09-24 | 2004-03-25 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
US20040073155A1 (en) * | 2000-01-14 | 2004-04-15 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in tissue |
US20040073241A1 (en) * | 2002-10-11 | 2004-04-15 | Spiration, Inc. | Implantable tissue constriction device and method for suppressing leakage of fluid from resectioned body tissue |
US20040078026A1 (en) * | 2002-10-21 | 2004-04-22 | Wagner Robert B. | Method and apparatus for pleural drainage |
US6837906B2 (en) * | 2001-08-03 | 2005-01-04 | Ensure Medical, Inc. | Lung assist apparatus and methods for use |
US20050005936A1 (en) * | 2003-06-18 | 2005-01-13 | Wondka Anthony David | Methods, systems and devices for improving ventilation in a lung area |
US6846292B2 (en) * | 2002-02-19 | 2005-01-25 | Mohamed Bakry | Pleural biopsy and brushing needle |
US20050022809A1 (en) * | 2003-04-25 | 2005-02-03 | Wondka Anthony David | Methods, systems and devices for desufflating a lung area |
US20050025816A1 (en) * | 2003-07-15 | 2005-02-03 | Don Tanaka | Methods and devices to accelerate wound healing in thoracic anastomosis applications |
US6852108B2 (en) * | 2002-05-14 | 2005-02-08 | Spiration, Inc. | Apparatus and method for resecting and removing selected body tissue from a site inside a patient |
US20050033344A1 (en) * | 2002-05-17 | 2005-02-10 | Dillard David H. | One-way valve devices for anchored implantation in a lung |
US20050043751A1 (en) * | 2001-09-04 | 2005-02-24 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20050043745A1 (en) * | 2000-03-23 | 2005-02-24 | Alferness Clifton A. | Tissue resection device, system, and method |
US20050060044A1 (en) * | 1999-08-05 | 2005-03-17 | Ed Roschak | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20050056292A1 (en) * | 1999-08-05 | 2005-03-17 | Cooper Joel D. | Devices for maintaining patency of surgically created channels in tissue |
US20050060042A1 (en) * | 2001-09-04 | 2005-03-17 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US20050060041A1 (en) * | 2001-09-04 | 2005-03-17 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US20050061322A1 (en) * | 2003-01-20 | 2005-03-24 | Pulmonx | Method and arrangement for reducing the volume of a lung |
US20050066976A1 (en) * | 2003-08-18 | 2005-03-31 | Wondka Anthony D. | Method and device for non-invasive ventilation with nasal interface |
US20060004400A1 (en) * | 2004-06-16 | 2006-01-05 | Mcgurk Erin | Method of treating a lung |
US20060025815A1 (en) * | 2004-07-08 | 2006-02-02 | Mcgurk Erin | Lung device with sealing features |
US6997189B2 (en) * | 1998-06-05 | 2006-02-14 | Broncus Technologies, Inc. | Method for lung volume reduction |
US20060047291A1 (en) * | 2004-08-20 | 2006-03-02 | Uptake Medical Corporation | Non-foreign occlusion of an airway and lung collapse |
US7011094B2 (en) * | 2001-03-02 | 2006-03-14 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
US7014628B2 (en) * | 1995-07-07 | 2006-03-21 | Bousquet Gerald G | Transcutaneous access device |
US20070005083A1 (en) * | 1997-04-30 | 2007-01-04 | Sabaratham Sabanathan | Occlusion device |
US20070027434A1 (en) * | 2003-06-02 | 2007-02-01 | Ole Pedersen | Adhesive face plate for an ostomy appliance, an ostomy appliance and a method for cleaning a face plate |
US7172581B2 (en) * | 2001-09-24 | 2007-02-06 | Coloplast A/S | Ostomy appliance with a removable, washable and reusable sealing member |
US7175644B2 (en) * | 2001-02-14 | 2007-02-13 | Broncus Technologies, Inc. | Devices and methods for maintaining collateral channels in tissue |
US20070043350A1 (en) * | 2005-08-17 | 2007-02-22 | Pulmonx | Selective lung tissue ablation |
US20070055175A1 (en) * | 2005-05-25 | 2007-03-08 | Pulmosonix Pty Ltd | Devices and methods for tissue analysis |
US20070051372A1 (en) * | 2005-08-23 | 2007-03-08 | Don Tanaka | Collateral ventilation bypass system with retention features |
US7192420B2 (en) * | 2003-08-08 | 2007-03-20 | Whiteford Bruce W | Ostomy adapter with multiple adhesives for reliable sealing |
US7195017B2 (en) * | 2003-07-03 | 2007-03-27 | Cordis Corporation | Collateral ventilation bypass trap system |
US7195016B2 (en) * | 2004-01-07 | 2007-03-27 | E. Benson Hood Laboratories | Transtracheal oxygen stent |
Family Cites Families (296)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US733152A (en) | 1902-08-30 | 1903-07-07 | Murdoch Chisholm | Empyema drainage device. |
US753922A (en) * | 1903-05-23 | 1904-03-08 | John Scheidler | Fence-post. |
US953922A (en) * | 1907-06-17 | 1910-04-05 | John B Rogers | Tracheal cannula or tube. |
US1596754A (en) * | 1923-10-30 | 1926-08-17 | Judson D Moschelle | Reenforced tubing |
US2206687A (en) | 1937-11-29 | 1940-07-02 | Martha F Mckesson | Pleural diagnosis and treatment |
US2599521A (en) * | 1949-06-02 | 1952-06-03 | Robert A Berman | Respiratory device |
US2873742A (en) | 1954-07-14 | 1959-02-17 | Research Corp | Surgical instruments |
US2991787A (en) | 1957-04-11 | 1961-07-11 | Sierra Eng Co | Tracheotomy instrument |
US2867213A (en) * | 1957-06-12 | 1959-01-06 | Jr Paul A Thomas | Flutter valve for drainage of the pleural cavity |
GB862795A (en) | 1958-06-12 | 1961-03-15 | Bodin Girin & Cie Tissus Ind | Tubular members provided with corrugated walls and method for producing same |
NL279576A (en) * | 1961-06-13 | |||
FR1322998A (en) * | 1962-02-23 | 1963-04-05 | Improvements to aerosol production devices | |
NL108491C (en) * | 1962-11-12 | |||
US3253594A (en) * | 1963-07-30 | 1966-05-31 | Frank E Matthews | Peritoneal cannula |
US3463159A (en) | 1965-02-16 | 1969-08-26 | Henry J Heimlich | Instrument for drainage of the chest |
US3294355A (en) | 1965-02-23 | 1966-12-27 | Louis Rolnick | Wall hangers |
US3707146A (en) | 1967-03-07 | 1972-12-26 | Prod Res & Chem Corp | Means to inject a plastic into a cavity to produce a replica thereof |
US3511243A (en) | 1967-07-18 | 1970-05-12 | Frederic J Toy | Apparatus for providing a breathing conduit communicating with the trachea at the base of the neck |
US3556103A (en) * | 1968-03-15 | 1971-01-19 | Edward J Calhoun | Tracheotomy instrument |
US3638649A (en) * | 1969-07-07 | 1972-02-01 | Univ Minnesota | Implantable prosthetic pass-through device |
US3688773A (en) | 1970-04-16 | 1972-09-05 | Sol Weiss | Device for performing a tracheostomy and other surgical procedures |
US3682166A (en) | 1970-07-29 | 1972-08-08 | Harvey Barry Jacobs | Emergency percutaneous trans-tracheal high flow oxygen catheter-type resuscitator for restoration of breathing in non-breathing patients |
US3788326A (en) * | 1970-07-29 | 1974-01-29 | H Jacobs | Distally perforated catheter for use in ventilating system |
US3777757A (en) | 1971-01-08 | 1973-12-11 | R Gray | Sucking wound plug and chest aspirator |
US3766920A (en) | 1971-07-21 | 1973-10-23 | Ezem Co | Enemata administering device |
US3817250A (en) | 1972-10-24 | 1974-06-18 | Int Medical Devices Inc | Instrument for performing a tracheostomy and other surgical procedures |
US3916903A (en) | 1973-07-20 | 1975-11-04 | Reta M H Pozzi | Cricothyroid puncture apparatus |
US3924637A (en) * | 1974-12-23 | 1975-12-09 | Arthur H Swanson | Tracheotomy tube |
US4312992A (en) * | 1976-12-03 | 1982-01-26 | International Business Machines Corporation | Substituted heterofulvalenes |
US4153058A (en) | 1977-07-05 | 1979-05-08 | Nehme Alexander E | Pleural decompression catheter |
US4188946A (en) * | 1977-10-07 | 1980-02-19 | Rayburn Robert L | Controllable partial rebreathing anesthesia circuit and respiratory assist device |
DE2750447C2 (en) * | 1977-11-11 | 1986-04-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Device for measuring certain properties of particles suspended in a particle suspension |
US4291694A (en) | 1979-10-29 | 1981-09-29 | Chai S | Apparatus and method for performing a thoracic operation |
US4395260A (en) * | 1981-06-01 | 1983-07-26 | Sorenson Research Co., Inc. | Drip chamber |
US4439189A (en) | 1981-06-18 | 1984-03-27 | Bentley Laboratories, Inc. | Pleural drainage system |
US4465062A (en) | 1982-05-14 | 1984-08-14 | Gina Versaggi | Noninvasive seal for a sucking chest wound |
US4872869A (en) | 1982-06-09 | 1989-10-10 | Smith & Nephew (Latin America), Inc. | Low profile ostomy device |
AU562370B2 (en) * | 1982-10-02 | 1987-06-11 | Smith & Nephew Associated Companies Plc | Moisture vapour permeable adhesive surgical dressing |
US4527559A (en) * | 1982-10-18 | 1985-07-09 | Roxburg Dwight W | Endotracheal tube anchoring mechanism |
FR2538705B1 (en) * | 1982-12-29 | 1987-12-31 | Vincent Michel | MEDICAL APPARATUS FOR THE EXSUFFLATION OF TIRES |
US4513739A (en) * | 1983-02-15 | 1985-04-30 | Howmedica, Inc. | Wound dressing |
US4502482A (en) | 1983-05-23 | 1985-03-05 | Deluccia Victor C | Endotracheal tube complex |
JPS6129720U (en) | 1984-07-28 | 1986-02-22 | 高砂医科工業株式会社 | Intestinal anastomosis aid |
US4583977A (en) * | 1984-08-15 | 1986-04-22 | Vsesojuzny Nauchno-Issledovatelsky Institut Meditsiuskikh Polimerov | Device for lengthy fixation of a tube introduced into the patient's body |
DK151044C (en) | 1984-12-07 | 1988-05-16 | Coloplast As | STOMI EQUIPMENT CONSISTING OF A BANDAGE, A STOMIPOUS AND A CIRCUIT, AND PLATE COUPLING AND POCKET COUPLING FOR USE THEREOF |
US4664660A (en) | 1985-04-01 | 1987-05-12 | Becton, Dickinson And Company | Chest drainage apparatus with ambient air sealing |
US4717385A (en) * | 1985-04-12 | 1988-01-05 | The Beth Israel Hospital Association | Surgical tube anchoring device and method for using same |
DK158827C (en) | 1986-09-04 | 1991-01-14 | Coloplast As | REUSABLE CLUTCHING ORGANIZATION FOR STOMPOSE BAGS AND DISPOSAL AND STOMIPOUS SYSTEM FOR USE IN CONNECTION WITH IT |
EP0323451B1 (en) | 1986-09-16 | 1991-08-28 | Edward Michael Goldberg | Chest drainage apparatus |
US4889534A (en) | 1986-12-04 | 1989-12-26 | Hollister Incorporated | Ostomy appliance with three-lement coupling ring assembly |
GB8629424D0 (en) | 1986-12-09 | 1987-01-21 | Craig Med Prod Ltd | Ostomy bag coupling |
US4944724A (en) | 1987-06-05 | 1990-07-31 | Uresil Corporation | Apparatus for locating body cavities having signaling indicator |
US5356386A (en) | 1987-06-05 | 1994-10-18 | Uresil Corporation | Apparatus for locating body cavities |
US5199424A (en) | 1987-06-26 | 1993-04-06 | Sullivan Colin E | Device for monitoring breathing during sleep and control of CPAP treatment that is patient controlled |
US4869717A (en) | 1988-04-25 | 1989-09-26 | Adair Edwin Lloyd | Gas insufflation needle with instrument port |
US4959054A (en) | 1988-11-23 | 1990-09-25 | Clemson University | Pharmaceutically protected percutaneous devices |
US5006401A (en) * | 1988-11-23 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Composite compression and support dressing |
US4976688A (en) | 1989-02-03 | 1990-12-11 | Rosenblum Jeffrey L | Position-adjustable thoracic catheter |
US4905694A (en) * | 1989-04-04 | 1990-03-06 | Ethicon, Inc. | Intracorporeal temporary wound closure |
US5141516A (en) | 1989-07-26 | 1992-08-25 | Detweiler Mark B | Dissolvable anastomosis stent and method for using the same |
US5217441A (en) | 1989-08-15 | 1993-06-08 | United States Surgical Corporation | Trocar guide tube positioning device |
US5336206A (en) | 1989-08-15 | 1994-08-09 | United States Surgical Corporation | Trocar penetration depth indicator and guide tube positioning device |
CA2028618C (en) | 1989-11-17 | 2001-12-11 | Peter Leslie Steer | Ostomy coupling |
US5281204A (en) * | 1989-12-26 | 1994-01-25 | Nissho Corporation | Device for forming an inserting hole and method of using and making the same |
US5060645A (en) | 1990-08-14 | 1991-10-29 | Russell David N | Tracheostomy tube assembly |
US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
US5073169A (en) | 1990-10-02 | 1991-12-17 | Steve Raiken | Trocar support |
US5218957A (en) | 1990-10-19 | 1993-06-15 | Ballard Medical Products | Multi-layered transtracheal catheter |
US5230332A (en) | 1990-10-22 | 1993-07-27 | Ballard Medical Products | Methods and apparatus for a micro-tracheal catheter hub assembly |
US5137509A (en) | 1991-04-17 | 1992-08-11 | Dexide, Inc. | Surgical insufflation instrument |
US5139485A (en) | 1991-05-03 | 1992-08-18 | Ethicon, Inc. | Verress needle with enhanced acoustical means |
US5230350A (en) | 1991-05-29 | 1993-07-27 | Tabex Industries, Inc. | Moisture barrier for indwelling catheters and the like |
US6461296B1 (en) * | 1998-06-26 | 2002-10-08 | 2000 Injectx, Inc. | Method and apparatus for delivery of genes, enzymes and biological agents to tissue cells |
US5207652A (en) * | 1991-10-23 | 1993-05-04 | Bioderm | Medical apparatus fixation and infection control device |
FR2683150B1 (en) * | 1991-10-30 | 1994-01-21 | Robert Bezicot | ARTIFICIAL NOSE FOR TRACHEOTOMIZED SUBJECT, WITH A SURGICAL ORIFICE ENDING THE TRACHEA WITH THE SKIN. |
USD340989S (en) * | 1991-11-26 | 1993-11-02 | Upstate Design and Marketing, Inc. | Adhesive bandage |
USD340987S (en) * | 1991-11-26 | 1993-11-02 | Upstate Design and Marketing, Inc. | Adhesive bandage |
US5376376A (en) | 1992-01-13 | 1994-12-27 | Li; Shu-Tung | Resorbable vascular wound dressings |
US5947914A (en) * | 1995-02-21 | 1999-09-07 | Augustine Medical, Inc. | Wound covering |
GR930100244A (en) * | 1992-06-30 | 1994-02-28 | Ethicon Inc | Flexible endoscopic surgical port |
GB9214716D0 (en) * | 1992-07-10 | 1992-08-19 | Emmark Technology | Tracheostomy filter |
US5263939A (en) | 1992-10-09 | 1993-11-23 | Surgin Surgical Instrumentation, Inc. | Retainer for laparoscopic cannula |
US5357946A (en) * | 1992-10-19 | 1994-10-25 | Sherwood Medical Company | Ventilator manifold with accessory access port and adaptors therefore |
US5344410A (en) | 1992-11-17 | 1994-09-06 | Kolkin Yakov G | Device for draining the pleural cavity |
US5407433A (en) | 1993-02-10 | 1995-04-18 | Origin Medsystems, Inc. | Gas-tight seal accommodating surgical instruments with a wide range of diameters |
US5315992A (en) | 1993-03-10 | 1994-05-31 | Dalton William J | Triple cuff endobronchial tube with selective multiple outlets served by a single airflow passage |
US5312331A (en) | 1993-04-15 | 1994-05-17 | Knoepfler Dennis J | Method and apparatus for talc pleurodesis |
US5478333A (en) | 1994-03-04 | 1995-12-26 | Asherman, Jr.; Richard E. | Medical dressing for treating open chest injuries |
US5318523A (en) * | 1993-07-13 | 1994-06-07 | Lu Jieh Shan | Drug-feeder for children |
US5366478A (en) | 1993-07-27 | 1994-11-22 | Ethicon, Inc. | Endoscopic surgical sealing device |
US5354283A (en) | 1994-01-07 | 1994-10-11 | Little Rapids Corporation | Trocar retention apparatus |
US5431633A (en) | 1994-05-06 | 1995-07-11 | Global Fury, Inc. | Noninvasive device for preventing pressure build-up in pleural space and reducing possibility of development of a tension pneumothorax from an open pneumothorax |
US5685859A (en) * | 1994-06-02 | 1997-11-11 | Nikomed Aps | Device for fixating a drainage tube and a drainage tube assembly |
US6056744A (en) | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
JP3394327B2 (en) * | 1994-07-11 | 2003-04-07 | テルモ株式会社 | Tube inner surface treatment method |
US5695504A (en) | 1995-02-24 | 1997-12-09 | Heartport, Inc. | Devices and methods for performing a vascular anastomosis |
GB9507666D0 (en) | 1995-04-13 | 1995-05-31 | Squibb & Sons Inc | Ostomy coupling |
US5634937A (en) | 1995-05-19 | 1997-06-03 | General Surgical Innovations, Inc. | Skin seal with inflatable membrane |
US5588424A (en) | 1995-06-28 | 1996-12-31 | The Cleveland Clinic Foundation | Bronchial blocker endotracheal apparatus |
JPH0928666A (en) * | 1995-07-21 | 1997-02-04 | Olympus Optical Co Ltd | Trocar |
US5660175A (en) | 1995-08-21 | 1997-08-26 | Dayal; Bimal | Endotracheal device |
JP3229809B2 (en) * | 1995-08-31 | 2001-11-19 | 三洋電機株式会社 | Semiconductor device |
JP3024069U (en) * | 1995-09-13 | 1996-05-17 | 富士システムズ株式会社 | Thoracoscopic insertion aid |
US5836311A (en) | 1995-09-20 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for temporarily immobilizing a local area of tissue |
US5735661A (en) * | 1995-10-31 | 1998-04-07 | Nynex Science & Technology, Inc. | Transporter for storing and carrying multiple articles, such as coin collection boxes |
WO1997021459A1 (en) * | 1995-12-13 | 1997-06-19 | Nikomed Aps | A device for fixating a drainage tube |
US6273912B1 (en) | 1996-02-28 | 2001-08-14 | Impra, Inc. | Flanged graft for end-to-side anastomosis |
US5951588A (en) | 1996-02-29 | 1999-09-14 | Moenning; Stephen P. | Apparatus and method for protecting a port site opening in the wall of a body cavity |
US5931821A (en) | 1996-03-05 | 1999-08-03 | Tyco Group S.A.R.L. | Chest drainage unit with controlled automatic excess negativity relief feature |
US5736661A (en) * | 1996-03-12 | 1998-04-07 | Armstrong; Paul R. | System and method for tuning an instrument to a meantone temperament |
US5755709A (en) * | 1996-04-25 | 1998-05-26 | Cuppy; Michael J. | Catheter system for percutaneously introducing a liquid |
CA2186656C (en) | 1996-08-20 | 2007-11-06 | Peter Leslie Steer | An ostomy coupling |
AUPO322396A0 (en) | 1996-10-25 | 1996-11-21 | Robinson, Gavin J.B. Dr | A method of measuring cardiac output by pulmonary exchange of oxygen and an inert gas with the blood utilising a divided airway |
US5807341A (en) | 1996-12-11 | 1998-09-15 | Team Medical Llc | Medical catheter dressing device |
US5779649A (en) * | 1996-12-17 | 1998-07-14 | Pabban Development, Inc. | Surgical suction wand with filter |
WO1998027878A1 (en) * | 1996-12-20 | 1998-07-02 | Fundação E.J. Zerbini | A prosthesis for thoracostomy and method for its implantation |
WO1998032380A1 (en) * | 1997-01-24 | 1998-07-30 | University Of Massachusetts | Auxiliary thoracic endoscope for minimally invasive surgery |
JPH10309321A (en) | 1997-03-11 | 1998-11-24 | San Medical Gijutsu Kenkyusho:Kk | Skin button |
US5743053A (en) * | 1997-03-25 | 1998-04-28 | Somerville; Ronald E. | Protective barrier for arresting the fall of a person on a stairway |
US5961090A (en) | 1997-04-03 | 1999-10-05 | Parkin; Emanuel | Mounting device |
US5972026A (en) | 1997-04-07 | 1999-10-26 | Broncus Technologies, Inc. | Bronchial stenter having diametrically adjustable electrodes |
US6083255A (en) | 1997-04-07 | 2000-07-04 | Broncus Technologies, Inc. | Bronchial stenter |
US6283988B1 (en) | 1997-04-07 | 2001-09-04 | Broncus Technologies, Inc. | Bronchial stenter having expandable electrodes |
US6273907B1 (en) | 1997-04-07 | 2001-08-14 | Broncus Technologies, Inc. | Bronchial stenter |
US6411852B1 (en) | 1997-04-07 | 2002-06-25 | Broncus Technologies, Inc. | Modification of airways by application of energy |
US6488673B1 (en) | 1997-04-07 | 2002-12-03 | Broncus Technologies, Inc. | Method of increasing gas exchange of a lung |
US5891159A (en) * | 1997-05-02 | 1999-04-06 | Cardiothoratic Systems, Inc. | Automatic purse string suture device |
US6222090B1 (en) * | 1997-05-05 | 2001-04-24 | Shower-Seal, Inc. | Waterproof injection port cover |
US5954636A (en) | 1997-07-15 | 1999-09-21 | Schwartz; Roy E. | Pediatric endotracheal tube with bronchial blocker and method for selectively blocking respiratory airflow to a pediatric patient's lung |
US20060239930A1 (en) * | 1997-08-04 | 2006-10-26 | Herbert Lamche | Process for nebulizing aqueous compositions containing highly concentrated insulin |
ES2235361T3 (en) | 1997-08-26 | 2005-07-01 | Absolute Closure Innovations, Inc. | CLOSURE DEVICE TO CREATE A WATERPROOF SEAL BETWEEN FABRICS OR OTHER MATERIALS. |
US5954766A (en) | 1997-09-16 | 1999-09-21 | Zadno-Azizi; Gholam-Reza | Body fluid flow control device |
US20040199202A1 (en) * | 1997-11-12 | 2004-10-07 | Genesis Technologies Llc | Biological passageway occlusion removal |
DE69836764T2 (en) * | 1997-11-14 | 2007-10-04 | Boston Scientific Ltd., St. Michael | CATHETER WITH MULTIPLE CASE FOR INTRODUCING A PROSTHESIS |
US6014972A (en) * | 1997-12-11 | 2000-01-18 | Thayer Medical Corporation | Dry drug particle delivery system and method for ventilator circuits |
US6651670B2 (en) * | 1998-02-13 | 2003-11-25 | Ventrica, Inc. | Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication |
US6330882B1 (en) | 1998-03-06 | 2001-12-18 | Ronald French | Emergency apparatus for evacuating air from the body cavity |
US5997509A (en) * | 1998-03-06 | 1999-12-07 | Cornell Research Foundation, Inc. | Minimally invasive gene therapy delivery device and method |
US6106495A (en) * | 1998-05-20 | 2000-08-22 | Howmedica Inc. | Methods and apparatus for delivering antibiotic powders into the femoral canal for the reduction of orthopaedic sepsis during total hip arthroplasty |
US6599311B1 (en) | 1998-06-05 | 2003-07-29 | Broncus Technologies, Inc. | Method and assembly for lung volume reduction |
US7198635B2 (en) | 2000-10-17 | 2007-04-03 | Asthmatx, Inc. | Modification of airways by application of energy |
US6293930B1 (en) | 1998-06-11 | 2001-09-25 | Hollister Incorporated | Low-profile ostomy faceplate with recessed coupling ring |
US6736797B1 (en) | 1998-06-19 | 2004-05-18 | Unomedical A/S | Subcutaneous infusion set |
JP2000060862A (en) * | 1998-08-20 | 2000-02-29 | Sumitomo Bakelite Co Ltd | Pallial tube for insertion of thoracoscope with cuff |
US6135111A (en) * | 1998-08-31 | 2000-10-24 | Vital Signs Inc. | Tracheostomy tube with removable inner cannula |
SE512807C2 (en) | 1998-09-02 | 2000-05-15 | Bjoern Flodin | Device for supplying inhalation gas to and removing exhalation gas from a patient |
DE19852848C1 (en) | 1998-11-11 | 2000-08-24 | Klaus Affeld | Method for forming an infection protection cuff for the passage of a channel through the skin into the interior of the body and device therefor |
JP2000197706A (en) * | 1999-01-06 | 2000-07-18 | Hideo Horii | Supporsitor insertion tool |
US6028255A (en) * | 1999-02-16 | 2000-02-22 | Myronyk; Charles E. | Detachable neck for a guitar |
US9814869B1 (en) | 1999-06-15 | 2017-11-14 | C.R. Bard, Inc. | Graft-catheter vascular access system |
EP1191977A1 (en) | 1999-06-18 | 2002-04-03 | Powerlung Inc | Pulmonary exercise device |
US20050137715A1 (en) | 1999-08-05 | 2005-06-23 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US7022088B2 (en) | 1999-08-05 | 2006-04-04 | Broncus Technologies, Inc. | Devices for applying energy to tissue |
US20050177144A1 (en) | 1999-08-05 | 2005-08-11 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20030130657A1 (en) | 1999-08-05 | 2003-07-10 | Tom Curtis P. | Devices for applying energy to tissue |
US6712812B2 (en) | 1999-08-05 | 2004-03-30 | Broncus Technologies, Inc. | Devices for creating collateral channels |
US7462162B2 (en) * | 2001-09-04 | 2008-12-09 | Broncus Technologies, Inc. | Antiproliferative devices for maintaining patency of surgically created channels in a body organ |
US6749606B2 (en) | 1999-08-05 | 2004-06-15 | Thomas Keast | Devices for creating collateral channels |
US7422584B2 (en) | 2002-07-05 | 2008-09-09 | Broncus Technologies, Inc. | Extrapleural airway device and method |
US6179804B1 (en) * | 1999-08-18 | 2001-01-30 | Oxypatch, Llc | Treatment apparatus for wounds |
US6416554B1 (en) | 1999-08-24 | 2002-07-09 | Spiration, Inc. | Lung reduction apparatus and method |
US6293951B1 (en) | 1999-08-24 | 2001-09-25 | Spiration, Inc. | Lung reduction device, system, and method |
JP4006612B2 (en) * | 1999-09-27 | 2007-11-14 | ソニー株式会社 | DATA PROCESSING DEVICE AND DATA PROCESSING METHOD, RECORDING MEDIUM, DIGITAL BROADCAST RECEIVING DEVICE, AND RECORDING / REPRODUCING METHOD IN DIGITAL BROADCAST RECEIVING DEVICE |
US6402754B1 (en) | 1999-10-20 | 2002-06-11 | Spiration, Inc. | Apparatus for expanding the thorax |
US6398775B1 (en) | 1999-10-21 | 2002-06-04 | Pulmonx | Apparatus and method for isolated lung access |
WO2001045568A1 (en) | 1999-12-20 | 2001-06-28 | Dexterity Surgical, Inc. | Adjustable surgical wound protector and retractor |
US6901927B2 (en) | 2000-03-04 | 2005-06-07 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US6770070B1 (en) | 2000-03-17 | 2004-08-03 | Rita Medical Systems, Inc. | Lung treatment apparatus and method |
US6945969B1 (en) | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6701928B2 (en) * | 2000-04-06 | 2004-03-09 | Wake Forest University | Inhaler dispensing system adapters for laryngectomized subjects and associated methods |
US6274787B1 (en) * | 2000-04-30 | 2001-08-14 | Eric Downing | Transparent, span-over-the-wound bandage |
US6459917B1 (en) * | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
US6719749B1 (en) * | 2000-06-01 | 2004-04-13 | Medical Components, Inc. | Multilumen catheter assembly and methods for making and inserting the same |
US6363932B1 (en) * | 2000-07-06 | 2002-04-02 | Clinical Technologies, Inc. | Aerosol enhancement device |
CA2415297A1 (en) * | 2000-07-15 | 2002-01-24 | Glaxo Group Limited | Medicament dispenser |
US6443156B1 (en) | 2000-08-02 | 2002-09-03 | Laura E. Niklason | Separable double lumen endotracheal tube |
US6569121B1 (en) * | 2000-10-12 | 2003-05-27 | Benjamin Warren Purow | Sheath device with dressing for prevention of pneumothorax |
US20060135947A1 (en) | 2000-10-27 | 2006-06-22 | Pulmonx | Occlusal stent and methods for its use |
US6585639B1 (en) | 2000-10-27 | 2003-07-01 | Pulmonx | Sheath and method for reconfiguring lung viewing scope |
US6692449B1 (en) * | 2000-12-15 | 2004-02-17 | Northwestern University | Methods and system for assessing limb position sense during movement |
US20030186904A1 (en) | 2001-01-08 | 2003-10-02 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US6890295B2 (en) | 2002-10-31 | 2005-05-10 | Medtronic, Inc. | Anatomical space access tools and methods |
WO2002056794A2 (en) | 2001-01-18 | 2002-07-25 | The Brigham And Women's Hospital, Inc. | Prosthetic device for respiratory patients |
US20020112729A1 (en) | 2001-02-21 | 2002-08-22 | Spiration, Inc. | Intra-bronchial obstructing device that controls biological interaction with the patient |
US9132253B2 (en) * | 2001-02-23 | 2015-09-15 | Lawrence A. Lynn | Asthma resuscitation system and method |
US6609521B1 (en) | 2001-04-09 | 2003-08-26 | Regents Of The University Of Minnesota | Endotracheal tube |
US6969373B2 (en) * | 2001-04-13 | 2005-11-29 | Tricardia, Llc | Syringe system |
RU2192185C1 (en) | 2001-05-04 | 2002-11-10 | Фатихов Рашит Габдуллович | Pleural cavity drainage apparatus |
US6871228B2 (en) * | 2001-06-29 | 2005-03-22 | International Business Machines Corporation | Methods and apparatus in distributed remote logging system for remote adhoc data analysis customized with multilevel hierarchical logger tree |
US6638253B2 (en) | 2001-07-17 | 2003-10-28 | Eugene Michael Breznock | Method and apparatus for chest drainage |
KR100813755B1 (en) | 2001-07-18 | 2008-03-13 | 스미토모 베이클리트 컴퍼니 리미티드 | Medical treating instrument |
US7364565B2 (en) | 2001-07-27 | 2008-04-29 | Ramot At Tel Aviv University Ltd. | Controlled enzymatic removal and retrieval of cells |
US20050137611A1 (en) | 2001-09-04 | 2005-06-23 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US7883471B2 (en) | 2001-09-10 | 2011-02-08 | Pulmonx Corporation | Minimally invasive determination of collateral ventilation in lungs |
WO2003030975A2 (en) | 2001-10-11 | 2003-04-17 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
US6592594B2 (en) | 2001-10-25 | 2003-07-15 | Spiration, Inc. | Bronchial obstruction device deployment system and method |
US20030127090A1 (en) | 2001-11-14 | 2003-07-10 | Emphasys Medical, Inc. | Active pump bronchial implant devices and methods of use thereof |
US6840242B1 (en) * | 2002-01-23 | 2005-01-11 | Mccoy Stephen Craig | Tracheostomy aspiration suction tube |
US6827086B2 (en) | 2002-02-01 | 2004-12-07 | Spiration, Inc. | Device and method of isolating deleterious body tissue located within healthy body tissue |
US20030154576A1 (en) | 2002-02-20 | 2003-08-21 | Eddia Mirharooni | Eddia cuff link |
US20030154988A1 (en) | 2002-02-21 | 2003-08-21 | Spiration, Inc. | Intra-bronchial device that provides a medicant intra-bronchially to the patient |
US6929637B2 (en) | 2002-02-21 | 2005-08-16 | Spiration, Inc. | Device and method for intra-bronchial provision of a therapeutic agent |
US20060235432A1 (en) | 2002-02-21 | 2006-10-19 | Devore Lauri J | Intra-bronchial obstructing device that controls biological interaction with the patient |
US7041083B2 (en) * | 2002-02-26 | 2006-05-09 | Scimed Life Systems, Inc. | Medical catheter assembly including a removable inner sleeve and method of using the same |
WO2003075796A2 (en) | 2002-03-08 | 2003-09-18 | Emphasys Medical, Inc. | Methods and devices for inducing collapse in lung regions fed by collateral pathways |
WO2003078579A2 (en) | 2002-03-11 | 2003-09-25 | Aeris Therapeutics, Inc. | Compositions and methods for treating emphysema |
US20030181922A1 (en) | 2002-03-20 | 2003-09-25 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
US7001367B2 (en) * | 2002-04-16 | 2006-02-21 | Arkinstall William W | Valved ostomy drainage device |
US20030195385A1 (en) | 2002-04-16 | 2003-10-16 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
US20030195511A1 (en) | 2002-04-16 | 2003-10-16 | Spiration, Inc. | Device for and method of removing deleterious body tissue from a site within a patient |
EP1509168A4 (en) | 2002-04-19 | 2009-07-22 | Broncus Tech Inc | Devices for maintaining surgically created openings |
US6770063B2 (en) | 2002-04-23 | 2004-08-03 | Uresil, L.P. | Thoracic vent kit |
ES2385556T3 (en) * | 2002-04-26 | 2012-07-26 | Teleflex Medical Incorporated | Floating shutter set for a trocar |
JP4381973B2 (en) * | 2002-05-09 | 2009-12-09 | タイコ ヘルスケア グループ エルピー | Adjustable balloon mooring trocar |
US7207946B2 (en) * | 2002-05-09 | 2007-04-24 | Spiration, Inc. | Automated provision of information related to air evacuation from a chest cavity |
US20030212412A1 (en) | 2002-05-09 | 2003-11-13 | Spiration, Inc. | Intra-bronchial obstructing device that permits mucus transport |
US6809230B2 (en) * | 2002-06-04 | 2004-10-26 | Betty Hancock | Waterproof venipuncture site cover |
DE10225281C1 (en) * | 2002-06-07 | 2003-11-06 | Dornier Gmbh | Structure element for a portable container, as a working space, has outer reinforced plastics claddings with rib spacers, to take insulation layers between them for a light weight with high mechanical strength |
ITMI20021273A1 (en) | 2002-06-11 | 2003-12-11 | Milano Politecnico | SYSTEM AND METHOD FOR THE AUTOMATIC DETECTION OF THE EXPIRATORY FLOW LIMITATION |
US7819908B2 (en) | 2002-06-17 | 2010-10-26 | Aeris Therapeutics, Inc. | Compositions and methods for reducing lung volume |
US7134273B2 (en) * | 2002-09-04 | 2006-11-14 | Ford Global Technologies, Llc | Exhaust emission control and diagnostics |
US6905484B2 (en) * | 2002-09-30 | 2005-06-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for rapid deployment chest drainage |
US20040144387A1 (en) | 2003-01-28 | 2004-07-29 | David Amar | Double-balloon endobronchial catheter for one lung isolation anesthesia and surgery |
US20040210248A1 (en) | 2003-03-12 | 2004-10-21 | Spiration, Inc. | Apparatus, method and assembly for delivery of intra-bronchial devices |
US7100616B2 (en) | 2003-04-08 | 2006-09-05 | Spiration, Inc. | Bronchoscopic lung volume reduction method |
US7811274B2 (en) * | 2003-05-07 | 2010-10-12 | Portaero, Inc. | Method for treating chronic obstructive pulmonary disease |
US7426929B2 (en) | 2003-05-20 | 2008-09-23 | Portaero, Inc. | Intra/extra-thoracic collateral ventilation bypass system and method |
US7533667B2 (en) | 2003-05-29 | 2009-05-19 | Portaero, Inc. | Methods and devices to assist pulmonary decompression |
US6916310B2 (en) | 2003-05-30 | 2005-07-12 | Codman & Shurtleff, Inc. | Percutaneous access device |
US7252086B2 (en) | 2003-06-03 | 2007-08-07 | Cordis Corporation | Lung reduction system |
US7377278B2 (en) | 2003-06-05 | 2008-05-27 | Portaero, Inc. | Intra-thoracic collateral ventilation bypass system and method |
US8002740B2 (en) | 2003-07-18 | 2011-08-23 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US20050103340A1 (en) | 2003-08-20 | 2005-05-19 | Wondka Anthony D. | Methods, systems & devices for endobronchial ventilation and drug delivery |
US20050066041A1 (en) * | 2003-09-19 | 2005-03-24 | Chin Kwan Wu | Setting up a name resolution system for home-to-home communications |
US7135010B2 (en) | 2003-09-30 | 2006-11-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for rapid deployment chest drainage |
US20050171396A1 (en) | 2003-10-20 | 2005-08-04 | Cyberheart, Inc. | Method for non-invasive lung treatment |
WO2005046426A2 (en) | 2003-11-17 | 2005-05-26 | Spirojet Medical Ltd. | Spirometer |
US7036509B2 (en) | 2003-12-04 | 2006-05-02 | Emphasys Medical, Inc. | Multiple seal port anesthesia adapter |
US20050178389A1 (en) | 2004-01-27 | 2005-08-18 | Shaw David P. | Disease indications for selective endobronchial lung region isolation |
US7121280B2 (en) | 2004-03-17 | 2006-10-17 | Cook Critical Care Incorporated | Medical devices and methods of selectively and alternately isolating bronchi or lungs |
US20060142790A1 (en) * | 2004-03-23 | 2006-06-29 | Michael Gertner | Methods and devices to facilitate connections between body lumens |
WO2005122953A2 (en) | 2004-05-11 | 2005-12-29 | Oregon Health And Science University | Interfacial stent and method of maintaining patency of surgical fenestrations |
US7448385B2 (en) * | 2004-06-07 | 2008-11-11 | Purepharm Inc. | Nasal adaptation of an oral inhaler device |
US7775968B2 (en) | 2004-06-14 | 2010-08-17 | Pneumrx, Inc. | Guided access to lung tissues |
US7553810B2 (en) | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
US7608579B2 (en) | 2004-06-16 | 2009-10-27 | Pneumrx, Inc. | Lung volume reduction using glue compositions |
US20050281799A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting damaged lung tissue using compositions |
US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
EP1773425A4 (en) * | 2004-07-07 | 2012-01-04 | Egret Medical Products Inc | Suction catheter assembly |
EP1781182B1 (en) * | 2004-07-08 | 2019-11-13 | PneumRx, Inc. | Pleural effusion treatment device |
WO2006014732A2 (en) | 2004-07-19 | 2006-02-09 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20060130830A1 (en) | 2004-09-07 | 2006-06-22 | Uptake Medical Corporation | Intra-bronchial implants for improved attachment |
US7460941B2 (en) * | 2004-09-29 | 2008-12-02 | Caterpillar Inc. | Slope-limited retarding control for a propelled machine |
US20060079845A1 (en) * | 2004-10-08 | 2006-04-13 | Eben Howard And Pamela A. Howard | Movable inflatable anchor for medical devices |
US20060079838A1 (en) * | 2004-10-08 | 2006-04-13 | Walker Steven C | Movable Balloon anchor for medical devices |
US20060162731A1 (en) | 2004-11-16 | 2006-07-27 | Pulmonx | Pulmonary occlusal stent delivery catheter, loading system and methods of use |
BRPI0518437A2 (en) | 2004-11-16 | 2008-11-18 | Brian Cran | lung treatment device and method |
US20060118126A1 (en) | 2004-11-19 | 2006-06-08 | Don Tanaka | Methods and devices for controlling collateral ventilation |
US8220460B2 (en) | 2004-11-19 | 2012-07-17 | Portaero, Inc. | Evacuation device and method for creating a localized pleurodesis |
US7398782B2 (en) * | 2004-11-19 | 2008-07-15 | Portaero, Inc. | Method for pulmonary drug delivery |
US7824366B2 (en) * | 2004-12-10 | 2010-11-02 | Portaero, Inc. | Collateral ventilation device with chest tube/evacuation features and method |
US7832394B2 (en) * | 2004-12-22 | 2010-11-16 | Schechter Alan M | Apparatus for dispensing pressurized contents |
US20060137681A1 (en) * | 2004-12-28 | 2006-06-29 | Ric Investments, Llc. | Actuator for a metered dose inhaler |
US20070186932A1 (en) | 2006-01-06 | 2007-08-16 | Pulmonx | Collateral pathway treatment using agent entrained by aspiration flow current |
US7731651B2 (en) | 2005-03-17 | 2010-06-08 | Spiration, Inc. | Device to deploy a resilient sleeve to constrict on body tissue |
WO2006130873A2 (en) | 2005-06-01 | 2006-12-07 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US20070142742A1 (en) | 2005-07-13 | 2007-06-21 | Pulmonx | Methods and systems for segmental lung diagnostics |
US7268096B2 (en) * | 2005-07-21 | 2007-09-11 | Chevron Phillips Chemical Company Lp | Diimine metal complexes, methods of synthesis, and methods of using in oligomerization and polymerization |
US20070038177A1 (en) * | 2005-08-12 | 2007-02-15 | Sinha Anil K | Self securing chest tubes and methods |
KR20130066707A (en) | 2005-09-21 | 2013-06-20 | 다스크 테크날러지, 엘엘씨 | Methods and compositions for organ and tissue functionality |
AR055498A1 (en) | 2005-10-07 | 2007-08-22 | Pablo C Luchetti | SURGICAL DEVICE FOR INCISION AND SKIN CLOSURE |
NZ550487A (en) | 2005-10-11 | 2008-04-30 | Bristol Myers Squibb Co | Ostomy coupling |
DE102005050902A1 (en) * | 2005-10-21 | 2007-05-03 | Khs Ag | Device for aligning containers and labeling machine with such a device |
US20070186933A1 (en) | 2006-01-17 | 2007-08-16 | Pulmonx | Systems and methods for delivering flow restrictive element to airway in lungs |
US7406963B2 (en) * | 2006-01-17 | 2008-08-05 | Portaero, Inc. | Variable resistance pulmonary ventilation bypass valve and method |
EP1815821A1 (en) | 2006-02-02 | 2007-08-08 | Dr. Karel Volenec - ELLA - CS | Stent delivery system |
US20070256688A1 (en) * | 2006-04-21 | 2007-11-08 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
US20080234660A2 (en) * | 2006-05-16 | 2008-09-25 | Sarah Cumming | Steerable Catheter Using Flat Pull Wires and Method of Making Same |
CA2652544A1 (en) * | 2006-05-18 | 2007-12-13 | Breathe Technologies, Inc. | Tracheostoma spacer, tracheotomy method, and device for inserting a tracheostoma spacer |
EP2142208A4 (en) * | 2007-04-03 | 2013-01-16 | Aeris Therapeutics Llc | Lung volume reduction therapy using crosslinked biopolymers |
US20080281151A1 (en) | 2007-05-11 | 2008-11-13 | Portaero, Inc. | Pulmonary pleural stabilizer |
US8163034B2 (en) | 2007-05-11 | 2012-04-24 | Portaero, Inc. | Methods and devices to create a chemically and/or mechanically localized pleurodesis |
US7931641B2 (en) | 2007-05-11 | 2011-04-26 | Portaero, Inc. | Visceral pleura ring connector |
US20080287878A1 (en) | 2007-05-15 | 2008-11-20 | Portaero, Inc. | Pulmonary visceral pleura anastomosis reinforcement |
US20080283065A1 (en) | 2007-05-15 | 2008-11-20 | Portaero, Inc. | Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung |
US8062315B2 (en) * | 2007-05-17 | 2011-11-22 | Portaero, Inc. | Variable parietal/visceral pleural coupling |
US20080295829A1 (en) | 2007-05-30 | 2008-12-04 | Portaero, Inc. | Bridge element for lung implant |
US8181651B2 (en) * | 2007-07-24 | 2012-05-22 | Passy-Muir, Inc. | Hand powered suction device with mucus trap and suction catheter for tracheostomy tubes |
MX2010003560A (en) * | 2007-10-18 | 2010-04-21 | Convatec Technologies Inc | Aspiration system for removing liquid discharged by the human body, and liquid sensor therefor. |
EP3184141B1 (en) * | 2007-10-30 | 2019-01-02 | UTI Limited Partnership | Method for sustained-release of sclerosing agent |
US8336540B2 (en) | 2008-02-19 | 2012-12-25 | Portaero, Inc. | Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease |
US8475389B2 (en) | 2008-02-19 | 2013-07-02 | Portaero, Inc. | Methods and devices for assessment of pneumostoma function |
EP2242527A4 (en) | 2008-02-19 | 2011-07-13 | Portaero Inc | Devices and methods for delivery of a therapeutic agent through a pneumostoma |
US8347881B2 (en) | 2009-01-08 | 2013-01-08 | Portaero, Inc. | Pneumostoma management device with integrated patency sensor and method |
US8518053B2 (en) * | 2009-02-11 | 2013-08-27 | Portaero, Inc. | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
-
2009
- 2009-02-17 EP EP09711701A patent/EP2242527A4/en not_active Withdrawn
- 2009-02-17 WO PCT/US2009/034322 patent/WO2009105432A2/en active Application Filing
- 2009-02-18 US US12/388,441 patent/US8491602B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,470 patent/US8021320B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,451 patent/US20090205645A1/en not_active Abandoned
- 2009-02-18 US US12/388,467 patent/US8347880B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,438 patent/US20090205643A1/en not_active Abandoned
- 2009-02-18 US US12/388,465 patent/US7909803B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,462 patent/US7927324B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,455 patent/US20090205658A1/en not_active Abandoned
- 2009-02-18 US US12/388,446 patent/US20090209909A1/en not_active Abandoned
- 2009-02-18 CA CA2752159A patent/CA2752159A1/en not_active Abandoned
- 2009-02-18 US US12/388,453 patent/US8252003B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,468 patent/US8365722B2/en not_active Expired - Fee Related
- 2009-02-18 WO PCT/US2009/034374 patent/WO2009105455A2/en active Application Filing
- 2009-02-18 AU AU2009215579A patent/AU2009215579A1/en not_active Abandoned
- 2009-02-18 BR BRPI0908784A patent/BRPI0908784A2/en not_active IP Right Cessation
- 2009-02-18 US US12/388,466 patent/US8453638B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,461 patent/US8348906B2/en not_active Expired - Fee Related
- 2009-02-18 WO PCT/US2009/034406 patent/WO2009105473A2/en active Application Filing
- 2009-02-18 EP EP09712130A patent/EP2242530A4/en not_active Withdrawn
- 2009-02-18 JP JP2010547718A patent/JP2011512232A/en active Pending
- 2009-02-18 US US12/388,460 patent/US8464708B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,469 patent/US8474449B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/388,459 patent/US20090205665A1/en not_active Abandoned
- 2009-02-18 JP JP2010547719A patent/JP2011512233A/en active Pending
- 2009-02-18 US US12/388,447 patent/US8453637B2/en not_active Expired - Fee Related
- 2009-02-18 WO PCT/US2009/034380 patent/WO2009105458A2/en active Application Filing
- 2009-02-18 US US12/388,458 patent/US8430094B2/en not_active Expired - Fee Related
- 2009-02-18 EP EP09712329A patent/EP2242529A4/en not_active Withdrawn
- 2009-02-18 CN CN2009801137738A patent/CN102006904A/en active Pending
- 2009-02-18 US US12/388,435 patent/US20090209856A1/en not_active Abandoned
-
2011
- 2011-01-25 US US13/012,962 patent/US8231581B2/en not_active Expired - Fee Related
- 2011-08-19 US US13/213,279 patent/US8273051B2/en not_active Expired - Fee Related
-
2012
- 2012-07-06 US US13/543,588 patent/US8506577B2/en not_active Expired - Fee Related
-
2013
- 2013-03-27 US US13/851,545 patent/US20130218134A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4799494A (en) * | 1986-10-22 | 1989-01-24 | Wang Ko P | Percutaneous aspiration lung biopsy needle assembly |
US4813929A (en) * | 1987-02-19 | 1989-03-21 | Neal Semrad | Chest tube device and method of inserting device |
US5004456A (en) * | 1989-03-10 | 1991-04-02 | Arrow International Investment Corporation | In-dwelling catheter |
US5078689A (en) * | 1990-05-14 | 1992-01-07 | Keller Alan M | Device for removing body fluids |
US5401262A (en) * | 1990-07-20 | 1995-03-28 | Atrium Medical Corporation | Fluid recovery system |
US5501678A (en) * | 1991-08-30 | 1996-03-26 | Coloplast A/S | Adapter for use in connection with ostomy equipment |
US5403264A (en) * | 1992-09-04 | 1995-04-04 | Ethicon, Inc. | Endoscopic closure inspection device |
US5616131A (en) * | 1992-09-23 | 1997-04-01 | Lasersurge, Inc. | Apparatus and method for anchoring surgical instrumentation |
US5484401A (en) * | 1992-11-04 | 1996-01-16 | Denver Biomaterials, Inc. | Treatment method for pleural effusion |
US5496297A (en) * | 1993-02-22 | 1996-03-05 | Coloplast A/S | Ostomy coupling |
US5389077A (en) * | 1993-03-03 | 1995-02-14 | Uresil Corporation | Minimally invasive body cavity penetrating instruments |
US5501677A (en) * | 1993-06-25 | 1996-03-26 | Jensen; Ole R. | Two-piece ostomy appliance and low-profile coupling ring assembly |
US5897531A (en) * | 1994-01-07 | 1999-04-27 | Amirana; Omar | Adhesive surgical retaining device |
US5738661A (en) * | 1995-06-16 | 1998-04-14 | Larice; Gennaro | Medical device for holding a feeding tube and use thereof |
US7014628B2 (en) * | 1995-07-07 | 2006-03-21 | Bousquet Gerald G | Transcutaneous access device |
US5728066A (en) * | 1995-12-13 | 1998-03-17 | Daneshvar; Yousef | Injection systems and methods |
US5730735A (en) * | 1996-03-12 | 1998-03-24 | Hollister Incorporated | Convex ostomy faceplate with floating flange and finger recess |
US6702812B2 (en) * | 1996-09-20 | 2004-03-09 | Ioan Cosmescu | Multifunctional telescopic monopolar/bipolar surgical device and method therefor |
US6200333B1 (en) * | 1997-04-07 | 2001-03-13 | Broncus Technologies, Inc. | Bronchial stenter |
US20070005083A1 (en) * | 1997-04-30 | 2007-01-04 | Sabaratham Sabanathan | Occlusion device |
US6550475B1 (en) * | 1998-03-11 | 2003-04-22 | Oldfield Family Holdings Pty. Limited | Endotracheal tube for selective bronchial occlusion |
US6997189B2 (en) * | 1998-06-05 | 2006-02-14 | Broncus Technologies, Inc. | Method for lung volume reduction |
US6174323B1 (en) * | 1998-06-05 | 2001-01-16 | Broncus Technologies, Inc. | Method and assembly for lung volume reduction |
US20040031494A1 (en) * | 1998-06-10 | 2004-02-19 | Broncus Technologies, Inc. | Methods of treating asthma |
US6197010B1 (en) * | 1998-06-11 | 2001-03-06 | Hollister Incorporated | Ostomy appliance faceplate with concealed coupling ring flange |
US6358269B1 (en) * | 1998-11-02 | 2002-03-19 | Ralph Aye | Method of treating peripheral bronchopleural fistulas |
US6334441B1 (en) * | 1998-11-23 | 2002-01-01 | Mallinckrodt Medical, Inc. | Phonation valve for breathing tube |
US6682506B1 (en) * | 1998-12-22 | 2004-01-27 | Francis Navarro | Device for maintaining at least a tube |
US20050015106A1 (en) * | 1999-07-02 | 2005-01-20 | Pulmonx | Methods, systems, and kits for lung volume reduction |
US6709401B2 (en) * | 1999-07-02 | 2004-03-23 | Pulmonx | Methods, systems, and kits for lung volume reduction |
US7186259B2 (en) * | 1999-07-02 | 2007-03-06 | Pulmonx | Methods, systems, and kits for lung volume reduction |
US20040073201A1 (en) * | 1999-08-05 | 2004-04-15 | Broncus Technologies, Inc. | Methods for treating chronic obstructive pulmonary disease |
US6692494B1 (en) * | 1999-08-05 | 2004-02-17 | Broncus Technologies, Inc. | Methods and devices for creating collateral channels in the lungs |
US20020042564A1 (en) * | 1999-08-05 | 2002-04-11 | Cooper Joel D. | Devices for creating collateral channels in the lungs |
US20050049615A1 (en) * | 1999-08-05 | 2005-03-03 | Broncus Technologies, Inc. | Methods for treating chronic obstructive pulmonary disease |
US20050056292A1 (en) * | 1999-08-05 | 2005-03-17 | Cooper Joel D. | Devices for maintaining patency of surgically created channels in tissue |
US20050060044A1 (en) * | 1999-08-05 | 2005-03-17 | Ed Roschak | Methods and devices for maintaining patency of surgically created channels in a body organ |
US6517519B1 (en) * | 1999-08-13 | 2003-02-11 | The Johns Hopkins University | Device and method for rapid chest tube insertion |
US20040073155A1 (en) * | 2000-01-14 | 2004-04-15 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in tissue |
US6679264B1 (en) * | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US20040016435A1 (en) * | 2000-03-04 | 2004-01-29 | Deem Mark E. | Methods and devices for use in performing pulmonary procedures |
US6840243B2 (en) * | 2000-03-04 | 2005-01-11 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US6694979B2 (en) * | 2000-03-04 | 2004-02-24 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US7165548B2 (en) * | 2000-03-04 | 2007-01-23 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US20050043745A1 (en) * | 2000-03-23 | 2005-02-24 | Alferness Clifton A. | Tissue resection device, system, and method |
US6514290B1 (en) * | 2000-03-31 | 2003-02-04 | Broncus Technologies, Inc. | Lung elastic recoil restoring or tissue compressing device and method |
US20040010289A1 (en) * | 2000-10-17 | 2004-01-15 | Broncus Technologies, Inc. | Control system and process for application of energy to airway walls and other mediums |
US6997918B2 (en) * | 2000-10-27 | 2006-02-14 | Pulmonx | Methods and devices for obstructing and aspirating lung tissue segments |
US20040073191A1 (en) * | 2000-10-27 | 2004-04-15 | Pulmonx | Methods and devices for obstructing and aspirating lung tissue segments |
US6527761B1 (en) * | 2000-10-27 | 2003-03-04 | Pulmonx, Inc. | Methods and devices for obstructing and aspirating lung tissue segments |
US7175644B2 (en) * | 2001-02-14 | 2007-02-13 | Broncus Technologies, Inc. | Devices and methods for maintaining collateral channels in tissue |
US7011094B2 (en) * | 2001-03-02 | 2006-03-14 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
US20040055606A1 (en) * | 2001-03-02 | 2004-03-25 | Emphasys Medical, Inc. | Bronchial flow control devices with membrane seal |
US6520183B2 (en) * | 2001-06-11 | 2003-02-18 | Memorial Sloan-Kettering Cancer Center | Double endobronchial catheter for one lung isolation anesthesia and surgery |
US6860847B2 (en) * | 2001-07-10 | 2005-03-01 | Spiration, Inc. | Constriction device viewable under X ray fluoroscopy |
US20030069488A1 (en) * | 2001-07-10 | 2003-04-10 | Spiration, Inc. | Constriction device including fixation structure |
US7182772B2 (en) * | 2001-07-10 | 2007-02-27 | Spiration, Inc. | Constriction device including fixation structure |
US20030013935A1 (en) * | 2001-07-10 | 2003-01-16 | Spiration, Inc. | Constriction device viewable under X ray fluoroscopy |
US20030018344A1 (en) * | 2001-07-19 | 2003-01-23 | Olympus Optical Co., Ltd. | Medical device and method of embolizing bronchus or bronchiole |
US6837906B2 (en) * | 2001-08-03 | 2005-01-04 | Ensure Medical, Inc. | Lung assist apparatus and methods for use |
US20050060041A1 (en) * | 2001-09-04 | 2005-03-17 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US20050060042A1 (en) * | 2001-09-04 | 2005-03-17 | Broncus Technologies, Inc. | Methods and devices for maintaining surgically created channels in a body organ |
US20050043751A1 (en) * | 2001-09-04 | 2005-02-24 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20030051733A1 (en) * | 2001-09-10 | 2003-03-20 | Pulmonx | Method and apparatus for endobronchial diagnosis |
US20030055331A1 (en) * | 2001-09-11 | 2003-03-20 | Pulmonx | Methods of endobronchial diagnosis using imaging |
US20050033310A1 (en) * | 2001-09-11 | 2005-02-10 | Alferness Clifton A. | Intra-bronchial valve devices |
US20030050648A1 (en) * | 2001-09-11 | 2003-03-13 | Spiration, Inc. | Removable lung reduction devices, systems, and methods |
US7172581B2 (en) * | 2001-09-24 | 2007-02-06 | Coloplast A/S | Ostomy appliance with a removable, washable and reusable sealing member |
US20030065339A1 (en) * | 2001-10-02 | 2003-04-03 | Spiration, Inc. | Constriction device including reinforced suture holes |
US20030078469A1 (en) * | 2001-10-18 | 2003-04-24 | Spiration, Inc. | Constriction device including tear resistant structures |
US6843767B2 (en) * | 2001-10-18 | 2005-01-18 | Spiration, Inc. | Constriction device including tear resistant structures |
US6695791B2 (en) * | 2002-01-04 | 2004-02-24 | Spiration, Inc. | System and method for capturing body tissue samples |
US6846292B2 (en) * | 2002-02-19 | 2005-01-25 | Mohamed Bakry | Pleural biopsy and brushing needle |
US6852108B2 (en) * | 2002-05-14 | 2005-02-08 | Spiration, Inc. | Apparatus and method for resecting and removing selected body tissue from a site inside a patient |
US20050033344A1 (en) * | 2002-05-17 | 2005-02-10 | Dillard David H. | One-way valve devices for anchored implantation in a lung |
US20040047855A1 (en) * | 2002-06-17 | 2004-03-11 | Bistech, Inc., A Delaware Corporation | Compositions and methods for reducing lung volume |
US20040010209A1 (en) * | 2002-07-15 | 2004-01-15 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
US20040024356A1 (en) * | 2002-07-31 | 2004-02-05 | Don Tanaka | Long term oxygen therapy system |
US20040040555A1 (en) * | 2002-08-28 | 2004-03-04 | Don Tanaka | Collateral ventilation bypass trap system |
US20040059263A1 (en) * | 2002-09-24 | 2004-03-25 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
US20040073241A1 (en) * | 2002-10-11 | 2004-04-15 | Spiration, Inc. | Implantable tissue constriction device and method for suppressing leakage of fluid from resectioned body tissue |
US20040078026A1 (en) * | 2002-10-21 | 2004-04-22 | Wagner Robert B. | Method and apparatus for pleural drainage |
US6849061B2 (en) * | 2002-10-21 | 2005-02-01 | Robert B. Wagner | Method and apparatus for pleural drainage |
US20050061322A1 (en) * | 2003-01-20 | 2005-03-24 | Pulmonx | Method and arrangement for reducing the volume of a lung |
US20050022809A1 (en) * | 2003-04-25 | 2005-02-03 | Wondka Anthony David | Methods, systems and devices for desufflating a lung area |
US20070027434A1 (en) * | 2003-06-02 | 2007-02-01 | Ole Pedersen | Adhesive face plate for an ostomy appliance, an ostomy appliance and a method for cleaning a face plate |
US20050005936A1 (en) * | 2003-06-18 | 2005-01-13 | Wondka Anthony David | Methods, systems and devices for improving ventilation in a lung area |
US7195017B2 (en) * | 2003-07-03 | 2007-03-27 | Cordis Corporation | Collateral ventilation bypass trap system |
US20050025816A1 (en) * | 2003-07-15 | 2005-02-03 | Don Tanaka | Methods and devices to accelerate wound healing in thoracic anastomosis applications |
US7192420B2 (en) * | 2003-08-08 | 2007-03-20 | Whiteford Bruce W | Ostomy adapter with multiple adhesives for reliable sealing |
US20050066976A1 (en) * | 2003-08-18 | 2005-03-31 | Wondka Anthony D. | Method and device for non-invasive ventilation with nasal interface |
US7195016B2 (en) * | 2004-01-07 | 2007-03-27 | E. Benson Hood Laboratories | Transtracheal oxygen stent |
US20060009748A1 (en) * | 2004-06-16 | 2006-01-12 | Mathis Mark L | Method of compressing a portion of a lung |
US20060004400A1 (en) * | 2004-06-16 | 2006-01-05 | Mcgurk Erin | Method of treating a lung |
US20060025815A1 (en) * | 2004-07-08 | 2006-02-02 | Mcgurk Erin | Lung device with sealing features |
US20060047291A1 (en) * | 2004-08-20 | 2006-03-02 | Uptake Medical Corporation | Non-foreign occlusion of an airway and lung collapse |
US20070055175A1 (en) * | 2005-05-25 | 2007-03-08 | Pulmosonix Pty Ltd | Devices and methods for tissue analysis |
US20070043350A1 (en) * | 2005-08-17 | 2007-02-22 | Pulmonx | Selective lung tissue ablation |
US20070051372A1 (en) * | 2005-08-23 | 2007-03-08 | Don Tanaka | Collateral ventilation bypass system with retention features |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8323230B2 (en) | 2003-07-15 | 2012-12-04 | Portaero, Inc. | Methods and devices to accelerate wound healing in thoracic anastomosis applications |
US20080077038A1 (en) * | 2004-11-02 | 2008-03-27 | Children's Hospital Of Philadelphia | Respiratory Volume/Flow Gating, Monitoring, and Spirometry System for Mri |
US8491602B2 (en) | 2008-02-19 | 2013-07-23 | Portaero, Inc. | Single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US8365722B2 (en) | 2008-02-19 | 2013-02-05 | Portaero, Inc. | Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US8021320B2 (en) | 2008-02-19 | 2011-09-20 | Portaero, Inc. | Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma |
US8475389B2 (en) | 2008-02-19 | 2013-07-02 | Portaero, Inc. | Methods and devices for assessment of pneumostoma function |
US8231581B2 (en) | 2008-02-19 | 2012-07-31 | Portaero, Inc. | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US8252003B2 (en) | 2008-02-19 | 2012-08-28 | Portaero, Inc. | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
US7909803B2 (en) | 2008-02-19 | 2011-03-22 | Portaero, Inc. | Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease |
US8336540B2 (en) | 2008-02-19 | 2012-12-25 | Portaero, Inc. | Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease |
US8348906B2 (en) | 2008-02-19 | 2013-01-08 | Portaero, Inc. | Aspirator for pneumostoma management |
US8506577B2 (en) | 2008-02-19 | 2013-08-13 | Portaero, Inc. | Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease |
US8347880B2 (en) | 2008-02-19 | 2013-01-08 | Potaero, Inc. | Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease |
US7927324B2 (en) | 2008-02-19 | 2011-04-19 | Portaero, Inc. | Aspirator and method for pneumostoma management |
US8430094B2 (en) | 2008-02-19 | 2013-04-30 | Portaero, Inc. | Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US8453638B2 (en) | 2008-02-19 | 2013-06-04 | Portaero, Inc. | One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease |
US8453637B2 (en) | 2008-02-19 | 2013-06-04 | Portaero, Inc. | Pneumostoma management system for treatment of chronic obstructive pulmonary disease |
US8464708B2 (en) | 2008-02-19 | 2013-06-18 | Portaero, Inc. | Pneumostoma management system having a cosmetic and/or protective cover |
US8474449B2 (en) | 2008-02-19 | 2013-07-02 | Portaero, Inc. | Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease |
US8347881B2 (en) | 2009-01-08 | 2013-01-08 | Portaero, Inc. | Pneumostoma management device with integrated patency sensor and method |
US8518053B2 (en) | 2009-02-11 | 2013-08-27 | Portaero, Inc. | Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease |
US9179891B2 (en) * | 2009-09-18 | 2015-11-10 | B-K Medicals Aps | Ultrasound probe |
US20120174675A1 (en) * | 2009-09-18 | 2012-07-12 | B-K Medical Aps | Ultrasound Probe |
US10188298B2 (en) | 2009-11-10 | 2019-01-29 | Illumigyn Ltd. | Optical speculum |
US20110112408A1 (en) * | 2009-11-10 | 2011-05-12 | Lior Greenstein | Optical Speculum |
US9259157B2 (en) | 2009-11-10 | 2016-02-16 | Illumigyn Ltd. | Optical speculum |
US9271640B2 (en) | 2009-11-10 | 2016-03-01 | Illumigyn Ltd. | Optical speculum |
US9314162B2 (en) | 2009-11-10 | 2016-04-19 | Illumigyn Ltd. | Optical speculum |
US8638995B2 (en) * | 2009-11-10 | 2014-01-28 | Illumigyn Ltd. | Optical speculum |
US9603528B2 (en) | 2009-11-10 | 2017-03-28 | Illumigyn Ltd. | Optical speculum |
US9603529B2 (en) | 2009-11-10 | 2017-03-28 | Illumigyn Ltd. | Optical speculum |
US9629556B2 (en) | 2009-11-10 | 2017-04-25 | Illumigyn Ltd. | Optical speculum |
US10694954B2 (en) | 2009-11-10 | 2020-06-30 | Illumigyn Ltd. | Optical speculum |
US9877644B2 (en) | 2009-11-10 | 2018-01-30 | Illumigyn Ltd. | Optical speculum |
US9968262B2 (en) | 2009-11-10 | 2018-05-15 | Illumigyn Ltd. | Optical speculum |
US10058332B2 (en) | 2012-08-01 | 2018-08-28 | Terumo Kabushiki Kaisha | Method for treatment of chronic obstructive pulmonary disease |
US20160166320A1 (en) * | 2014-12-11 | 2016-06-16 | Boston Scientific Scimed, Inc. | Medical device and methods of use |
CN106999195A (en) * | 2014-12-11 | 2017-08-01 | 波士顿科学医学有限公司 | Medical treatment device and its application method |
US11344356B2 (en) | 2018-02-28 | 2022-05-31 | Medtronic Cryocath Lp | Apparatus and method for targeted bronchial denervation by cryo-ablation |
US11369424B2 (en) * | 2018-10-10 | 2022-06-28 | Korust Co., Ltd. | Ultrasound apparatus of body cavity insertable type having separable sealing cover |
US11666370B2 (en) | 2020-07-27 | 2023-06-06 | Medtronic, Inc. | Apparatus and method for targeted temporary bronchial nerve modulation by cryo-ablation for prevention and treatment of acute respiratory distress syndromes |
WO2022248456A1 (en) * | 2021-05-26 | 2022-12-01 | Universität Rostock | Cleaning element for cleaning tissues and/or implants |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8475389B2 (en) | Methods and devices for assessment of pneumostoma function | |
US20090205665A1 (en) | Methods and devices for follow-up care and treatment of a pneumostoma | |
US8347881B2 (en) | Pneumostoma management device with integrated patency sensor and method | |
US20110180064A1 (en) | Methods and devices for follow-up care and treatment of a pneumstoma | |
US10034999B2 (en) | Steerable device for accessing a target site and methods | |
JP5457178B2 (en) | Airway bypass site selection and treatment planning | |
US6685666B1 (en) | Catheters for breast surgery | |
US8409070B2 (en) | Brachytherapy apparatus and method for use with minimally invasive surgeries of the lung | |
US20120053485A1 (en) | Catheter Having Needle And Expandable Support Member And Methods Of Use | |
Bagley et al. | Endoscopic ureteropyelostomy: opening the obliterated ureteropelvic junction with nephroscopy and flexible ureteropyeloscopy | |
CN207561888U (en) | Bronchoscope with Stent assembly | |
US20220395309A1 (en) | Method for treating emphysema with condensable thermal vapor | |
ES2547384T3 (en) | High pressure and high temperature steam catheters and systems | |
Garg et al. | Equipment planning | |
KR20210048267A (en) | Apparatus for endoscopy-guided thoracostomy | |
Soloway et al. | Surgical techniques for endoscopic resection of bladder cancer | |
US20220202397A1 (en) | Systems and methods for liquid flooding of lung to enhance endobronchial energy transfer for use in imaging, diagnosis and/or treatment | |
US20150150630A1 (en) | Disposable holder for special medical procedure devices | |
JP2003111761A (en) | Apparatus for detecting radiation | |
RU2232548C2 (en) | Method for differential diagnostics of rhinitis | |
Bopparaju et al. | Evolution of bronchoscopy | |
Kizi | MINIMALLY INVASIVE TECHNOLOGIES IN SURGERY | |
Rathinam | Bronchoscopy: Rigid and Flexible | |
Garg | Department Wise Equipment Detailing | |
WO2022144695A2 (en) | Systems and methods for liquid flooding of lung to enhance endobronchial energy transfer for use in imaging, diagnosis and/or treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PORTAERO, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TANAKA, DON;WIESMAN, JOSHUA P.;PLOUGH, DAVID C.;REEL/FRAME:022296/0386 Effective date: 20090217 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |